

10/798,198

**EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1626	544/405 or 544/406	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:43
L2	✓ 23	L1 AND (TGF OR (TRANSFORMING ADJ GROWTH))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:44
L3	55	L1 AND (CRF OR CORTICOTROPIN)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:44
L4	✓ 55	L3 NOT L2	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:46

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SGSPAL623ZCT

PASSWORD:  
TERMINAL (ENTER 1, 2, 3, OR 7):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the  
IPC reform  
NEWS 4 DEC 23 New IPCs SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 5 JAN 13 IPC 8 searching in IPAT, IFIUDS, and IFICDB  
NEWS 6 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 7 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 8 JAN 17 IPC 8 in the MPI family of databases including WPIFV  
NEWS 9 JAN 30 Saved answer limit increased  
NEWS 10 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA  
NEWS 11 FEB 21 STN AnaVist, Version 1.1, lets you share your STN AnaVist  
visualization results  
NEWS 12 FEB 22 Status of current WO (PCT) information on STN  
NEWS 13 FEB 22 The IPC thesaurus added to additional patent databases on STN  
NEWS 14 FEB 22 Updates in EPFULL: IPC 8 enhancements added  
NEWS 15 FEB 27 New STN AnaVist pricing effective March 1, 2006  
NEWS 16 FEB 28 MEDLINE/LMDLINE reload improves functionality  
NEWS 17 FEB 28 TOXCENTER reloaded with enhancements  
NEWS 18 FEB 28 REGISTRY/ZREGISTRY enhanced with more experimental spectral  
property data  
NEWS 19 MAR 01 INSPEC reloaded and enhanced  
NEWS 20 MAR 03 Updates in PATDPA: addition of IPC 8 data without attributes  
NEWS 21 MAR 08 X.25 communication option no longer available after June 2006  
NEWS 22 MAR 22 EMBASE is now updated on a daily basis  
NEWS 23 APR 03 New IPC 8 fields and IPC thesaurus added to PATDPAFULL  
NEWS 24 APR 03 Bibliographic data updates resume; new IPC 8 fields and IPC  
thesaurus added in PCIFULL  
NEWS 25 APR 04 STN AnaVist \$500 visualization usage credit offered

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,  
CURRENT MACINTOSH VERSION IS V6.0c(ENQ) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 AND V6.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT  
<http://download.cas.org/express/v8.0-Discover/>  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 08:59:18 ON 06 APR 2006

	SINCE FILE	TOTAL
	ENTRY	SESSION
FILE 'REGISTRY' ENTERED AT 09:01:43 ON 06 APR 2006	0.84	0.84

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4  
DICTIONARY FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/US/regprops.html>

>> ...Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

>> Uploading C:\Program Files\Stnexp\Queries\MUNCHOF TOP.str

10/798,198  
STN SEARCH TRANSCRIPT



chain nodes :  
9 11 12 13 14 15 22 23  
ring nodes :  
1 2 3 4 5 6 16 17 18 19 20 21  
chain bonds :  
2-16 3-15 5-9 6-11 9-22 9-23 11-12 11-13 13-14  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21  
exact/norm bonds :  
5-9 11-12 11-13  
exact bonds :  
2-16 3-15 6-11 9-22 9-23 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21  
isolated ring systems :  
containing 1 :

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 11:CLASS 12:CLASS  
13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom  
22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED


>> que L1

L2 QUE L1

>> D L2

L2 HAS NO ANSWERS

L1 STR



G1 C,N

Structure attributes must be viewed using STN Express query preparation.  
L2 QUE ABB-ON PLU-ON L1

>> S L2  
SAMPLE SEARCH INITIATED 09:02:07 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 134 TO ITERATE

100.0% PROCESSED 134 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	1986 TO	3374
PROJECTED ANSWERS:	981 TO	2019

L3 50 SEA SSS SAM L1

	SINCE FILE	TOTAL
	ENTRY	SESSION
FILE 'CAPLUS' ENTERED AT 09:02:20 ON 06 APR 2006	0.44	1.28

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
held by the publishers listed in the PUBLISHER (PB) field (available  
for records published or updated in Chemical Abstracts after December  
26, 1996), unless otherwise indicated in the original publications.  
The CA Lexicon is the copyrighted intellectual property of the  
American Chemical Society and is provided to assist you in searching  
databases on STN. Any dissemination, distribution, copying, or storing  
of this information, without the prior written consent of CAS, is  
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2006 VOL 144 ISS 15  
FILE LAST UPDATED: 4 Apr 2006 (20060404/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L3

L4 7 L3

=> D 1-7 IBIB ABS HITSTR

L4 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:104528 CAPLUS

DOCUMENT NUMBER: 144:192275

TITLE: Preparation of quinoxalinone derivatives useful for

the regulation of glucose homeostasis and food intake

INVENTOR(S): Rudolph, Joachim; O'Connor, Stephen; Coish, Philip;

Wickens, Philip; Bondar, Georgiy; Chuang, Chih-Yuan;

Ramsden, Philip; Lowe, Derek; Bierer, Donald; Chen,

Libing; Pu, Wenlang; Khire, Uday; Liu, Xiao-Geo;

McClure, Andrea; Wang, Lei; Yi, Lin; Esler, William

Bayer Pharmaceuticals Corporation, USA

PCT Int. Appl., 559 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2006012577	A3	20060202	MO 2005-US26192	20050722
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MU, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPL. INFO.: US 2004-590804P P 20040722

OI



AB The invention is related to substituted quinoxalinone deriva. I (R1 = (un)substituted pyrrolidin-3-yl, piperidin-3-yl, morpholin-4-yl, etc.; R2 = H, (un)substituted cycloalkyl, pyridinyl, Ph, etc.; R3 = H, halo, haloalkyl, (un)substituted Ph, alkyl, etc.; L = a bond, O, CO, S, SO2, NH, SO2, NH and deriva., etc.; X = (CH2)n; n = 0-2; Y = (CH2)n; n = 1-2; p = 0-2; with proviso), and their pharmaceutically acceptable salts, and their compns., and methods for treating diabetes, obesity and related disorders, and regulation of glucose homeostasis and food intake (e.g., stimulation and suppression) (no data). The invention is also related to the preparation of quinoxalinones I. Five biol. tests are given (no data). Thus, II-TFA was prepared by amination of 5-fluoro-2-nitrobenzoic acid with N-methylbutylamine, reduction of the nitro compound, cyclocondensation with o-anisoyl chloride, reaction with tert-Bu 3-(aminomethyl)piperidine-1-carboxylate (intermediate not isolated), and Boc-deprotection in the presence of TFA.


IT 875270-21-6P, tert-Butyl 3-[[[4-amino-4'-chlorobiphenyl-3-yl]carbonyl]amino]methyl]piperidine-1-carboxylate

RM: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of quinoxalinones useful for regulation of glucose homeostasis and food intake)

RN 875270-21-6 CAPLUS

CN 1-piperidinecarboxylic acid, 3-[[[4-amino-4'-chloro[1,1'-biphenyl]-3-yl]carbonyl]amino]methyl-, 1,1-dimethylethyl ester (SCI) (CA INDEX NAME)



L4 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216619 CAPLUS

DOCUMENT NUMBER: 142:297864

TITLE: Preparation of aniline derivatives and related

INVENTOR(S): compounds as c-kit modulators  
Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.; Xu, Wei; Bajjalieh, William

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2005020921	A3	20050310	MO 2004-US28001	20040627
MO 2005020921	A3	20051006		
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, HD, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MU, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, GU, HD, IL, IN, JP, KE, KG, KM, KN, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MH, MK, MN, MU, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, SN, TD, TG				

PRIORITY APPL. INFO.: US 2003-499224P P 20030829

OTHER SOURCE(S): MARPAT 142:297864

OI



AB Compds. I [wherein ring A is a five- to fourteen-membered heterocyclic; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclyl; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidene, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HCl(Ost) and NaH3 in AcOH followed by NaH2O2/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-kit kinase with a IC50 of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.


IT 847608-73-SP 847609-35-2P

RM: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(modulator; preparation of anilines and related compds. as C-kit modulators)


RN 847608-73-5 CAPLUS

CN 1-pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-[2-(dimethylamino)ethyl]- (SCI) (CA INDEX NAME)



RN 847609-35-2 CAPLUS

CN 1-piperidinecarboxylic acid, 3-[[[4-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (SCI) (CA INDEX NAME)



L4 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:759828 CAPLUS

DOCUMENT NUMBER: 141:260774

TITLE: Preparation of pyrazinecarboxamide compounds as

inhibitors of transforming growth factor (TGF)

signaling pathway

INVENTOR(S): Munchhof, Michael J.

PATENT ASSIGNEE(S): Pfizer Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004180905	A1	20040916	US 2004-798198	20040310
CA 2517730	AA	20040923	CA 2004-2517730	20040223

AN 2004-759828

APPLICANTS


MO 2004060982 A1 20040923 MO 2004-1B581 20040223  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV,  
 TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG  
 EP 1606267 A1 20051221 EP 2004-713617 20040223  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 PRIORITY APPLN. INFO.: US 2003-453784P P 20030311  
 MO 2004-1B581 W 20040223  
 OTHER SOURCE(S): MARPAT 141:260774  
 GI




AB Pyrazine compds. of formula I [R = (substituted) Ph, heterocyclyl, heteroaryl, aryl; R1 = H, R2 = alkyl, cycloalkyl, aryl, heteroaryl, etc.; NR2R2 = (substituted) heterocyclyl, heteroaryl] are prepared. The compds. are potent inhibitors of transforming growth factor (TGF)- $\beta$  signaling pathway. They are useful in the treatment of various TGF-related disease states including, for example, cancer and fibrotic diseases. Thus, II was prepared, and had IC50 of 1.19  $\mu$ M.

IT 756521-58-1P 756521-87-6P 756522-48-2P  
 756523-62-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of pyrazinecarboxamides as inhibitors of TGF- $\beta$  signaling pathway)

RN 756521-58-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[3-(dimethylamino)-2,2-dimethylpropyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 756521-87-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-phenyl- (9CI) (CA INDEX NAME)




RN 756522-48-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-[(1S)-2-hydroxy-1-phenylethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 756523-62-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyethyl)-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:534197 CAPLUS  
 DOCUMENT NUMBER: 141:89115  
 TITLE: Preparation of novel pyrazinamine or pyridin-2-amine derivative having selective inhibiting effect at GSK3  
 INVENTOR(S): Berg, Stefan; Hellberg, Sven  
 PATENT ASSIGNEE(S): Aastrazenece Ab, Swed.; Soederman, Peter  
 SOURCE: PCT Int. Appl., 76 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
MO 2004055009	A1	20040701	WO 2003-SE1957	20031215
MO 2004055009	C1	20050630		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
 GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI,  
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ,  
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,  
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, TD, TG  
 CA 2506045 AA 20040701 CA 2003-2508045 20031215  
 AU 2003287137 A1 20040709 AU 2003-287137 20031215  
 EP 1575942 A1 20050921 EP 2003-781206 20031215  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003017299 A 20051108 BR 2003-17299 20031215  
 NO 2005003459 A 20050812 NO 2005-3459 20050715  
 PRIORITY APPLN. INFO.: SE 2002-3753 A 20021217  
 WO 2003-SE1957 W 20031215  
 OTHER SOURCE(S): MARPAT 141:89115  
 GI




AB The title compds. [I; 2 = N; Y = CONRS, NR5CO, SO2NRS, NR5SO2, CH2NRS, NR5CONRS, CH2CO, CO, CH2O; X = CH, N; P = Ph or 5-6 membered heteroarom. ring containing one or more heteroatoms selected from N, O or S and said Ph ring or 5-6 membered heteroarom. ring may optionally be fused with a 5-6 membered saturated, partially saturated or unsatd. ring containing one or more atoms selected from C, N, O or S; Q = CONRS, alkenyl or alkynyl; R = CHO, FCH2O, F2CHO, F3CO, etc.; R3 = halo, NO2, CHO, etc.; R4 = halo, NO2, CHO, etc.; m, n = 0-4; R5 = H, alkyl], were prepared and formulated. Thus, treating 1-(4-bromophenyl)sulfonylpyrrolidine with n-butyllithium and triisopropyl borate in THF followed by reacting the intermediate with 3-amino-6-bromo-N-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2 and Na2CO3 in THF afforded 26% 3-amino-N-(2-morpholin-4-ylethyl)-6-[4-(pyrrolidin-1-yl)sulfonylphenyl]pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. I are in the range of about 0.001 to about 10.000 nM in GSK3 $\beta$  assay.

IT 714218-88-9P 714218-93-6P 714218-94-7P  
 714218-97-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of novel pyrazinamine or pyridin-2-amine deriva. having selective inhibiting effect at GSK3)


RN 714218-88-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3-amino-3-oxopropyl)-6-[4-(1-pyrrolidinylsulfonylphenyl)- (9CI) (CA INDEX NAME)



RN 714218-93-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[2-(4-morpholinyl)ethyl]-6-[4-(1-pyrrolidinylsulfonylphenyl)- (9CI) (CA INDEX NAME)




RN 714218-94-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[2-(1H-imidazol-4-yl)ethyl]-6-[4-(1-pyrrolidinylsulfonylphenyl)- (9CI) (CA INDEX NAME)






RN 714218-97-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyethyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9C1) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2004:534194 CAPLUS  
DOCUMENT NUMBER: 141:89114  
TITLE: Preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3  
INVENTOR(S): Berg, Stefan; Mellberg, Sven  
PATENT ASSIGNER(S): AstraZeneca AB, Sweden; Soederman, Peter  
SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055006	A1	20040701	WO 2003-SE1956	20031215
WO 2004055006	C1	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GR, GU, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG				
AU 2003267136	A1	20040709	AU 2003-287136	20031215
EP 1575939	A1	20050921	EP 2003-781205	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
SE 2002-3752 A 20021217				
WO 2003-SE1956 W 20031215				
PRIORITY APPLN. INFO.: MARPAT 141:89114				
OTHER SOURCE(S):				
GI				




AB The title compds. [I; Z = N; X = N; Y = CONR5; P = Ph; Q = Ph or 5-6 membered aromatic heteroatom, ring containing one or more heteroatoms selected from N, O, S; R = alkyl(SO2)NR1R2, alkyl(CONR1R2, OalkylNR1R2 (wherein R1, R2 = H, alkyl, 5-6 membered heterocyclyl, etc.; NR1R2 = 5-6 membered heterocyclyl); R3, R4 = halo, NO2, CF3, etc.; m, n = 0-1; R5 = H, as a free base or a pharmaceutically acceptable salt], were prepared and formulated. Thus, treating 4-bromo-N-((1R)-2-methoxy-1-methylethyl)benzenesulfonamide with n-butyllithium and triisopropyl borate in THF followed by reacting the intermediate with 3-amino-6-bromo-N-((pyridin-3-yl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2, and H2O in THF (prepn. of reactants given) afforded 35 3-amino-6-[4-(((1R)-2-methoxy-1-methylethyl)amino)sulfonyl]phenyl-N-((pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. 1 are in the range of about 0.001 to about 10,000 nM in GSK-3β assay.

IT 714237-30-6P  
R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)

RN 714237-30-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(((1R)-2-methoxy-1-methylethyl)amino)carbonyl]phenyl]-N-((pyridin-3-yl)pyrazine-2-carboxamide hydrochloride (9C1) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2004:143094 CAPLUS  
DOCUMENT NUMBER: 140:199743  
TITLE: Preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic acids as antagonists of factor IX for inhibiting the intrinsic pathway of blood coagulation  
INVENTOR(S): Mjalli, Adnan M. M.; Andrews, Robert C.; Quo, Xiao-chuan; Christen, Daniel Peter; Gohimmukula, Devi Reddy; Huang, Guoxiang; Rothlein, Robert; Tyagi, Sameer; Yamasu, Tripura; Behme, Christopher  
PATENT ASSIGNER(S): Transact Pharm, Inc., USA  
SOURCE: PCT Int. Appl., 326 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014844	A2	20040219	WO 2003-US25045	20030808
WO 2004014844	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BO, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HK, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PA, PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, TC, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, GM, ML, MR, NE, SN, TD, TG				
CA 2493008	AA	20040219	CA 2003-2493008	20030808
AU 2003265398	A1	20040225	AU 2003-265398	20030808
US 2004110832	A1	20040610	US 2003-637900	20030808
EP 1546089	A2	20050629	EP 2003-785150	20030808
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 200535710	T2	20051124	JP 2004-527986	20030808
PRIORITY APPLN. INFO.: US 2002-402272P P 20030808				
WO 2003-US25045 W 20030808				
OTHER SOURCE(S): MARPAT 140:199743				

AB The title compds. Ar2XCH(Var1)(CH2)CO [I; c = 0-2; G = H, CO2R1, CH2OR1, COR1, CR1NOR2, an acid isostere (wherein R1, R2 = H, alkyl, aryl, etc.); V = (CH2)BO(CH2)2, (CH2)BNR7(CH2)2, (CH2)BO, (CH2)NR7, (CH2)2, a bond (a = 0-2; b = 1-2; R7 = H, alkyl, aryl, etc.); X = NR8, COR8, NR8CO, etc. (R8 = H, alkyl, aryl, etc.); Ar1 = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; Ar2 = (un)substituted aryl or heteroaryl], useful as antagonists, or more preferably, partial antagonists of factor IX and thus, may be used to inhibit the intrinsic pathway of blood coagulation, were prepared. Thus, reacting Me 3-1-amino-3-biphenyl-4-yl-propionate with isosquinoiline-3-carboxylic acid followed by hydrolysis afforded 11 3-biphenyl-4-yl-(2S)-[(isosquinoiline-3-carboxyl)amino]propionic acid. The compds. 1 inhibit factor IX with IC50 of less than 30 μM, and are useful in a variety of applications including the management, treatment and/or control of diseases caused in part by the intrinsic clotting pathway utilizing factor IX. Such diseases or disease states include stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures, long periods of confinement, and acquired or inherited pro-coagulant states. The pharmaceutical composition comprising the compound 1 is claimed.


IT 660826-89-1P 660826-99-3P  
R1: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted (2S)-(arylamino)-3-(biphenyl-4-yl)propionic acids as antagonists of factor IX for inhibiting intrinsic pathway of blood coagulation)


RN 660826-89-1 CAPLUS  
CN [1,1'-Biphenyl]-4-propionic acid, α-[[[4'-cyano-4-[[4-(1,1-dimethylethyl)benzoyl]amino][1,1'-biphenyl]-3-yl]carbonyl]amino]-, (αS)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.



RN 660826-99-3 CAPLUS  
CN [1,1'-Biphenyl]-4-propionic acid, α-[[[4'-[[4-(1,1-dimethylethyl)benzoyl]amino]-4'-(trifluoromethyl)][1,1'-biphenyl]-3-yl]carbonyl]amino]-, (αS)- (9C1) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2003:892800 CAPLUS  
DOCUMENT NUMBER: 139:395950  
TITLE: Preparation of substituted pyrazines as protein kinase modulators

INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tsafai, Zorom; Wang, Longcheng; Co, Erick Wang; Ephraim, Sergey; Kennedy, Abigail R.; Chen, Baoli; Dubenko, Larisa; Anand, Neel Kumar; Teang, Taze H.; Nuss, John M.; Peto, Cease J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Kather; Forsyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy  
 PATENT ASSIGNER(S): Exelixis, Inc., USA  
 SOURCE: PCT Int. Appl., 468 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093297	A2	20031113	WO 2003-US13869	20030502
WO 2003093297	A3	20040701		

W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GR, HU, IE, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LU, LR, LS, LT, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO  
 CA 2484209 AA 20031113 CA 2003-2484209 20030502  
 EP 1501514 A2 20050202 EP 2003-728690 20030502  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 JP 2005530760 T2 20051013 JP 2004-501436 20030502  
 PRIORITY APPL. INFO.: US 2002-377933P P 20020503  
 WO 2003-US13869 W 20030502


OTHER SOURCE(S): MARPAT 139:395950  
 OI



AB This invention relates to compds. I (R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = M, CH; A = CO, C9, C10, NR6), R7 (when A = R7, R7 does not exist); R6 = H, MO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NNR2R3, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heterocyclyl; M = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-3O, etc.; Y = H, alkyl, aryl, etc.; with proviso(s) for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is




RN 625462-78-4 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-5-(trifluoromethyl)benzoyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625463-06-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-[[[3-methoxyphenyl]methyl]amino]-6-[3-[[[3R]-1-[(3-methoxyphenyl)methyl]-3-pyrrolidinyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

RN 625463-17-4 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[(phenylmethyl)amino]phenyl]- (9CI) (CA INDEX NAME)


described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 625462-41-1P 625462-43-3P 625462-63-7P  
 625462-78-4P 625463-06-1P 625463-17-4P  
 625463-50-5P 625463-65-2P 625463-68-5P  
 625464-08-6P 625464-16-6P 625464-17-7P  
 625464-49-5P 625464-92-8P 625465-43-2P  
 625465-94-3P 625466-03-7P 625466-11-7P  
 625466-88-8P 625466-89-9P 625466-92-1P  
 625467-21-2P 625467-45-0P 625467-86-3P  
 625468-00-0P 625468-32-8P 625468-57-7P  
 625469-24-1P 625469-41-2P 625469-56-9P  
 625469-71-8P 625469-94-5P 625470-13-5P  
 625470-21-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOD (Biological study); PREP (Preparation); USES (Uses)

(preparation of protein kinase modulators)


RN 625462-41-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-fluoro-4-methylphenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-43-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-3,6-difluorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-63-7 CAPLUS  
 CN Carbamate acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 625463-50-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-(1H-benzimidazol-2-yl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-65-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(2-thienyl)phenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-68-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-fluorophenyl]methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-08-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2,3-dihydro-1-hydroxy-1H-inden-2-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-16-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-17-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-49-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2R)-2-(phenylmethoxy)cyclopentyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625464-92-8 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-43-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-94-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-(4-pyridinylcarbonyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625466-03-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[2-[[4-(pyridinylcarbonyl)amino]ethyl]- (9CI) (CA INDEX NAME)



RN 625466-11-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethyl-4-isoxazolyl)amino]carbonyl]amino]ethyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




PAGE 1-A



RN 625466-88-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-


[fluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-89-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-(methylthio)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-99-1 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2-pyridinylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 2-A




RN 625467-21-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-3-benzofuran-1-yl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-45-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-86-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3-dihydro-3-benzofuran-1-yl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3-dihydro-3-benzofuran-1-yl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-24-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-hydroxy-2-pyridinyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-41-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chloro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


NAME)

Absolute stereochemistry.




RN 625468-00-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-32-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromobenzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-57-7 CAPLUS




RN 625469-56-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-71-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-94-5 CAPLUS  
CN 3-Pyridinecarboxamide, 2-amino-5-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 625470-13-5 CAPLUS  
CN Carbamic acid, [[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 625470-21-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 625470-34-0P 625470-90-8P  
RI: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of protein kinase modulators)  
RN 625470-34-0 CAPLUS  
CN Benzoic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-2-chloro-, methyl ester (9CI) (CA INDEX NAME)



RN 625470-90-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(bromomethyl)phenyl]-N-ethyl-, (9CI) (CA INDEX NAME)



=> FILE REQ  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL  
44.05 45.33

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL  
CA SUBSCRIBER PRICE -5.25 -5.25

FILE 'REGISTRY' ENTERED AT 09:12:50 ON 06 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4  
DICTIONARY FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.


REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> Uploading C:\Program Files\Stnexp\Queries\MUNCHOF.TGF.str



chain nodes :  
9 11 12 13 14 15 22 23

ring nodes :  
1 2 3 4 5 6 16 17 18 19 20 21  
chain bonds :  
2-16 3-15 5-9 6-11 9-22 9-23 11-12 11-13 13-14  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21  
exact/norm bonds :  
5-9 11-12 11-13  
exact bonds :  
2-16 3-15 6-11 9-22 9-23 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 16-17 16-21 17-18 18-19 19-20 20-21  
isolated ring systems :  
containing 1 :

G1:C,N

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 9:CLASS 11:CLASS 12:CLASS  
13:CLASS 14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:Atom 21:Atom  
22:CLASS 23:CLASS

L5 STRUCTURE UPLOADED


=> que L5

L6 QUE L5

=> D L5

L5 HAS NO ANSWERS

L5



G1 C,N

Structure attributes must be viewed using STN Express query preparation.

=> LOG HOLD  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE ENTRY TOTAL  
1.32 46.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE ENTRY TOTAL  
CA SUBSCRIBER PRICE 0.00 -5.25

THE REAL  
SEARCH  
STARTS  
HERE.

NO R1 - R2 JOINED TO  
FORM A HETEROCYCLE  
SEARCHED.

AND

PHENYL ONLY

SESSION WILL BE HELD FOR 60 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 09:14:50 ON 06 APR 2006  
Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1623ZCT

PASSWORD:

\*\*\*\*\* RECONNECTED TO STN INTERNATIONAL \*\*\*\*\*  
SESSION RESUMED IN FILE 'REGISTRY' AT 09:20:22 ON 06 APR 2006  
FILE 'REGISTRY' ENTERED AT 09:20:22 ON 06 APR 2006  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.32	46.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.25

=> D HIS

(FILE 'HOME' ENTERED AT 08:59:18 ON 06 APR 2006)

FILE 'REGISTRY' ENTERED AT 09:01:43 ON 06 APR 2006  
L1 STRUCTURE UPLOADED  
L2 QUS L1  
L3 50 S L2

FILE 'CAPLUS' ENTERED AT 09:02:20 ON 06 APR 2006  
L4 7 S L3

FILE 'REGISTRY' ENTERED AT 09:12:50 ON 06 APR 2006  
L5 STRUCTURE UPLOADED  
L6 QUS L5

=> S L5 SSS FULL  
FULL SEARCH INITIATED 09:20:35 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 1748 TO ITERATE

100.0% PROCESSED 1748 ITERATIONS 1337 ANSWERS  
SEARCH TIME: 00.00.01

L7 1337 SEA SSS FUL L5

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	168.26	213.59


DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.25

FILE 'CAPLUS' ENTERED AT 09:20:45 ON 06 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UO/regprops.html>

=> D L5  
L5 HAS NO ANSWERS  
L5 STR



01 C,N

Structure attributes must be viewed using STN Express query preparation.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.44	214.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.25

FILE 'CAPLUS' ENTERED AT 09:21:16 ON 06 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2006 VOL 144 ISS 15  
FILE LAST UPDATED: 4 Apr 2006 (20060404/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 6 Apr 2006 VOL 144 ISS 15  
FILE LAST UPDATED: 4 Apr 2006 (20060404/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> FILE REHQ  
'REHQ' IS NOT A VALID FILE NAME  
SESSION CONTINUES IN FILE 'CAPLUS'  
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.46	214.05

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-5.25

FILE 'REGISTRY' ENTERED AT 09:21:09 ON 06 APR 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4  
DICTIONARY FILE UPDATES: 4 APR 2006 HIGHEST RN 879269-14-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

\*\*\*\*\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the SD field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*\*\*\*\*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

=> S L7

L8 26 L7

=> S L8 NOT 2004:759828/AN

L9 1 2004:759828/AN


L9 25 L8 NOT 2004:759828/AN

=> D L9 1-25 IBIB ABS HITSTR

L9 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2005:962046 CAPLUS  
DOCUMENT NUMBER: 143:266952  
TITLE: Preparation of bipyridyl amides as modulators of metabotropic glutamate receptor-5  
INVENTOR(S): Bonnefous, Celine; Kamenecka, Theodore M.; Vernier, Jean-Michel  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 79 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079802	A1	20050901	WO 2005-US3952	20050209
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RM: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, KP, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, NG, SN, TD, TO				

PRIORITY APPLN. INFO.: US 2004-544627P P 20040212  
OTHER SOURCE(S): MARPAT 143:266952  
01



AB The title compds. I [X = N, C; Y = N, C (halo); R1 = H, alkyl, cycloalkyl, etc.; R2 = H, alkyl, aryl, etc.; R3 = aryl, halo, alkyl, etc.; R4 and R5 may be joined together with the atoms to which they are attached to form a (un)saturated 4-7 membered ring containing 0-2 heteroatoms selected from O, S and N; R4 = aryl, heteroaryl, halo, etc.] which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders,

THIS EXCLUDES APPLICANT'S WORK

and panic, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases, were prepared. Thus, amidation of pyridin-2-amine with 3-amino-5,6-diphenylpyrazine-2-carboxylic acid afforded the amide II. The exemplified compds. I have  $\alpha$ 1uRS inhibitory activity as shown by inhibition at 10  $\mu$ M or less in the calcium flux assay or 100  $\mu$ M or less in the PI assay. The invention is also directed to pharmaceutical compns. comprising compds. I.


IT 863908-42-3P 863908-69-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses).

(preparation of bipyrindyl amides as modulators of metabotropic glutamate receptor-5)


RN 863908-42-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 863908-69-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-cyanophenyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:216619 CAPLUS

DOCUMENT NUMBER: 142:297864

TITLE: Preparation of aniline derivatives and related compounds as c-kit modulators

INVENTOR(S): Cheng, Wei; Co, Erick Wang; Kim, Moon Hwan; Klein, Rhett Ronald; Le Donna, T.; Lew, Amy; Nuss, John M.;

Xu, Wei; Bajjalieh, William

PATENT ASSIGNEE(S): Exelixis, Inc., USA

SOURCE: PCT Int. Appl., 169 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005020921	A2	20050310	WO 2004-US28001	20040827
WO 2005020921	A3	20051006		

W: AS, AQ, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MD, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: MARPAT 142:297864 US 2003-499224P P 20030829

OTHER SOURCE(S): GI



AB Compds. I [wherein ring A is a five- to fourteen-membered heterocyclic ring; R1, R2 and R3 are H, halo, trihalomethyl, cyano, nitro, etc.; L1 is a single bond, (un)substituted alkylene, O, CH2O, etc.; ring B is five- to ten-membered aryl or heterocyclic; ring C is five- to ten-membered (hetero)aryl; L2 is alkylene, alkylidene, alkylidene, etc.; with some limitations and exclusions, and pharmaceutically acceptable salts, hydrates or prodrugs thereof], as exemplified by carbonyl compds. of anilines, were prepared as c-kit kinase modulators. For example, 3-aminophenoxyacetic acid, which was obtained from the corresponding nitro compound in 76% yield via catalytic hydrogenation, was treated with HCl and NaOH in AcOH followed by NaNO2/HCl to give a tetrazole in 61% yield. This acid was coupled with 5-amino-2-chlorobenzotrifluoride in the presence of HATU to afford acetamide II in 46% yield, which showed inhibition against c-kit kinase with a IC50 of < 50 nM. Therefore, I and pharmaceutical compns. thereof are useful for modulating c-kit kinase activity and for treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities.

IT 847608-88-6P 847608-73-5P 847608-93-9P 847608-94-0P 847608-95-1P 847608-96-2P 847609-35-2P 847609-36-3P 847609-39-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)

(modulator; preparation of anilines and related compds. as c-kit modulators)

RN 847608-88-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-

(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)



RN 847608-73-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)



RN 847608-93-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847608-94-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 847608-95-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A


RN 847608-96-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 847609-35-2 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxylate, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 847609-36-3 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]pyrazinyl]carboxylate, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 847609-39-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)



L9 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:817651 CAPLUS  
DOCUMENT NUMBER: 141:332206  
TITLE: Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers  
INVENTOR(S): Chakravarty, Prasun K.; Fisher, Michael H.; Parsons, William H.; Liang, Jun; Zhou, Bishen  
PATENT ASSIGNEE(S): Merck & Co., Inc., USA  
SOURCE: PCT Int. Appl., 125 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004084624	A2	20041007	WO 2004-US8532	20040319
WO 2004084624	A3	20050331		
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, CH, GM, KE, LB, MG, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				


BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2004224392 A1 20041007 AU 2004-224392 20040319  
CA 2519677 AA 20041007 CA 2004-2519677 20040319  
EP 1608622 A2 20051228 EP 2004-757920 20040319

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRIORITY APPL. INFO.: US 2003-456312P P 20030324  
WO 2004-US8532 A 20040319


OTHER SOURCE(S): MARPAT 141:332206  
GI



AB The title biaryl substituted pyridine, pyrimidine and pyrazine compds. [I or II; H-1 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; H-2 = (un)substituted pyridyl, pyrimidyl, pyrazinyl; R4, R5 = H, alkyl, alkoxy, aryloxy, etc.; R6-R8 = H, alkyl, cycloalkyl, alkoxy, etc.] which are sodium channel blockers useful for the treatment of pain (no data), were prepared e.g., a 2-step synthesis of III, starting from 2-bromo-6-methylpyridine and 3-bromophenylboronic acid, was given. Claimed pharmaceutical compds. comprise an effective amount of the instant compds. I, either alone, or in combination with one or more therapeutically active compds., and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compds., either alone, or in combination with one or more other therapeutically active compds.

IT 770726-23-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(Preparation of biaryl substituted 6-membered heterocycles as sodium channel blockers for treatment or prevention of pain)

RN 770726-23-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2'-(trifluoromethoxy)[1,1'-biphenyl]-3-yl]- (9CI) (CA INDEX NAME)




L9 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:534197 CAPLUS  
DOCUMENT NUMBER: 141:89115  
TITLE: Preparation of novel pyrazinamine or pyridin-2-amine derivative, having selective inhibiting effect at GSK3  
INVENTOR(S): Berg, Stefan; Hellberg, Sven  
PATENT ASSIGNEE(S): Astrazeneca Ab, Swed.; Soederman, Peter  
SOURCE: PCT Int. Appl., 76 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055009	A1	20040701	WO 2003-SE1957	20031215
WO 2004055009	C1	20050630		
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, CH, GM, KE, LB, MG, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
CA 2508045	AA	20040701	CA 2003-250845	20031215
AU 2003287137	A1	20040709	AU 2003-287137	20031215
EP 1575942	A1	20050921	EP 2003-781206	20031215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017299	A	20051108	BR 2003-17299	20031215
WO 200503459	A	20050812	WO 2005-3459	20050715
PRIORITY APPL. INFO.: SE 2002-3753 A 20021117 WO 2003-SE1957 W 20031215				

OTHER SOURCE(S): MARPAT 141:89115  
GI





AB The title compds. [1: Z = N; Y = CONR5, NR5CO, SO2NR5, NR5SO2, CH2NR5, NR5CONR5, CH2CO, CO, CH2O; X = CH, N; P = Ph or 5-6 membered heteroarom. ring containing one or more heteroatoms selected from N, O or S and said Ph ring or 5-6 membered heteroarom. ring may optionally be fused with a 5-6 membered saturated, partially saturated or unsatd. ring containing one or more


atoms selected from C, N, O or S; Q = alkyl, alkenyl or alkynyl; R = CHO, FCH2O, F2CHO, F3CO, etc.; R3 = halo, NO2, CHO, etc.; R4 = halo, NO2, CHO, etc.; m, n = 0-4; R5 = H, alkyl], were prepared and formulated. Thus, treating 1-[(4-bromophenyl)sulfonyl]pyrrolidine with n-butyllithium and triisopropyl borate in THF followed by reacting the intermediate with 3-amino-6-bromo-N-(2-morpholin-4-ylethyl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2 and Na2CO3 in THF afforded 264 3-amino-N-(2-morpholin-4-ylethyl)-6-[(4-(pyrrolidin-1-yl)sulfonyl)phenyl]pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. I are in the range of about 0.001 to about 10.000 nM in GSK3β assay.

IT 714218-71-0P 714218-72-1P 714218-74-3P  
714218-75-4P 714218-76-5P 714218-77-6P  
714218-78-7P 714218-79-8P 714218-80-1P  
714218-81-2P 714218-82-3P 714218-83-4P  
714218-84-5P 714218-87-8P 714218-88-9P  
714218-89-0P 714218-90-3P 714218-91-4P  
714218-92-5P 714218-93-6P 714218-94-7P  
714218-96-9P 714218-97-0P 714218-98-1P  
714218-99-2P 714218-00-8P 714219-01-9P  
714219-02-0P 714219-03-1P 714219-04-2P  
714219-05-3P 714219-63-5P 714219-64-6P  
714219-70-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of novel pyrazinamine or pyridin-2-amine derive. having selective inhibiting effect at GSK3)

RN 714218-71-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(4-morpholinyl)ethyl]-6-[(4-(1-pyrrolidinyl)sulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714218-72-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(1H-imidazol-4-yl)ethyl]-6-[(4-(1-pyrrolidinyl)sulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714218-74-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-N-[2-(2-thienyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714218-75-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-N-(2-thienylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714218-76-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyethyl)-6-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714218-77-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-methoxypropyl]-6-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714218-78-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714218-79-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(cyanomethyl)-6-[(4-[(4-methyl-1-


piperazinyl)sulfonyl]phenyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 714218-80-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714218-81-2 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(methylsulfonyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714218-82-3 CAPLUS


CN Pyrazinecarboxamide, N-[2-(acetylamino)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714218-83-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 714218-84-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[2-(aminosulfonyl)ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714218-87-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-88-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[3-amino-3-oxopropyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-89-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(2-nitrophenyl)methyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-90-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(2-methoxyphenyl)methyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-91-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[3-(4-morpholinyl)propyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-92-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[3-(4-methyl-1-piperazinyl)propyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-93-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(4-morpholinyl)ethyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-94-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(1H-imidazol-4-yl)ethyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714218-96-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-thienylmethyl]- (9CI) (CA INDEX NAME)




RN 714218-97-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyethyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714218-98-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-methoxypropyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714218-99-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(2-oxo-1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)



RN 714219-00-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(cyanomethyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714219-01-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(1-pyrrolidinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 714219-02-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)


NAME)




RN 714219-03-1 CAPLUS  
CN Pyrazinecarboxamide, N-[2-(acetylaminomethyl)ethyl]-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714219-04-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[2-(2-oxo-1-imidazolidinyl)ethyl]- (9CI) (CA INDEX NAME)



RN 714219-05-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(aminoethyl)sulfonyl]ethyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-63-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-((1H-imidazol-1-yl)propyl)-6-((1-pyrrolidinylsulfonyl)phenyl)]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-64-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-((1H-imidazol-1-yl)propyl)-6-((1-pyrrolidinylsulfonyl)phenyl)]-, (9CI) (CA INDEX NAME)




RN 714237-70-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-((4-methyl-1-piperazinyl)sulfonyl)phenyl]-N-(2-(2-thienyl)ethyl)]-, (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:534194 CAPLUS  
DOCUMENT NUMBER: 141:89114  
TITLE: Preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3  
INVENTOR(S): Berg, Stefan; Hellberg, Sven  
PATENT ASSIGNEE(S): AstraZeneca Ab, Swed.; Soederman, Peter  
SOURCE: PCT Int. Appl., 62 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: English  
PATENT INFORMATION: 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004055006	A1	20040701	WO 2003-SE1956	20031215
WO 2004055006	C1	20050630		
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RM: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GW, MD, MR, NE, SN, TD, TO</p>				
AU 2003287136	A1	20040709	AU 2003-287136	20031215
EP 1575939	A1	20050921	EP 2003-781205	20031215
<p>R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK</p>				
PRIORITY APPLN. INFO.:			SE 2002-3752	A 20021217
			WO 2003-SE1956	W 20031215
OTHER SOURCE(S):			MARPAT 141:89114	
OI				



AB The title compds. [1; Z = N; X = N; Y = CONR5; P = Ph; Q = Ph or 5-6 membered aromatic heteroarom. ring containing one or more heteroatoms selected from N, O, S; R = alkyl(SO2)NR1R2, alkylCONR1R2, alkylNR1R2 (wherein R1, R2 = H, alkyl, 5-6 membered heterocyclyl, etc.; NR1R2 = 5-6 membered heterocyclyl); R3, R4 = halo, NO2, CF3, etc.; m, n = 0-1; R5 = H; as a free base or a pharmaceutically acceptable salt], were prepared and formulated. Thus, treating 4-bromo-N-[(1R)-2-methoxy-1-methylethyl]benzenesulfonamide with n-butyllithium and triisopropyl borate in THF followed by reacting the intermediate with 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2, and Na2CO3 in THF (preps. of reactants given) afforded 35% 3-amino-6-[[4-((1R)-2-methoxy-1-methylethyl)amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. 1 are in the range of about 0.001 to about 10,000 nM in GSK-3β assay.


IT 486423-43-2P 714237-12-4P 714237-13-5P  
714237-14-6P 714237-15-7P 714237-16-8P  
714237-17-9P 714237-18-0P 714237-19-1P  
714237-20-4P 714237-21-5P 714237-22-6P  
714237-23-7P 714237-24-8P 714237-25-9P  
714237-26-0P 714237-27-1P 714237-28-2P  
714237-29-3P 714237-30-6P 714237-31-7P  
714237-32-8P 714237-33-9P 714237-34-0P  
714237-35-1P 714237-36-2P 714237-37-3P  
714237-38-4P 714237-39-5P 714237-40-6P  
714237-41-9P 714237-43-1P 714237-44-2P  
714237-45-3P 714237-46-4P 714237-47-5P  
714237-48-6P 714237-49-7P 714237-50-0P  
714237-51-1P 714237-52-2P 714237-53-3P  
714237-54-4P 714237-55-5P 714237-56-6P  
714237-57-7P 714237-58-8P 714237-60-0P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)

RN 486423-43-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-12-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[[(1R)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

RN 714237-13-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[[(1S)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714237-14-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-nitrophenyl)-6-[(4-methyl-1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714237-15-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(4-methyl-1-pyrrolidinylsulfonyl)phenyl]-N-(2-nitrophenyl)- (9CI) (CA INDEX NAME)




RN 714237-16-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[(4-methyl-1-pyrrolidinylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-17-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-18-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-(aminocarbonyl)phenyl]-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-19-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-20-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-21-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-22-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[(4-methyl-1-piperazinylsulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-23-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-1H-pyrazol-3-yl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-24-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[4-(aminocarbonyl)-1H-pyrazol-3-yl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-25-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-1H-imidazol-2-yl-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-26-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-27-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[1-ethyl-3-piperidinyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-28-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714237-29-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-methylbutyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 714237-30-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[1S]-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 714237-31-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-pyridinyl)-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-32-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-33-9 CAPLUS  
CN Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 714237-34-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 714237-35-1 CAPLUS  
CN Pyrazinecarboxamide, N-[3-(acetylamino)phenyl]-3-amino-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-36-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-(aminosulfonyl)phenyl]-6-[4-[[[4-methyl-1-piperazinyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-37-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-ethoxyethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 714237-38-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(fluoro-4-[2-(4-morpholinyl)ethoxy]phenyl)-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 714237-39-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[1-ethyl-3-piperidinyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-40-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[bis(2-methoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 714237-41-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(3-methylbutyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-43-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-44-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(1R)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 714237-45-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(1S)-2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 714237-46-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(2-ethoxyethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 714237-47-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(4-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-48-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-aminocarbonyl)phenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-49-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-(aminocarbonyl)phenyl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 714237-50-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-cyanophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-51-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-52-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-bromophenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)







RN 714237-53-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-(4-bromophenyl)-1H-pyrazol-3-yl- (9CI) (CA INDEX NAME)



RN 714237-54-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[4-(aminocarbonyl)-1H-pyrazol-3-yl]-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-55-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(1H-imidazol-2-yl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-56-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2-methoxy-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 714237-57-7 CAPLUS  
CN Pyrazinecarboxamide, N-(3-acetylphenyl)-3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 714237-58-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 714237-68-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyphenyl)-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



IT 486424-13-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of novel 3-aminopyrazine-2-carboxamides having selective inhibiting effect at GSK3)

RN 486424-13-9 CAPLUS  
CN Benzoic acid, 4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2004:534193 CAPLUS  
DOCUMENT NUMBER: 141:89113  
TITLE: Preparation of novel pyrazinamine or pyridin-2-amine derivatives having selective inhibiting effect at GSK3  
INVENTOR(S): Berg, Stefan; Hellberg, Sven; Soederman, Peter  
PATENT ASSIGNEE(S): AstraZeneca AB, Sued.  
SOURCE: PCT Int. Appl., 33 pp.  
CODEN: PIXKD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NO 2004055005	A1	20040701	NO 2003-SE1955	20031215
NO 2004055005	C1	20050630		

W: AR, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BN, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MO, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RD, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RM: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2508042 AA 20040701 CA 2003-2508042 20031215  
 AU 2003287135 A1 20040709 AU 2003-287135 20031215  
 EP 1575938 A1 20050921 EP 2003-781204 20031215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, 18, SI, LT, LV, FI, RO, MK, CY, AL, TR, BO, CZ, SE, HU, SK

BR 2003017294 A 20051108 BR 2003-17294 20031215  
 NO 2005003460 A 20050812 NO 2005-1460 20050715  
 SE 2002-3754 A 20021217  
 WO 2003-581955 W 20031215

PRIORITY APPLN. INFO.:  
 OTHER SOURCE(S): MARPAT 141:89113  
 GI




AB The title compds. [I: Z = N; X = CH, N; Y = CONRS, NRSCO, SO2NR5, etc.; P = Ph or 5-6 membered heteroarom. ring containing one or more heteroatoms selected from N, O or S (optionally fused); Q = Ph or 5-6 membered aromatic heterocyclic ring containing one or more N atoms (optionally fused); R = alkyl, alkenyl, alkynyl, alkylcycloalkyl, alkylheteroaryl or alkylheterocycloalkyl; R11 = alkyl, alkenyl, alkynyl, alkylcycloalkyl or alkylheterocycloalkyl; R2, R3 = H, alkyl, alkylaryl, etc.; R3, R4 = halo, NO2, CHO, etc.; m, n = 0-4; R5 = H, alkyl, alkylaryl, etc.; as a free base or a pharmaceutically acceptable salt], were prepared and formulated. Thus, treating N-[3-(4-bromophenyl)propyl]-N,N-dicyclobutylamine with n-butyllithium and triisopropyl borate in THF followed by reaction of the intermediate with 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide in the presence of Pd(dppf)Cl2 and Na2CO3 in THF (preps. of reactants were given) afforded 53% 3-amino-6-[4-[3-(dicyclobutylamino)propyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride. Typical Ki values for the compds. of the present invention are in the range of about 0.001 to about 10,000 nM in GSK-3β assay.

IT 713541-87-SP  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USRS (Uses)  
 (preparation of novel pyrazinamine or pyridin-2-amine derive. having selective inhibiting effect at GSK3)

RN 713541-87-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[3-(dicyclobutylamino)propyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)

NOT PRIOR ART.




● HCl

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2004:205967 CAPLUS  
 DOCUMENT NUMBER: 142:113926  
 TITLE: Product class 14: pyrazines  
 AUTHOR(S): Sato, N.  
 CORPORATE SOURCE: Germany  
 SOURCE: Science of Synthesis (2004), 16, 751-844  
 CODEN: SSCYJ9  
 PUBLISHER: Georg Thieme Verlag  
 DOCUMENT TYPE: Journal: General Review  
 LANGUAGE: English

AB A review. Methods for preparing pyrazines are reviewed including cyclization, ring transformation, aromatization and substituent modification.  
 IT 113424-66-1  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (review of preparation of pyrazines via cyclization, ring transformation, aromatization and substituent modification)  
 RN 113424-66-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




IT 19994-59-3P 113120-69-7P 113424-76-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (review of preparation of pyrazines via cyclization, ring transformation, aromatization and substituent modification)


RN 19994-59-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-phenyl-, 4-oxide (8CI, 9CI) (CA INDEX NAME)



RN 113120-69-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-phenyl- (9CI) (CA INDEX NAME)



RN 113424-76-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-phenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 506 THERE ARE 506 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L9 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2004:48253 CAPLUS  
 DOCUMENT NUMBER: 140:396760  
 TITLE: Characteristic IR spectra of 6-aryl-4(3H)-pteridinones  
 AUTHOR(S): Wang, Qiang; Ma, Xiu-yan; Chang, Jun-biao; Wang, Shi; Qiu, Rui-yun  
 CORPORATE SOURCE: Henan Analysis and Testing Center, Zhengzhou, 450002, Peop. Rep. China  
 SOURCE: Guangpuxue Yu Guangpu Fenxi (2003), 23(6), 1101-1103  
 CODEN: GYGFED; ISSN: 1000-0593  
 PUBLISHER: Beijing Daxue Chubanshe  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Chinese

AB The 6-Aryl-4(3H)-pteridinones and 2-amino-3-carbamoyl-5-phenylpyrazines, and their p-substitute of the Ph series compds. were prepared. Their IR spectra have been determined and the relations between the structures and the IR data have been studied. The results showed that the νC-H and δC-H vibration of the Ph was affected by different substituted groups attached on it, and bromine and chlorine have the same effect. We


have pointed out the range of Ph C-X vibration on the spectra, and it was also found that the spectra have changed notably after the cyclization. We can quickly and accurately determine whether the acyl was cyclized to lactam or not by IR spectra with the data in this article.

IT 16014-59-8 30838-86-9 113120-69-7  
 685887-32-5  
 RL: PRP (Properties)  
 (characteristic IR spectra of 6-aryl-4(3H)-pteridinones)


RN 16014-59-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 30838-86-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 113120-69-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-phenyl- (9CI) (CA INDEX NAME)




RN 685887-32-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-bromophenyl)- (9CI) (CA INDEX NAME)




L9 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2003:892800 CAPLUS  
 DOCUMENT NUMBER: 139:395950

TITLE: Preparation of substituted pyrazines as protein kinase modulators  
INVENTOR(S): Buhr, Chris A.; Baik, Tae-Gon; Ma, Sunghoon; Tsai, Zerong; Wang, Longcheng; Co, Erick Wang; Spehteyn, Sergey; Kennedy, Abigail R.; Chen, Balli; Dubenko, Larissa; Anand, Neel Kumar; Tsang, Tze H.; Nuss, John M.; Peto, Ceaba J.; Rice, Kenneth D.; Ibrahim, Mohamed Abdulkader; Schnepf, Kevin Luke; Shi, Xian; Leahy, James William; Chen, Jeff; Dalrymple, Lisa Esther; Foreyth, Timothy Patrick; Huynh, Tai Phat; Mann, Grace; Mann, Lary Wayne; Takeuchi, Craig Stacy  
PATENT ASSIGNEE(S): Exelixis, Inc., USA  
SOURCE: PCT Int. Appl., 468 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION: PCT Int. Appl., 468 pp.


PATENT NO. KIND DATE APPLICATION NO. DATE  
WO 2003093297 A2 20031113 WO 2003-US13869 20030502  
WO 2003093297 A3 20040701  
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MM, MZ, ND, NG, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2484209 AA 20031113 CA 2003-2484209 20030502  
EP 1501534 A2 20050202 EP 2003-728690 20030502  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
JP 2005530760 T2 20051013 JP 2004-501436 20030502  
PRIORITY APPL. INFO.: US 2002-377933P P 20020503  
WO 2003-US13869 W 20030502  
OTHER SOURCE(S): MARPAT 139:395950  
OI



AB This invention relates to compds. I [R1 = H, halo, CN, etc.; R2, R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; Z = N, CH; A = CO, CS, C(NR6), R7 (when A = R7, B does not exist); R6 = H, NO2, CN, etc.; R7 = (un)substituted 5-7 membered heterocyclyl; E = NR8R9, NR8R9, OR4, etc.; R8 = H, alkyl; R9 = H, heteroarylalkyl, etc.; NR8R9 = (un)substituted 5-7 membered heterocyclyl; W = 6-10 membered arylene, 5-10 membered heteroarylene; X = a bond, (un)substituted alkylene, O(CH2)2-30, etc.; Y = H, alkyl, aryl, etc.; with proviso] for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion, and



RN 625470-15-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(aminomethyl)phenyl)-N-methyl]- (9CI) (CA INDEX NAME)




IT 438190-84-2P 625459-21-4P 625459-24-7P  
625459-25-9P 625459-28-1P 625459-29-2P  
625459-30-5P 625459-31-6P 625459-32-7P  
625459-34-9P 625459-36-1P 625459-37-2P  
625459-38-3P 625459-40-7P 625459-42-9P  
625459-44-1P 625459-45-2P 625459-46-3P  
625459-47-4P 625459-49-6P 625459-51-0P  
625459-53-2P 625459-55-4P 625459-57-6P  
625459-59-8P 625459-60-1P 625459-62-3P  
625459-64-5P 625459-65-6P 625459-67-8P  
625459-69-0P 625459-71-4P 625459-72-5P  
625459-74-7P 625459-83-8P 625459-85-0P  
625459-87-2P 625459-89-4P 625459-90-7P  
625459-91-8P 625459-93-0P 625459-95-2P  
625459-94-1P 625459-95-2P 625459-96-3P  
625459-97-4P 625459-98-5P 625459-99-6P  
625460-00-6P 625460-01-7P 625460-02-8P  
625460-03-9P 625460-04-0P 625460-05-1P  
625460-07-3P 625460-08-4P 625460-09-5P  
625460-20-0P 625460-21-1P 625460-22-2P  
625460-23-3P 625460-24-4P 625460-25-5P  
625460-26-6P 625460-27-7P 625460-28-8P  
625460-29-9P 625460-30-2P 625460-31-3P  
625460-32-4P 625460-33-5P 625460-34-6P  
625460-35-7P 625460-36-8P 625460-37-9P  
625460-38-0P 625460-39-1P 625460-40-4P  
625460-41-5P 625460-42-6P 625460-43-7P  
625460-44-8P 625460-45-9P 625460-46-0P  
625460-47-1P 625460-48-2P 625460-49-3P  
625460-50-6P 625460-51-7P 625460-52-8P  
625460-53-9P 625460-54-0P 625460-55-1P  
625460-56-2P 625460-57-3P 625460-58-4P  
625460-59-5P 625460-60-8P 625460-61-9P  
625460-62-0P 625460-63-1P 625460-64-2P  
625460-65-3P 625460-66-4P 625460-67-5P  
625460-68-6P 625460-69-7P 625460-70-0P

ANSWER 9  
THIS  
ONE  
GOES  
ON  
FOR  
ABOUT  
100  
PAGES


NOT PRIOR ART

to pharmaceutical compns. containing such compds. Even more specifically, the invention relates to compds. I that inhibit, regulate and/or modulate kinases, particularly Checkpoint Kinases, even more particularly Checkpoint Kinase 1, or Chk1. Preparation of representative compds. I is described. Thus, amidation of 3-amino-6-phenylpyrazinecarboxylic acid (preparation given) with benzylamine afforded 67% 3-amino-6-phenyl-N-(phenylmethyl)pyrazine-2-carboxamide which showed IC50 of 10,000 nM or greater against Chk1. Table presenting activity data with respect to Chk1 for over 1000 compds. I is given. Methods of therapeutically or prophylactically using the compds. I and compns. to treat kinase-dependent diseases and conditions are also an aspect of the invention, and include methods of treating cancer, as well as other disease states associated with unwanted angiogenesis and/or cellular proliferation, by administering effective amts. of such compds.

IT 625461-86-1P 625461-87-2P 625464-74-6P  
625470-15-7P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of protein kinase modulators)  
RN 625461-86-1 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(cyclopropylamino)carbonyl]pyrazinyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 625461-87-2 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(ethylamino)carbonyl]pyrazinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 625464-74-6 CAPLUS  
CN Pyrazinecarboxylic acid, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-, hydrazide (9CI) (CA INDEX NAME)


Absolute stereochemistry.

625460-71-1P 625460-72-2P 625460-73-3P  
625460-74-4P 625460-75-5P 625460-76-6P  
625460-77-7P 625460-78-8P 625460-79-9P  
625460-80-2P 625460-81-3P 625460-82-4P  
625460-83-5P 625460-84-6P 625460-85-7P  
625460-86-8P 625460-87-9P 625460-88-0P  
625460-89-1P 625460-90-4P 625460-91-5P  
625460-92-6P 625460-93-7P 625460-94-8P  
625460-95-9P 625460-96-0P 625460-97-1P  
625460-98-2P 625460-99-3P 625461-00-9P  
625461-01-0P 625461-02-1P 625461-03-2P  
625461-04-3P 625461-05-4P 625461-06-5P  
625461-07-6P 625461-08-7P 625461-09-8P  
625461-10-1P 625461-11-2P 625461-12-3P  
625461-13-4P 625461-14-5P 625461-15-6P  
625461-16-7P 625461-17-8P 625461-18-9P  
625461-19-0P 625461-20-3P 625461-21-4P  
625461-22-5P 625461-23-6P 625461-24-7P  
625461-25-8P 625461-26-9P 625461-27-0P  
625461-28-1P 625461-29-2P 625461-30-5P  
625461-31-6P 625461-32-7P 625461-33-8P  
625461-34-9P 625461-35-0P 625461-36-1P  
625461-37-2P 625461-38-3P 625461-39-4P  
625461-40-7P 625461-41-8P 625461-42-9P  
625461-43-0P 625461-44-1P 625461-45-2P  
625461-46-3P 625461-47-4P 625461-48-5P  
625461-49-6P 625461-50-9P 625461-51-0P  
625461-52-1P 625461-53-2P 625461-54-3P  
625461-55-4P 625461-56-5P 625461-57-6P  
625461-58-7P 625461-59-8P 625461-60-1P  
625461-61-2P 625461-62-3P 625461-64-5P  
625461-65-6P 625461-67-8P 625461-69-0P  
625461-71-4P 625461-72-5P 625461-73-6P  
625461-74-7P 625461-75-8P 625461-76-9P  
625461-77-0P 625461-78-1P 625461-80-5P  
625461-81-6P 625461-82-7P 625461-83-8P  
625461-84-9P 625461-85-0P 625461-88-3P  
625461-89-4P 625461-90-7P 625461-91-8P  
625461-92-9P 625461-93-0P 625461-94-1P  
625461-95-2P 625461-96-3P 625461-97-4P  
625461-98-5P 625461-99-6P 625462-00-2P  
625462-01-3P 625462-02-4P 625462-03-5P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of protein kinase modulators)


RN 438190-84-2 CAPLUS  
CN Pyrazinecarboxylic acid, 3-amino-6-phenyl-, hydrazide (9CI) (CA INDEX NAME)




RN 625459-21-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)



RN 625459-24-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 625459-26-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-28-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(1R)-2,3-dihydro-1H-inden-1-yl]-6-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625459-29-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(1S)-2,3-dihydro-1H-inden-1-yl]-6-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625459-30-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2,3-dihydro-1H-inden-2-yl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-31-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-32-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclopentyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-34-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625459-36-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(cyclopropylmethyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-37-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(tetrahydro-2-furanyl)methyl]-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-38-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-40-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 625459-42-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625459-44-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-45-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-46-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-47-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)




RN 625459-49-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-fluorophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-51-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625459-53-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-ethoxyphenyl)- (9CI) (CA INDEX NAME)




RN 625459-55-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(1,3-benzodioxol-5-yl)- (9CI) (CA INDEX NAME)




RN 625459-57-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(1-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 625459-59-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 625459-60-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(trifluoromethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-62-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(aminocarbonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-64-5 CAPLUS  
CN Pyrazinecarboxamide, 6-[3-(acetylamino)phenyl]-3-amino- (9CI) (CA INDEX NAME)




RN 625459-65-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[1,1'-biphenyl]-4-yl- (9CI) (CA INDEX NAME)




RN 625459-67-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(dimethylamino)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-69-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 625459-71-4 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-(aminocarbonyl)pyrazinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 625459-72-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-74-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 625459-83-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-([1,1'-biphenyl]-3-yl)- (9CI) (CA INDEX NAME)




RN 625459-85-0 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-(aminocarbonyl)pyrazinyl]- (9CI) (CA INDEX NAME)




RN 625459-87-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-89-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-(phenylmethoxy)phenyl]- (9CI) (CA INDEX NAME)




RN 625459-90-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-hydroxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-91-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-methoxyethyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-92-9 CAPLUS  
CN Pyrazinecarboxamide, N-[2-(acetamino)ethyl]-3-amino-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-93-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-hydroxy-6-phenyl- (9CI) (CA INDEX NAME)




RN 625459-94-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-ethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-95-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-aminophenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-96-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-ethoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-97-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 625459-98-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625459-99-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[1,1'-biphenyl]-3-yl-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-00-6 CAPLUS  
CN Pyrazinecarboxamide, 6-[3-(acetamino)phenyl]-3-amino-N-methyl- (9CI) (CA INDEX NAME)



RN 625460-01-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(hydroxymethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-02-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(hydroxymethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-03-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[(1E)-1-(methylimino)ethyl]phenyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.




RN 625460-04-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-methoxyphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-05-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-fluoro-3-methylphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-07-3 CAPLUS  
CN Pyrazinecarboxamide, 6-[4-(acetylamino)phenyl]-3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-08-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[(methylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-09-5 CAPLUS  
CN Pyrazinecarboxamide, 6-[3-acetylphenyl]-3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-20-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(dimethylamino)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-21-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-[(methylsulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-22-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3,5-dimethylphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-23-3 CAPLUS  
CN Pyrazinecarboxamide, 6-(4-acetylphenyl)-3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-24-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3,4-dimethoxyphenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-25-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(benzoylamino)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-26-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[(methylsulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-27-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[(1H-tetrazol-5-yl)phenyl]]- (9CI) (CA INDEX NAME)




RN 625460-28-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(phenylmethyl)amino]carbonyl]phenyl- (9CI) (CA INDEX NAME)




RN 625460-29-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(aminocarbonyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-30-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[dimethylamino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-31-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 625460-32-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-aminophenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 625460-33-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluorophenyl)amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-34-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-35-7 CAPLUS  
CN Pyrazinecarboxamide, 6,6'-[carbonylbis(imino-3,1-phenylene)]bis[3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-36-8 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 625460-37-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[4-methyl-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625460-38-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[2-phenylethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-39-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-40-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-41-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625460-42-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-43-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[methyl(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)







RN 625460-44-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-45-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-methylphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-46-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-47-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-48-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-49-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-methoxybenzoyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625460-50-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxybenzoyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-51-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-52-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-1-(4-methoxyphenyl)ethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625460-53-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-54-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-55-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorobenzoyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-56-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1-(4-fluorophenyl)ethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-57-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-58-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[bis(phenylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-59-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-60-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[ethyl(4-pyridinylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-61-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[1-(phenylmethyl)-1-piperazinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-62-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[1-(phenylmethyl)-4-piperidinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-63-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[4-methylbenzoyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-64-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[3-[[[(5-methylpyrazinyl)methyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-65-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[3-[[[2-pyridinylmethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-66-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[3-[[[3-pyridinylmethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-67-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[3-[[[4-pyridinylmethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-68-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-furanylcarbonyl]amino]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-69-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[3-chlorophenyl]methyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-70-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-methoxyphenyl]ethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-71-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[[3-[[[2-phenylpropyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-72-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-chlorophenyl]methyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-73-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-(2-chlorophenyl)ethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-74-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-(2-methoxyphenyl)ethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-75-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[[3-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]phenyl]-N-methylpyrazine-2-carboxamide] (9CI) (CA INDEX NAME)




RN 625460-76-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(2-thienyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-77-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[cyclohexylamino]carbonyl]phenyl]-N-methyl]- (9CI) (CA INDEX NAME)




RN 625460-78-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]benzoyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625460-79-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-piperidinylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-80-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-(5-phenyl-1,2,4-oxadiazol-3-yl)phenyl]- (9CI) (CA INDEX NAME)




RN 625460-81-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[5-(phenylmethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)



RN 625460-82-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[5-(2-phenylethyl)-1,2,4-oxadiazol-3-yl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-83-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-84-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-85-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-86-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-87-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-88-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-89-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1,1-dimethylethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-90-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R)-1-phenylpropyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-91-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S)-1-phenylpropyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-92-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R,2S)-2-phenylcyclopropyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625460-93-7 CAPLUS  
CN Benzoic acid, 4-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 625460-94-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-95-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-[[[(2-phenylethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625460-96-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625460-97-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-[[[(4-methylphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625460-98-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625460-99-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-00-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(diphenylacetyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-01-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-02-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1-oxo-3-phenylpropyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-03-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625461-04-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625461-05-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3,4,5-trimethoxyphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-06-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S,2R)-2-(phenylmethoxy)cyclopentyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625461-07-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S,2S)-2-(phenylmethoxy)cyclopentyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625461-12-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-naphthalenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-13-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-tetrahydro-2-furanyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-14-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-15-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluoro-5-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-08-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-cyanophenyl)-N-methyl- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-09-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(cyclopentylcarbonyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-10-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-cyanobenzoyl)amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-11-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethyl)amino]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-16-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3,5-dimethoxyphenyl)ethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-17-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-phenylethoxy)phenyl]- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-18-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-methyl-1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-19-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-(4-hydroxyethyl)-1-piperidinyl)ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)]-pyrazinecarboxamide




RN 625461-20-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{2-[(1-hydroxy-1-pyrrolidinyl)ethoxy]phenyl}-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-21-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{2-[(ethyl(phenylmethyl)amino)ethoxy]phenyl}-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-22-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{2-[(diethylamino)ethoxy]phenyl}-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-23-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-{[(1,1'-biphenyl)-2-ylmethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-24-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(4-phenyl-1-piperazinyl)ethoxy]phenyl}- (9CI) (CA INDEX NAME)




RN 625461-25-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{[(1,1'-biphenyl)-4-ylmethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-26-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(methyl(phenylmethyl)amino)ethoxy]phenyl}- (9CI) (CA INDEX NAME)




RN 625461-27-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{[(4-phenoxypheyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-28-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(4-morpholinyl)ethoxy]phenyl}- (9CI) (CA INDEX NAME)




RN 625461-29-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{2-[(cyclopropylmethyl)propylamino]ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-30-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(4-phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-31-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(1-piperidinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-32-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{[(4-phenoxypheyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625461-33-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-{2-[(4-ethyl-1-piperazinyl)ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-34-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(4-phenylmethyl)-1-piperidinyl]ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-35-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-{2-[(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


piperazinyl)ethoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-36-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[2-[4-(2-hydroxyethyl)-1-piperazinyl]ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-37-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[2-[3,4-dihydro-2(1H)-isoquinolinyl]ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-38-3 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[2-[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenoxy]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 625461-39-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(1S)-1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625461-40-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(1R)-1-(phenylmethyl)-3-pyrrolidinyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625461-41-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(2-phenoxyethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-42-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(2-[4-(phenylmethyl)-1-piperazinyl]ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-43-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(1-(phenylmethyl)-4-piperidinyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-44-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(3-furanylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-45-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2,3-dihydro-1,4-benzodioxin-2-yl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-46-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2-furanylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-47-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[(4-(phenylmethyl)-2-morpholinyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625461-48-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-49-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(2,3-dihydro-5-benzofuranylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-50-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[(4H-1,3-benzodioxin-8-yl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-51-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichlorophenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-52-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-dichlorophenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-53-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-(trifluoromethyl)phenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-54-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethylphenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-55-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2-methylphenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-56-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethylphenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-57-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluorophenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-58-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-(methylthio)phenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-59-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-methylpropyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-60-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-(trifluoromethoxy)phenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-61-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(cyclopropylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-62-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(cyclopentylamino)carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-64-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-methylphenyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-65-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-67-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1,3-benzodioxol-5-ylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)







RN 625461-69-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(1,1'-biphenyl)-3-ylmethyl]amino carbonyl phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-71-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(1-methyl-1-phenylethyl)amino]carbonyl phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-72-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(2,4-difluorophenyl)methyl]amino carbonyl phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-73-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-74-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-75-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-76-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-aminophenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-77-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-aminophenyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-78-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-aminophenyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-80-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-(methylsulfonyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-81-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[4-[(2,3-dimethylphenyl)methyl]amino]carbonyl phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-82-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-hydroxyphenyl)-N-methyl- (9CI) (CA INDEX NAME)


INDEX NAME)




RN 625461-83-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(aminosulfonyl)phenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-84-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(dimethylamino)phenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-85-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-bromophenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-88-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dimethylphenyl]methyl]amino]carbonyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-89-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625461-90-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,5-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-91-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,6-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-92-9 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2-chloro-6-phenoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-93-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,5-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-94-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,6-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-95-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2-chloro-6-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-96-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-97-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,2-dimethylpropyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-98-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625461-99-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-00-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-01-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625462-02-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625462-03-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2,4,6-trimethoxyphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




IT 625462-04-6P 625462-08-0P 625462-09-1P  
625462-10-4P 625462-11-5P 625462-13-7P  
625462-15-9P 625462-18-2P 625462-19-3P  
625462-20-6P 625462-21-7P 625462-22-8P  
625462-23-9P 625462-24-0P 625462-25-1P  
625462-26-2P 625462-27-3P 625462-28-4P  
625462-29-5P 625462-30-6P 625462-31-7P  
625462-32-0P 625462-33-1P 625462-34-2P  
625462-35-3P 625462-36-4P 625462-37-5P  
625462-38-6P 625462-39-7P 625462-40-0P  
625462-41-1P 625462-42-2P 625462-43-3P  
625462-44-4P 625462-45-5P 625462-46-6P  
625462-47-7P 625462-48-8P 625462-49-9P  
625462-50-2P 625462-51-3P 625462-52-4P  
625462-53-5P 625462-54-6P 625462-55-7P  
625462-56-8P 625462-57-9P 625462-58-0P  
625462-59-1P 625462-60-4P 625462-61-5P  
625462-62-6P 625462-63-7P 625462-64-8P  
625462-65-9P 625462-66-0P 625462-67-1P  
625462-68-2P 625462-69-3P 625462-70-6P  
625462-71-7P 625462-72-8P 625462-73-9P  
625462-74-0P 625462-75-1P 625462-76-2P  
625462-77-3P 625462-78-4P 625462-79-5P  
625462-80-6P 625462-81-7P 625462-82-0P  
625462-83-1P 625462-84-2P 625462-85-3P  
625462-86-4P 625462-87-5P 625462-88-6P  
625462-89-7P 625462-90-0P 625462-91-1P  
625462-92-2P 625462-93-3P 625462-95-5P  
625462-96-6P 625462-97-7P 625462-98-8P  
625462-99-9P 625463-00-5P 625463-01-6P  
625463-02-7P 625463-03-8P 625463-04-9P  
625463-05-0P 625463-07-2P 625463-09-4P  
625463-10-7P 625463-11-8P 625463-12-9P  
625463-13-0P 625463-14-1P 625463-15-2P  
625463-16-3P 625463-17-4P 625463-18-5P  
625463-19-6P 625463-20-9P 625463-21-0P  
625463-22-1P 625463-23-2P 625463-24-3P  
625463-25-4P 625463-26-5P 625463-27-6P  
625463-28-7P 625463-29-8P 625463-30-1P  
625463-31-2P 625463-32-3P 625463-33-4P  
625463-34-5P 625463-35-6P 625463-36-7P  
625463-37-8P 625463-38-9P 625463-39-0P  
625463-40-3P 625463-41-4P 625463-42-5P  
625463-45-8P 625463-46-9P 625463-47-0P  
625463-48-1P 625463-49-2P 625463-50-5P  
625463-51-6P 625463-52-7P 625463-53-8P  
625463-55-0P 625463-56-1P 625463-57-2P  
625463-58-3P 625463-59-4P 625463-60-7P


625463-61-8P 625463-62-9P 625463-63-0P  
625463-64-1P 625463-65-2P 625463-66-3P  
625463-67-4P 625463-68-5P 625463-69-6P  
625463-70-9P 625463-71-0P 625463-72-1P  
625463-73-2P 625463-74-3P 625463-75-4P  
625463-76-5P 625463-77-6P 625463-78-7P  
625463-79-8P 625463-80-1P 625463-81-2P  
625463-82-3P 625463-83-4P 625463-84-5P  
625463-85-6P 625463-86-7P 625463-87-8P  
625463-88-9P 625463-89-0P 625463-90-3P  
625463-91-4P 625463-92-5P 625463-93-6P  
625463-94-7P 625463-95-8P 625463-96-9P  
625463-97-0P 625463-98-1P 625463-99-2P  
625464-00-8P 625464-01-9P 625464-02-0P  
625464-03-1P 625464-04-2P 625464-05-3P  
625464-06-4P 625464-07-5P 625464-08-6P  
625464-09-7P 625464-10-0P 625464-11-1P  
625464-12-2P 625464-13-3P 625464-14-4P  
625464-15-5P 625464-16-6P 625464-17-7P  
625464-19-9P 625464-20-2P 625464-24-6P  
625464-25-7P 625464-26-8P 625464-27-9P  
625464-28-0P 625464-29-1P 625464-30-4P  
625464-31-5P 625464-32-6P 625464-33-7P  
625464-34-8P 625464-35-9P 625464-36-0P  
625464-37-1P 625464-38-2P 625464-39-3P  
625464-40-6P 625464-41-7P 625464-42-8P  
625464-43-9P 625464-44-0P 625464-45-1P  
625464-47-3P 625464-48-4P 625464-49-5P  
625464-50-8P 625464-51-9P 625464-52-0P  
625464-53-1P 625464-54-2P 625464-56-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USSS (Uses)


(preparation of protein kinase modulators)  
RN 625462-04-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-methylphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-08-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromo-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-09-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625462-10-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-bis(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-11-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,2-diphenylethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-13-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethyl)amino]sulfonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


phenyl]- (9CI) (CA INDEX NAME)




RN 625462-15-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(1H-indol-5-yl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-18-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-19-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-cyclopropyl- (9CI) (CA INDEX NAME)




RN 625462-20-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-[3-[[[phenylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-21-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-6-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-ethyl- (9CI) (CA INDEX NAME)




RN 625462-22-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dichlorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-23-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-2-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-24-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,5-dichlorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-25-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[cyclopropylamino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-26-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dichlorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-27-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4'-fluoro[1,1'-biphenyl]-2-yl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-28-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2,3,4-trifluorophenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-29-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-chloro-2,6-difluorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-30-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[9H-fluoren-9-ylamino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-31-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-methylphenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-32-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dimethylphenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-33-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-fluoro-2-methylphenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-34-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-35-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-36-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methyl-1-piperazinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-37-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-fluoro-3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-38-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2,4,6-trichlorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-39-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-40-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-41-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-42-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-43-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-3,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-44-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-45-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-46-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-47-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(6-chloro-2-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-48-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-iodophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-49-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-50-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-51-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-bromophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-52-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2,3,6-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-53-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(benzoylamino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-54-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorobenzoyl)amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-55-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-difluorobenzoyl)amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-56-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-naphthalenylcarbonyl)amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-57-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethyl)thio]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625462-58-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethyl)sulfonyl]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-59-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethoxy)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-60-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(phenylmethyl)amino]methyl]ph


enyl]- (9CI) (CA INDEX NAME)




RN 625462-61-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-62-6 CAPLUS  
CN Carbamic acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 625462-63-7 CAPLUS  
CN Carbamic acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 625462-64-8 CAPLUS  
CN Carbamic acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 625462-65-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3,4-dichlorobenzoyl)amino]methylphenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-66-0 CAPLUS  
CN Carbamic acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625462-67-1 CAPLUS  
CN Carbamic acid, [3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]-, (1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625462-68-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[4-(4-hydroxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-69-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[3-[[[2-(4-morpholinyl)ethoxy]phenyl]methyl]amino]carbonyl]phenyl- (9CI) (CA INDEX NAME)




RN 625462-70-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[2-methoxyphenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-71-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[3-(4-hydroxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-72-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[2-(4-hydroxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-73-9 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-phenylhydrazide (9CI) (CA INDEX NAME)




RN 625462-74-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-hydroxyethyl)-6-[(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 625462-75-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[3-[[[phenylacetyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-76-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[4-(4-chlorophenyl)acetyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-77-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1,1'-biphenyl]-4-yl]carbonyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-78-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[2-chloro-5-(trifluoromethyl)benzoyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-79-5 CAPLUS  
CN 1H-Indole-2-carboxamide, N-[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 625462-80-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-hydroxy-2-pyridinyl)carbonyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-81-9 CAPLUS  
CN 1H-Indole-3-acetamide, N-[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 625462-82-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-83-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-84-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625462-85-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-iodophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-86-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-87-5 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-[2-(4-morpholinyl)ethoxy]phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625462-88-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-[2-(4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-89-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-[2-(4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-90-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-[2-(4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-91-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(3-[2-(4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-92-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-[2-(4-morpholinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625462-93-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-methoxy-3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-95-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-iodobenzoyl)amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-96-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-pentylbenzoyl)amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)







RN 625462-97-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,3-benzodioxol-5-yl]carbonyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-98-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625462-99-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1-(5-(trifluoromethyl)-2-pyrimidinyl)-4-piperidinyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625463-00-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(1-piperidinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-01-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(methylthio)phenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-02-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]benzoyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-03-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(3-pyrrolidinylamino)carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-04-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(1-(4-chlorophenyl)-3-pyrrolidinylamino)carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-05-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(1-(2,4-dichlorophenyl)methyl)-3-pyrrolidinylamino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-07-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(1-(2,6-dichlorophenyl)methyl)-3-pyrrolidinylamino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-09-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]benzoyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625463-10-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 2-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]benzoyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625463-11-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-(3-pyrrolidinylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-12-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-pyrrolidinylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-13-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-fluoro-5-[[[phenylmethyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-14-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4H-1,3-benzodioxin-5-ylacetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-15-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-4-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-16-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dimethoxyphenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-17-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[phenylmethyl]amino]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-18-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(1-methylethyl)benzoyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-19-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-20-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(1,1-dimethylethyl)benzoyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-21-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(1,1-dimethylethyl)benzoyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-22-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625463-23-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-24-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-amino-6-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-25-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-4-yl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


ylmethyl)amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-26-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-2-ylmethyl)amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-27-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-3-ylmethyl)amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-28-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1-(phenylmethyl)-2-pyrrolidinyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-29-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dihydro-2H-1,4-benzoxazin-6-yl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-30-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-difluorophenyl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625463-31-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,5-difluorophenyl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-32-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-difluorophenyl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-33-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(4-pyridinyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-34-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(3-pyridinyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-35-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(methylsulfonyl)phenyl)methyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-36-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,2-diphenylethyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-37-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1-(phenylmethyl)-3-pyrrolidinyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-38-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3-phenoxyphenyl)methyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-39-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-aminophenyl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-40-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-phenoxyphenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-41-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-dimethoxyphenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-42-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-fluorophenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-45-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-46-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625463-47-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-(1-piperidinyl)phenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-48-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluoro-2-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-49-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(6-(trifluoromethyl)-3-pyridinyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




(9CI) (CA INDEX NAME)




RN 625463-55-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-phenylamino)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)





RN 625463-56-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-ethylphenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-57-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(4-(3-pyridinyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-58-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1H-inden-2-yl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-50-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1H-benzimidazol-2-yl)phenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-51-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dichlorophenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-52-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dichlorophenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-53-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2-phenylethyl)amino]phenyl]- (9CI) (CA INDEX NAME)






RN 625463-59-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(1,3-dihydro-2H-indol-2-yl)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-60-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-61-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-66-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625463-67-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-propylphenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-68-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(1-chloro-2-fluorophenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-69-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3-

RN 625463-62-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3,4,5-trifluorophenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-63-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1R]-1-phenylethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-64-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R,2S]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-65-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(2-thienyl)phenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-70-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1S]-1-phenylethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-71-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R]-2-hydroxy-1-phenylethyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-72-1 CAPLUS  
CN Benzenecetic acid, α-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]amino]-, ethyl ester, (aS)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-73-2 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-(2,5-difluorophenyl)hydrazide (9CI) (CA INDEX NAME)



RN 625463-74-3 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-(2,3,5,6-tetrafluoro-4-methylphenyl)hydrazide (9CI) (CA INDEX NAME)




RN 625463-75-4 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-(2-fluorophenyl)hydrazide (9CI) (CA INDEX NAME)




RN 625463-76-5 CAPLUS


CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-(2,4-difluorophenyl)hydrazide (9CI) (CA INDEX NAME)



RN 625463-77-6 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, 2-(2,3,5,6-tetrafluorophenyl)hydrazide (9CI) (CA INDEX NAME)




RN 625463-78-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(5-methylpyrazinyl)methyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-79-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-80-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S)-1-(phenylmethyl)-3-pyrrolidinyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-81-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R)-1-(phenylmethyl)-3-pyrrolidinyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-82-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[ethyl(phenylmethyl)amino)methyl]phenyl]-N-methyl]- (9CI) (CA INDEX NAME)




RN 625463-83-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S,2S)-2-phenylcyclopropyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-84-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-(4-phenyl-1H-imidazol-2-yl)phenyl]- (9CI) (CA INDEX NAME)



RN 625463-85-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(5-bromo-2-propylphenyl)methyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-86-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-bromo-2-fluorophenyl)methyl]amino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-87-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2R]-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-88-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1-methyl-1-phenylethyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-89-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(9H-fluoren-9-ylamino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-90-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[1-naphthalenylamino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-91-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3'-fluoro[1,1'-biphenyl]-4-yl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-92-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-4-(3-thienyl)phenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625463-93-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-4-(2-furanyl)phenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-94-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-naphthalenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625463-95-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,2,3,4-tetrahydro-2-naphthalenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625463-96-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2S]-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625463-97-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4,7-difluoro-2,3-dihydro-1H-inden-1-yl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-98-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-bromo-2,3-dihydro-1H-inden-1-yl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625463-99-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-5-(3-thienyl)phenyl)methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-00-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-ethenyl-2-fluorophenyl]methyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-01-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4,7-difluoro-2,3-dihydro-3-methyl-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-02-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,6,2R]-2,3-dihydro-2-methoxy-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625464-03-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2R]-6-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-04-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2R]-6-bromo-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-05-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-06-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2S]-5-bromo-2,3-dihydro-1H-inden-2-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625464-07-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2,3-dihydro-1H-inden-2-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-08-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2,3-dihydro-1-hydroxy-1H-inden-2-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-09-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R,2S]-2,3-dihydro-2-methoxy-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625464-10-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[6-bromo-4-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-11-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-3-oxo-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-12-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-(2-furanyl)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-13-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)







RN 625464-14-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4,6-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-15-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[6-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-16-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5,6-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-17-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-chloro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-19-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-(2-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-20-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-24-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-(3-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-25-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,8-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-26-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,5,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625464-27-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[7-bromo-4-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-28-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[6-chloro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-29-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4,6-dichloro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-30-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-31-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,8-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-32-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-33-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-5-(2-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625464-34-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-phenyl-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-35-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-bromo-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-36-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-4-phenyl-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-37-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-6-(2-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-38-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-6-(2-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-39-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-(4-methyl-2-thienyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-40-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2R)-1,2,3,4-tetrahydro-6-phenyl-2-naphthalenyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-41-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-(2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 625464-42-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1S,2S)-2-(phenylmethoxy)cyclopentyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625464-43-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(cyclopentylamino)methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-44-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[6-bromo-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-45-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[7-fluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-47-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(1H-imidazol-1-ylmethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-48-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-[2-(4-morpholinyl)ethoxy]-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-49-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(1R,2R)-2-(phenylmethoxy)cyclopentyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625464-50-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-3-benzofuran-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-51-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[5-(cyanomethoxy)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-52-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-5-(4-methylphenyl)-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-53-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2-(dimethylamino)-1-phenylethyl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-54-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-5-(1H-1,2,4-triazol-1-yl)-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)



RN 625464-56-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-5-hydroxy-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




IT 625464-58-6P 625464-60-0P 625464-61-1P  
625464-62-2P 625464-63-3P 625464-70-2P  
625464-71-3P 625464-72-4P 625464-75-7P  
625464-77-9P 625464-78-0P 625464-79-1P  
625464-82-6P 625464-83-7P 625464-84-8P  
625464-85-9P 625464-86-0P 625464-87-1P  
625464-88-2P 625464-89-3P 625464-90-6P  
625464-92-8P 625464-93-9P 625464-98-4P  
625465-01-2P 625465-03-4P 625465-04-5P  
625465-06-7P 625465-07-8P 625465-08-9P  
625465-09-0P 625465-10-3P 625465-17-0P  
625465-21-6P 625465-22-7P 625465-30-7P  
625465-31-8P 625465-39-6P 625465-42-1P  
625465-43-2P 625465-56-7P 625465-57-8P  
625465-58-9P 625465-59-0P 625465-61-4P  
625465-62-5P 625465-89-6P 625465-90-9P  
625465-91-0P 625465-92-1P 625465-93-2P  
625465-94-3P 625465-95-4P 625465-96-5P  
625465-97-6P 625465-98-7P 625465-99-8P  
625466-00-4P 625466-03-7P 625466-04-8P  
625466-05-9P 625466-06-0P 625466-07-1P  
625466-08-2P 625466-09-3P 625466-10-6P  
625466-11-7P 625466-12-8P 625466-29-7P


625466-30-0P 625466-31-1P 625466-32-2P  
625466-33-3P 625466-34-4P 625466-35-5P  
625466-36-6P 625466-37-7P 625466-41-3P  
625466-42-4P 625466-45-7P 625466-51-5P  
625466-51-7P 625466-54-8P 625466-55-9P  
625466-56-0P 625466-57-1P 625466-58-2P  
625466-59-3P 625466-60-6P 625466-61-7P  
625466-62-8P 625466-71-9P 625466-72-0P  
625466-73-1P 625466-74-2P 625466-75-3P  
625466-82-2P 625466-83-3P 625466-84-4P  
625466-85-5P 625466-86-6P 625466-87-7P  
625466-88-8P 625466-89-9P 625466-92-4P  
625466-93-5P 625466-94-6P 625466-95-7P  
625466-98-0P 625466-99-1P 625467-00-7P  
625467-01-8P 625467-02-9P 625467-03-0P  
625467-04-1P 625467-05-2P 625467-06-3P  
625467-07-4P 625467-08-5P 625467-09-6P  
625467-10-9P 625467-11-0P 625467-12-1P  
625467-14-3P 625467-18-7P 625467-19-8P  
625467-20-1P 625467-21-2P 625467-22-3P  
625467-23-4P 625467-24-5P 625467-25-6P  
625467-26-7P 625467-27-8P 625467-28-9P  
625467-29-0P 625467-30-3P 625467-31-4P  
625467-32-5P 625467-35-8P 625467-36-9P  
625467-37-0P 625467-40-6P 625467-41-6P  
625467-42-7P 625467-43-8P 625467-44-9P  
625467-45-0P 625467-46-1P 625467-47-2P  
625467-48-3P 625467-50-7P 625467-51-8P  
625467-52-9P 625467-54-1P 625467-55-2P  
625467-56-3P 625467-57-4P 625467-59-6P  
625467-62-1P 625467-63-2P 625467-65-4P  
625467-66-5P 625467-71-2P 625467-72-3P  
625467-73-4P 625467-79-0P 625467-80-3P  
625467-81-4P 625467-82-5P 625467-83-6P  
625467-84-7P 625467-85-8P 625467-86-9P  
625467-87-0P 625467-88-1P 625467-89-2P  
625467-90-3P 625467-91-6P 625467-92-7P  
625467-93-8P 625467-94-9P 625467-95-0P  
625467-96-1P 625467-97-2P 625467-98-3P  
625467-99-4P 625468-00-0P 625468-01-1P  
625468-02-2P 625468-03-3P 625468-04-4P  
625468-06-6P 625468-07-7P 625468-08-8P  
625468-09-9P 625468-10-2P 625468-11-3P  
625468-12-4P 625468-13-5P 625468-14-6P  
625468-15-7P 625468-16-8P 625468-17-9P  
625468-18-0P 625468-19-1P 625468-20-4P  
625468-21-5P 625468-22-6P 625468-23-7P  
625468-24-8P 625468-25-9P 625468-26-0P  
625468-27-1P 625468-28-2P 625468-29-3P  
625468-30-6P 625468-31-7P 625468-32-8P  
625468-33-9P 625468-34-0P 625468-37-3P  
625468-38-4P 625468-39-5P 625468-40-8P  
625468-41-9P 625468-42-0P 625468-43-1P  
625468-44-2P 625468-45-3P 625468-46-4P  
625468-47-5P 625468-48-6P 625468-49-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of protein kinase modulators)  
RN 625464-58-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-4-(2-(4-morpholinyl)ethoxy)-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-60-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,3-dihydro-4-hydroxy-1H-inden-1-yl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-61-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[1-[(phenylmethyl)amino]-7-isoquinolinyl]- (9CI) (CA INDEX NAME)



RN 625464-62-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[2-(4-morpholinyl)-1-phenylethyl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)




RN 625464-63-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[[3-[[[1-phenyl-2-(1-pyrrolidinyl)ethyl]amino]methyl]phenyl]-1- (9CI) (CA INDEX NAME)




RN 625464-70-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[1-[[[2,3-dihydro-1H-inden-1-yl]amino]-7-isoquinolinyl]-N-methyl]-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-71-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[1-[[[2,3-dihydro-1H-inden-1-yl]amino]-2,3-dihydro-1H-inden-5-yl]-N-methyl]-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-72-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[2,3-dihydro-6-(3-hydroxypropyl)-1H-inden-1-yl]amino]methyl]phenyl]-N-methyl]-1- (9CI) (CA INDEX NAME)




RN 625464-75-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-1- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625464-77-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-naphthalenylmethyl)-1- (9CI) (CA INDEX NAME)




RN 625464-78-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclohexyl-6-[[3-[[[2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-1- (9CI) (CA INDEX NAME)




RN 625464-79-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(4-pyridinylmethyl)-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-82-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2,2,2-trifluoroethyl)-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-83-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(5-hydroxypentyl)-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-84-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(4-hydroxybutyl)-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-85-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-(1-pyrrolidinyl)ethyl)-1- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-86-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[2-(1-piperidinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-87-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[2-(4-morpholinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-88-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(cyclopropylmethyl)-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-89-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-90-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-92-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-hydroxyethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-93-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-cyclopropyl-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625464-98-4 CAPLUS  
CN Pyrazinecarboxylic acid, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-, 2-methylhydrazide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-01-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[2-(dimethylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-03-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[2-(1H-imidazol-1-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-04-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-06-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(3-hydroxypropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625465-07-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[3-amino-6-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625465-08-9 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[3-amino-6-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625465-09-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-(4-piperidinyl)- (9CI) (CA INDEX NAME)




RN 625465-10-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-(4-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 625465-17-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-(hydroxymethyl)phenyl]-N-[(2-phenylhydrazino)carbonyl]- (9CI) (CA INDEX NAME)



RN 625465-21-6 CAPLUS  
CN Glycine, N-[[3-amino-6-[[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 625465-22-7 CAPLUS  
CN Glycine, N-[[3-amino-6-[[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 625465-30-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-31-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[[3-(1H-imidazol-1-yl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-39-6 CAPLUS  
CN L-Glutamic acid, N-[[3-amino-6-[[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-42-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[[3-(methylamino)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-43-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-[[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-56-7 CAPLUS  
CN L-Tyrosine, N-[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-57-8 CAPLUS  
CN L-Tyrosine, N-[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-58-9 CAPLUS  
CN Carbamic acid, [3-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]amino]carbonyl]phenyl]-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


razinyl]carbonyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625465-59-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3-aminopropyl)-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625465-61-4 CAPLUS  
CN Carbamic acid, [2-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]amino]carbonyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 625465-62-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-aminoethyl)-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625465-89-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-90-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3R)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625465-91-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-(2-furanylcarbonyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625465-92-1 CAPLUS  
CN Pyrazinecarboxamide, N-[3-(acetamido)propyl]-3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625465-93-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-[[[2-furanylcarbonyl]amino]propyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625465-94-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-(4-pyridinylcarbonyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625465-95-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[[4-pyridinyl]carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 625465-96-5 CAPLUS  
CN 2-Quinoxalinecarboxamide, N-[3-[[[(3-amino-6-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 625465-97-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[[6-(trifluoromethyl)-3-pyridinyl]carbonyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 625465-98-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[[8-quinolinylsulfonyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 625465-99-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[[2-pyridinylsulfonyl]amino]propyl]- (9CI) (CA INDEX NAME)




RN 625466-00-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-[3-[[[(3,5-dimethyl-4-isoxazolyl)amino]carbonyl]amino]propyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625466-03-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[[2-[[4-pyridinyl]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)




RN 625466-04-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-[[2-furenyl]carbonyl]amino]ethyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625466-05-9 CAPLUS  
CN Pyrazinecarboxamide, N,N'-1,2-cyclohexanediylbis[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 625466-06-0 CAPLUS  
CN Pyrazinecarboxamide, N-[2-[[acetyl]amino]ethyl]-3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)






RN 625466-07-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[2-[(8-quinolinylsulfonyl)amino]ethyl]]- (9CI) (CA INDEX NAME)




RN 625466-08-2 CAPLUS  
CN 2-Quinoxalinecarboxamide, N-[2-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]ethyl]]- (9CI) (CA INDEX NAME)




RN 625466-09-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-[[[(2-chloro-3-

pyridinyl)carbonyl]amino]ethyl]]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]]- (9CI) (CA INDEX NAME)




RN 625466-10-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[2-[(2-pyridinylcarbonyl)amino]ethyl]]- (9CI) (CA INDEX NAME)




RN 625466-11-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-[[[3,5-dimethyl-4-isoxazolyl]amino]carbonyl]amino]ethyl]]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 625466-12-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-[2-[(2-pyridinylcarbonyl)amino]ethyl]]- (9CI) (CA INDEX NAME)




RN 625466-29-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-[[[4-(dimethylamino)phenyl]amino]propyl]]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]]- (9CI) (CA INDEX NAME)




RN 625466-30-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]]-N-[3S]-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-31-1 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[(1S)-3-[[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-1-pyrrolidinyl]]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-32-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-  
[(3S)-1-(4-piperidinyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-33-3 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 2-[[[(3S)-3-[[[(3-amino-6-[3-  
[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-1-  
pyrrolidinyl)methyl]-, 1,1-dimethylethyl ester, (2R)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 625466-34-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-  
[(3S)-1-[(2R)-2-pyrrolidinylmethyl]-3-pyrrolidinyl]- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 625466-35-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(3S)-1-(4-(dimethylamino)phenyl)methyl]-3-  
pyrrolidinyl-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA  
INDEX NAME)


Absolute stereochemistry.



RN 625466-36-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[2-[[[(4-(dimethylamino)phenyl)amino]carbonyl]amino]ethyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA  
INDEX NAME)




RN 625466-37-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-[[[(4-(dimethylamino)phenyl)amino]carbonyl]amino]-3-  
oxopropyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX  
NAME)




RN 625466-41-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-  
[(3S)-1-(2-pyridinylmethyl)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-42-4 CAPLUS  
CN L-Threonine, N-[[3-amino-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-45-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(3S)-1-ethyl-3-pyrrolidinyl]-6-[3-[[[(phenylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-51-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-ethyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-53-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-54-8 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-55-9 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R)-1-phenylethyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-56-8 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(3,4-dihydro-2(1H)-isoquinolinyl]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-57-1 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2-phenylethyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-58-2 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-1-phenylethyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-59-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R]-1-phenylethyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-60-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2R]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-61-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-1-phenylethyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-62-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-71-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R,2S]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-72-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R,2S]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(1-ethyl-3-pyrrolidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-73-1 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-74-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-75-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(1-ethyl-3-piperidinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-82-2 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-83-3 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-84-4 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[2-chloro-6-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-85-5 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[4-(4-methylthio)phenyl]methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-86-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-87-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[4-(4-methoxyphenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-88-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-6-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-89-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-methylthio)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625466-92-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S]-1-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]ethyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-93-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-94-6 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-95-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3R)-3-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625466-98-0 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625466-99-1 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2-pyridinylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-00-7 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(3-pyridinylmethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-01-8 CAPLUS

CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(3,4-dihydro-2H-1-benzopyran-4-yl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-02-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-03-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-pyridinylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625467-04-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-pyridinylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-05-2 CAPLUS  
CN 1,3-Benzenedicarboxylic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazine-1-yl]-, dimethyl ester (9CI) (CA INDEX NAME)




RN 625467-06-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-07-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3R)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-08-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-09-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[2-(1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-10-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-11-0 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-12-1 CAPLUS  
CN 1H-Azepine-1-carboxylic acid, 4-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-14-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-4-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-18-7 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-19-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-20-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dihydro-2H-1-benzopyran-4-yl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-21-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-3-benzofuranyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA  
INDEX NAME)

**Absolute stereochemistry.**




RN 625467-22-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3R)-3-pyrrolidinylmethyl]- (9CI)  
(CA INDEX NAME)

**Absolute stereochemistry.**




RN 625467-23-4 CAPLUS  
CN 1H-Azepine-1-carboxylic acid, 4-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]hexahydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 625467-24-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1R,2S]-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 625467-25-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazol-2-yl]phenyl]-N-(hexahydro-1H-azepin-4-yl)- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




RN 625467-26-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[1S]-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-27-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-3-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 625467-28-9 CAPLUS  
 CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 625467-29-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-5-fluorophenyl]-N-methyl- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




RN 625467-30-3 CAPLUS  
CN 1,3-Benzenedicarboxylic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyraziny  
1]-, monomethyl ester (9CI) (CA INDEX NAME)



RN 625467-31-4 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-5-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**



RN 625467-32-5 CAPLUS  
CN 1,3-Benzenedicarboxamide, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-N-  
[(1S)-2,3-dihydro-1H-inden-1-yl]-N'-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


**Absolute stereochemistry.**






RN 625467-35-8 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-36-9 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-37-0 CAPLUS  
CN 1,3-Benzenedicarboxamide, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-N-


[[[(1R)-2,3-dihydro-1H-inden-1-yl]-N'-(3R)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-40-5 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1-methyl-1-phenylethyl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-41-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1-methyl-1-phenylethyl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-42-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-43-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]-N-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-44-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-45-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-methyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-46-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]methyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-47-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-48-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-50-7 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-51-8 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]-pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2,3,6-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-56-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2,3,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-57-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-52-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]sulfonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-54-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-pyrrolidinyl-6-[3-[[[(2,4,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-55-2 CAPLUS




RN 625467-59-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-1-azabicyclo[2.2.2]oct-3-yl-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-62-1 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-63-2 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-65-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-66-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-71-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-72-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-73-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[1,1-dimethylethoxy]carbonyl]amino]methyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-79-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(aminomethyl)phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-80-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(hydroxyphenyl)-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-81-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(aminomethyl)phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-82-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-83-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-84-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-4-ylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-85-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(1,2,3-thiadiazol-5-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625467-86-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625467-87-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-2-ylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


ylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-88-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-difluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-89-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-90-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-fluoro-3-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-91-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(naphthalenylmethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-92-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(dimethylamino)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-93-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-5-yl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-94-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2-thienyl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-95-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-96-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-97-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-98-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625467-99-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methylsulfonyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-00-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-01-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-02-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-03-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-04-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(methylthio)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-06-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,2-diphenylethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-07-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,4-difluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-08-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,5-difluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-09-9 CAPLUS  
CN Benzoic acid, 4-[[[3-[5-amino-6-[[[3S]-3-piperidinylamino]carbonyl]pyrazinyl]benzoyl]amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-10-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-bromophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-11-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-bromo-2-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-12-4 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-bromophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-13-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluoro-2-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-14-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-15-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3R)-3-pyrrolidinylmethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-16-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3R)-3-pyrrolidinylamino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-17-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-18-0 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-phenylethyl)amino]carbonyl]phenyl]-


N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-19-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methoxyethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-20-4 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-iodophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-21-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-22-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluorobenzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-23-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)benzoyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-24-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorobenzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-25-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-26-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,6-dichlorophenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-27-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[pentafluorophenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-28-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-4-(fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-29-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(methylthio)phenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-30-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-dichlorophenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-31-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-chlorophenyl)-2-thienyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-32-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-bromobenzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-33-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-naphthalenylcarbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-34-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(4-phenyl-1-piperazinyl)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-37-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-difluorophenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 625468-38-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[2-(2-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-39-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[5-(2-chloro-5-(trifluoromethyl)phenyl)-2-furanyl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-40-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-((dimethylamino)-1-naphthalenyl)carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-41-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[4-((1,2,3-thiadiazol-5-yl)benzoyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-42-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[1,3-dimethyl-1H-pyrazol-5-yl]carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-43-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-((dimethylamino)benzoyl)amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-44-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(2-hydroxyethoxy)phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-45-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-benzofuranyl]sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-46-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,3,4-dihydro-2H-1,5-benzodioxepin-7-yl]sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-47-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-48-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-4-ylamino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-49-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-bromo-2-fluorophenyl)amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 625468-50-0P 625468-51-1P 625468-52-2P  
625468-53-3P 625468-54-4P 625468-55-5P  
625468-56-6P 625468-57-7P 625468-58-8P  
625468-59-9P 625468-60-2P 625468-61-3P  
625468-62-4P 625468-64-6P 625468-65-7P  
625468-66-8P 625468-67-9P 625468-68-0P  
625468-69-1P 625468-70-4P 625468-71-5P  
625468-72-6P 625468-73-7P 625468-74-8P  
625468-75-9P 625468-76-0P 625468-77-1P  
625468-78-2P 625468-86-2P 625468-87-3P  
625468-88-4P 625468-89-5P 625468-90-8P  
625468-91-9P 625468-92-0P 625468-93-1P  
625468-94-2P 625468-95-3P 625468-96-4P  
625468-97-5P 625468-98-6P 625468-99-7P  
625469-00-3P 625469-01-4P 625469-02-5P  
625469-03-6P 625469-04-7P 625469-05-8P  
625469-06-9P 625469-07-0P 625469-08-1P  
625469-09-2P 625469-10-5P 625469-11-6P  
625469-12-7P 625469-13-8P 625469-14-9P  
625469-15-0P 625469-16-1P 625469-17-2P  
625469-18-3P 625469-19-4P 625469-20-7P  
625469-21-8P 625469-22-9P 625469-23-0P  
625469-24-1P 625469-25-2P 625469-26-3P  
625469-27-4P 625469-28-5P 625469-29-6P  
625469-30-9P 625469-31-0P 625469-32-1P


625469-33-2P 625469-34-3P 625469-35-4P  
625469-36-5P 625469-37-6P 625469-38-7P  
625469-39-8P 625469-40-1P 625469-41-2P  
625469-42-3P 625469-43-4P 625469-44-5P  
625469-45-6P 625469-46-7P 625469-47-8P  
625469-48-9P 625469-49-0P 625469-50-3P  
625469-51-4P 625469-52-5P 625469-53-6P  
625469-54-7P 625469-55-8P 625469-56-9P  
625469-57-0P 625469-58-1P 625469-59-2P  
625469-60-5P 625469-61-6P 625469-62-7P  
625469-63-8P 625469-64-9P 625469-65-0P  
625469-66-1P 625469-67-2P 625469-68-3P  
625469-69-4P 625469-70-7P 625469-71-8P  
625469-72-9P 625469-73-0P 625469-74-1P  
625469-75-2P 625469-76-3P 625469-77-4P  
625469-78-5P 625469-79-6P 625469-80-9P  
625469-81-0P 625469-82-1P 625469-83-2P  
625469-84-3P 625469-85-4P 625469-86-5P  
625469-87-6P 625469-88-7P 625469-89-8P  
625469-90-1P 625469-91-2P 625470-04-4P  
625470-05-5P 625470-07-7P 625470-08-8P  
625470-09-9P 625470-10-2P 625470-11-3P  
625470-12-4P 625470-13-5P 625470-14-6P  
625470-16-8P 625470-17-9P 625470-18-0P  
625470-19-1P 625470-20-4P 625470-21-5P  
625470-22-6P 625471-65-0P 625471-70-7P  
625471-71-8P 625471-72-9P 625471-85-4P  
625471-86-5P 625471-88-7P 625478-21-9P  
625515-65-3P 625518-57-6P 625596-74-9P  
625605-58-5P 625614-94-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)

(preparation of protein kinase modulators)


RN 625468-50-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[(3-quinolinylamino)carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-51-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[6-methoxy-3-benzofuranyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-52-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-yl]carbonyl]amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-53-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,5-bis(trifluoromethyl)phenyl]acetyl]amino]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-54-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-difluorophenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-55-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethyl)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-56-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-57-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-58-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethyl)phenyl]sulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-59-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-60-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(methylthio)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-61-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-bromo-5-methylphenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-62-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-bromophenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-64-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-methyl-1-piperazinyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-65-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(4-fluorophenyl)ethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-66-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(4-morpholinylethyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-67-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(2-pyrrolidinylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-68-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-(2-pyrrolidinylmethyl)amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-69-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(cyclopentylamino)carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-70-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-71-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-72-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-methoxybenzoyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-73-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,1'-biphenyl]-4-yl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-74-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-furanylcarbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-75-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-1,4-benzodioxin-6-yl]sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-76-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-5-benzofuranyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-77-1 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-1,4-benzodioxin-6-yl]sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-78-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dihydro-1,4-benzodioxin-2-yl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-86-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-(hexahydro-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-87-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


thiazolylcarbonyl)amino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-88-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[5-(2-thienyl)-1-pyridinyl]carbonyl]amino)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-89-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(1,1-dimethylethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625468-90-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,4-dichloro-6-(4-tert-butylphenyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-91-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3,5-dichlorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-92-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2-chienylsulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-96-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-methoxyphenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625468-97-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-fluorophenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-98-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-(dimethylamino)ethoxy]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 625468-93-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[3-thienylsulfonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-94-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chlorophenyl]sulfonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-95-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[1,3-benzodioxol-5-ylamino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625468-99-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[4-(2-methoxyethyl)oxy]phenyl}-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-00-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-methoxyphenyl)-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-01-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-ethoxyphenyl)-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-02-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(3S)-3-piperidinyl]-6-[[[4-[(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-03-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[2-(ethylamino)ethoxy]phenyl}-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-04-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[2-[3-{[5-amino-6-[(3S)-3-piperidinylamino]carbonyl]pyrazinyl]phenoxy]ethyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-05-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[4-[(dimethylamino)phenyl]amino]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-06-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[1-(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-07-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[1-(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1-(phenylmethyl)-1H-


azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-08-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[1-(1S,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-09-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-{[4-(chlorophenyl)amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-10-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1-(phenylmethyl)-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-11-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-12-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-1H-azepin-3-yl]-6-(3-methylphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-13-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methylphenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-14-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[3-(trifluoromethyl)phenyl]acetyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-15-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-methoxyphenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-16-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(6-methyl-3-pyridinyl)carbonyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-17-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-18-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[3-pyridinylacetyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-19-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[3-pyridinylacetyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-20-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-difluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-21-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(2-fluorophenyl)acetyl]amino]phenyl]-N-(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-22-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-23-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-(4-nitrophenyl)-2-furanyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-24-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-hydroxy-2-pyridinyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-25-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[4-(trifluoromethoxy)phenoxy]acetyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-26-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-methyl-3-isoxazolyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-27-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-isoxazolyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-28-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[1,2,3-thiadiazol-5-yl]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-29-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,5-dichloro-3-thienyl]carbonyl]amino]methyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-30-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[5-chloro-2-methylphenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 625469-31-0 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-32-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-6-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-33-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-2-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-34-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-2-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-35-4 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-5-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-36-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[3-chloro-2,6-


difluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-37-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-38-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2-chloro-4-fluorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-39-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[2,3-dichlorophenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-40-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[2,3,6-trifluorophenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-41-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[3-[[[4-chloro-3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-42-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-43-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-44-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-45-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-46-7 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-47-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(6-chloro-2-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-48-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-49-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-3,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-50-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-51-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3,4-trifluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-52-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-53-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluoro-4-methylphenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-54-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-55-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-56-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-chloro-6-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-57-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-58-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-59-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-hexahydro-1H-azepin-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-60-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-[(3S)-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-61-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,6-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-62-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-4-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-63-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(3,4,5-


trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-64-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-fluoro-3-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-65-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2,3,5-trifluorophenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-66-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-fluoro-2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-67-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-bromo-5-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-68-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(1H-pyrazol-1-yl)phenyl)methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-69-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1,1'-biphenyl)-3-yl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-70-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-methylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-71-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-72-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625469-73-0 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dimethylphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-74-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-methoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-75-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[phenylmethyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-76-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,5-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625469-77-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3,4-dimethoxyphenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625469-78-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(3S)-hexahydro-1H-azepin-3-yl]-6-[3-[[[4-(1H-pyrazol-1-yl)phenyl]methyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 625469-79-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N,6-diphenyl- (9CI) (CA INDEX NAME)




RN 625469-80-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-oxo-2-phenylethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 625469-81-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2-hydroxyphenyl)methyl]amino]carbonyl]phenyl]-N-methyl-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 625462-72-6  
CMF C20 H19 N5 O3




CN 2


CRN 76-05-1  
CMF C2 H F3 O2



RN 625469-82-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-(4-morpholinyl)ethoxy]phenyl]methyl]amino]carbonylphenyl]- (9CI) (CA INDEX NAME)




RN 625469-83-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-methyl-1-piperazinyl]methyl]amino]carbonylphenyl]- (9CI) (CA INDEX NAME)




RN 625469-84-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3-(4-morpholinyl)phenyl]methyl]amino]methylphenyl]- (9CI) (CA INDEX NAME)



RN 625469-85-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[3-(4-morpholinyl)phenyl]methyl]amino]methylphenyl]- (9CI) (CA INDEX NAME)




RN 625469-86-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[4-(4-morpholinyl)phenyl]methyl]amino]methylphenyl]- (9CI) (CA INDEX NAME)



RN 625469-87-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-hydroxyethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625469-88-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-1-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]ethyl]phenyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625469-89-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[(4-chlorophenyl)methyl]-6-[3-[[[(1R)-1-[(4-chlorophenyl)methyl]-3-pyrrolidinyl]amino]carbonylphenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625469-90-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625469-91-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[3-[[[2-naphthalenyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)




RN 625470-04-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[2-(cyclopropylpropylamino)ethoxy]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-05-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(methylsulfonyl)methyl]phenyl)-(9CI)] (CA INDEX NAME)



RN 625470-07-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(2,3-dihydro-1H-inden-1-yl)amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-08-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(2-thienyl)phenyl]methyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)




RN 625470-09-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)

yl]phenyl]methyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)




RN 625470-10-2 CAPLUS  
CN Benzeneacetic acid, α-[[[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]amino]-, methyl ester, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625470-11-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1-phenylmethyl)-3-pyrrolidinyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)




RN 625470-12-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1-(2S)-2-phenylcyclopropyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625470-13-5 CAPLUS  
CN Carbamic acid, [[3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]phenyl]methyl]-, 9H-fluoren-9-ylmethyl ester (9CI) (CA INDEX NAME)




RN 625470-14-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1,2,3,4-tetrahydro-6-phenyl-2-naphthalenyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)




RN 625470-16-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1,1'-biphenyl)-4-yl]acetyl]amino]methyl]phenyl-N-methyl- (9CI) (CA INDEX NAME)



RN 625470-17-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-[(2-chloro-5-(trifluoromethyl)phenyl]acetyl]amino]methyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-18-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-methyl-6-[(3-[(1-[5-(trifluoromethyl)-2-pyrimidinyl]-4-piperidinyl]carbonyl]amino]methyl]phenyl- (9CI) (CA INDEX NAME)



RN 625470-19-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-[(1,1'-biphenyl)-5,7-difluoro-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-ethyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625470-20-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(2-naphthalenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625470-21-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-fluoro-4-(trifluoromethyl)phenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 625470-22-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-chloro-2,6-difluorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 625471-65-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S,2R)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-1-ethyl-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625471-70-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1R,2S)-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino]carbonyl]phenyl]-N-[(3S)-3-pyrrolidinylmethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 625471-71-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-chloro-3-[[[(phenylmethyl)amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625471-72-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-chloro-2-fluorophenyl)methyl]amino]carbonyl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625471-85-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(4-chlorophenyl)acetyl]amino]phenyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 625471-86-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(1S)-2,3-dihydro-1H-inden-1-yl]amino]methyl]phenyl]-N-(hexahydro-1H-azepin-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-88-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(3S)-3-piperidinyl-6-[3-[[[(2-thienyl)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 625478-21-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-difluorophenyl)methyl]amino]meth]yl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625515-65-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,4-dichlorophenyl)methyl]amino]carbonyl]phenyl]-N-(3S)-3-piperidinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625528-57-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]phenyl]-N-(3S)-3-pyrrolidinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625596-74-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(5-bromo-2,3-dihydro-1H-inden-2-yl)amino]meth]yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625605-58-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[[(3-furanyl)-2,3-dihydro-1H-inden-1-yl)amino]meth]yl]phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625614-94-0 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[3-[[[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl]phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 625471-08-1 625471-11-6 625471-14-9  
625471-16-1 625471-19-4 625471-20-7  
RL: RCT (Reactant): RACT (Reactant or reagent)  
(preparation of protein kinase modulators)  
RN 625471-08-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(bromomethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625471-11-6 CAPLUS  
CN 1-Pyrrolidinecarboxylic acid, 3-[[[3-amino-6-[(methylethylamino)carbonyl]pyrazinyl]benzoyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 625471-14-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-(chloromethyl)phenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 625471-16-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-[3-(hydroxymethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 625471-19-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(methoxycarbonyl)phenyl]pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625471-20-7 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[3-(aminophenyl)pyrazinyl]carbonyl]amino]-, 1,1-dimethylethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 625470-25-9P 625470-31-7P 625470-32-8P  
625470-34-0P 625470-35-1P 625470-51-1P  
625470-52-2P 625470-53-3P 625470-54-4P  
625470-66-0P 625470-68-0P 625470-75-9P  
625470-81-7P 625470-90-8P 625470-92-0P  
625470-93-1P 625470-98-6P 625470-99-7P  
625471-00-3P 625471-01-4P 625471-06-9P  
625471-07-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PRSP (Preparation); RACT (Reactant or reagent)  
(preparation of protein kinase modulators)


RN 625470-25-9 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 625470-31-7 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(ethylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 625470-32-8 CAPLUS  
CN Benzoic acid, 3-[5-amino-6-[(cyclopropylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 625470-34-0 CAPLUS  
CN Benzoic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-2-chloro-, methyl ester (9CI) (CA INDEX NAME)




RN 625470-35-1 CAPLUS  
CN Benzoic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-2-chloro- (9CI) (CA INDEX NAME)




RN 625470-51-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-formylphenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-52-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(hydroxymethyl)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-53-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(aminoiminomethyl)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-54-4 CAPLUS  
CN Pyrazinecarboxamide, 6-[3-[(3-[(acetyloxy)amino]iminomethyl)phenyl]-3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-66-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-[(3-[(1,1-dimethylethyl)dimethylsilyloxy]propyl)-2,3-dihydro-1H-inden-1-yl]]-3-amino-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-68-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(hydroxymethyl)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-75-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(2-bromoethoxy)phenyl)-N-methyl- (9CI) (CA INDEX NAME)



RN 625470-81-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(azidomethyl)phenyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 625470-90-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[(3-(bromomethyl)phenyl)-N-ethyl- (9CI) (CA INDEX NAME)




RN 625470-92-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-carboxyphenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625470-93-1 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625470-98-6 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 625471-01-4 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 625471-06-9 CAPLUS  
CN Benzoic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-2-fluoro-, methyl ester (9CI) (CA INDEX NAME)




RN 625471-07-0 CAPLUS  
CN Benzoic acid, 5-[5-amino-6-[(methylamino)carbonyl]pyrazinyl]-2-fluoro-, (9CI) (CA INDEX NAME)




RN 625470-99-7 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 625471-00-3 CAPLUS  
CN 1-Piperidinecarboxylic acid, 3-[[[3-amino-6-[(3-aminophenyl)pyrazinyl]carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (3S)-(9CI) (CA INDEX NAME)



Absolute stereochemistry.



L9 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:42553 CAPLUS  
DOCUMENT NUMBER: 138:106713  
TITLE: Preparation of heterocyclic amines for the treatment of conditions associated with GSK3  
INVENTOR(S): Berg, Stefan; Hellberg, Sven  
PATENT ASSIGNER(S): Astrazeneca AB, Swed.  
SOURCE: PCT Int. Appl., 62 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004475	A1	20030116	WO 2002-581340	20020703
W:	AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, BR, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CP, CO, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TO			
EP 1406877	A1	20040414	EP 2002-749475	20020703
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2004536110	T2	20041202	JP 2003-510642	20020703
US 2004186113	A1	20040923	US 2003-481699	20031222
PRIORITY APPLN. INFO.:			SE 2001-2438	A 20010705
			WO 2002-581340	W 20020703
OTHER SOURCE(S):		MARPAT 138:106713		
GI				



AB Title compds. I [Y = carboxamido, amido, sulfonamido, etc.; X = CH, N; P, Q = Ph, 5-6-membered heteroarom. ring, etc.; R1 = halo, NO2, alkyl-CN, alkyl-alkoxy, fluoromethyl, alkyl-amino, etc.; R2 = halo, NO2, CHO, alkyl-nitrile, etc.; n = 0-5; m = 0-4; R14 = H, Me, F, Cl, Br, etc.] are prepared. For instance, 3-amino-6-bromo-pyrazinecarboxylate (DBU) to give II. Example compds. had Ki in the range of 0.001 to 10,000 nM for glycogen synthase kinase-3 (GSK3). I are used for the treatment of Parkinson's Disease, etc.

IT 486424-13-9P, 4-[5-Amino-6-((pyridin-3-yl)amino)carbonyl]pyrazine-2-yl]benzoic acid 487034-96-8P, 3-Amino-6-(2,4-dichlorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide 487034-97-9P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide 487035-01-6P, 3-Amino-6-(4-hydroxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of heterocyclic amines for treatment of conditions associated with

gsk-3)


RN 486424-13-9 CAPLUS

CN Benzoic acid, 4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)




RN 487034-96-8 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-[4-(2-(1-pyrrolidinylethyl)-3-pyridinyl)- (9CI) (CA INDEX NAME)




RN 487034-97-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-fluorophenyl)-N-[4-(2-(1-pyrrolidinylethyl)-3-pyridinyl)- (9CI) (CA INDEX NAME)



RN 487035-01-6 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-hydroxyphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



IT 487034-72-0P, 3-Amino-6-phenyl-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-73-1P, 3-Amino-6-(2-methylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-74-2P, 3-Amino-6-(4-cyanophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-75-3P, 3-Amino-6-(3,4-methylenedioxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-77-5P, 3-Amino-6-(3-nitrophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-78-6P, 3-Amino-6-(3,5-

bis(trifluoromethyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-83-3P, 3-Amino-6-(4-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-83-3P, 3-Amino-6-(4-chlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-84-4P, 3-Amino-6-(2,3-dichlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-85-5P, 3-Amino-6-(2,4-dichlorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-86-6P, 3-Amino-6-(2,4-difluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-87-7P, 3-Amino-6-(3,4-difluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-88-8P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-90-2P, 3-Amino-6-(4-fluoro-3-methylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-91-3P, 3-Amino-6-(3,4-dimethylphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-92-4P, 3-Amino-6-(3-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-93-5P, 3-Amino-6-(2-fluorophenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide 487034-98-0P, 3-Amino-6-(2,4-dichlorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide hydrochloride 487034-99-1P, 3-Amino-6-(3-chloro-4-fluorophenyl)-N-[4-(2-(pyrrolidin-1-yl)ethyl)pyridin-3-yl]pyrazine-2-carboxamide hydrochloride 487035-02-9P, 3-Amino-6-(4-hydroxyphenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 487035-03-0P, 3-Amino-6-(4-aminocarbonyl)phenyl)-N-(pyridin-3-yl)pyrazine-2-carboxamide


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of heterocyclic amines for treatment of conditions associated with

gsk-3)


RN 487034-72-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-73-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(2-methylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-74-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(4-cyanophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-75-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(1,3-benzodioxol-5-yl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-77-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-(3-nitrophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-78-6 CAPLUS


CN Pyrazinecarboxamide, 3-amino-6-[3,5-bis(trifluoromethyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-82-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-83-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-84-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2,3-dichlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-85-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-86-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2,4-difluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-87-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3,4-difluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-88-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-90-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-fluoro-3-methylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-91-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3,4-dimethylphenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-92-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 487034-93-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2-fluorophenyl)-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 487034-98-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(2,4-dichlorophenyl)-N-[4-(2-(1-pyrrolidinylethyl)-3-pyridinyl)]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 487034-99-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(3-chloro-4-(chlorophenyl)phenyl)-N-[4-((1-pyrrolidinyl)sulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 487035-02-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-hydroxyphenyl)-N-[4-((pyrrolidin-1-yl)sulfonyl)phenyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 487035-03-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(aminocarbonyl)phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)





REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2003:42250 CAPLUS  
DOCUMENT NUMBER: 138:106712  
TITLE: Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors  
INVENTOR(S): Berg, Stefan; Hellberg, Sven  
PATENT ASSIGNOR(S): AstraZeneca AB, Swed.  
SOURCE: PCT Int. Appl., 158 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004472	A1	20030116	WO 2002-SE1339	20020703
WO 2003004472	C1	20030313		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,


LS, LT, LU, LV, MA, MD, ME, MK, MN, MW, MX, MY, MZ, NA, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
CA 2452666 A 20030116 CA 2002-2452666 20020703  
EP 1414801 A1 20040506 EP 2002-747795 20020703  
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK  
BR 2002010838 A 20040713 BR 2002-10838 20020703  
CN 1551869 A 20041201 CN 2002-813545 20020703  
JP 200505515 T2 20050224 JP 2003-510640 20020703  
US 2006052396 A1 20060309 US 2003-481721 20031222  
ZA 2003009977 A 20050323 ZA 2003-9977 20031222  
NO 2004000014 A 20040302 NO 2004-14 20040102  
SE 2001-2439 A 20010705  
WO 2002-SE1339 W 20020703  
PRIORITY APPLN. INFO.:  
OTHER SOURCE(S): MARPAT 138:106712  
GI




AB The title compds. [I; Z = CH, N; Y = CONRS, NR5CO, SO2NR5, etc.; X = CH, N; P = Ph or 5-6 membered heteroaryl which may optionally be fused with 5-6 membered (un)saturated ring containing one or more atoms selected from C, O or S; Q = Ph or 5-6 membered heteroaryl containing one or more heteroatoms selected from N, O or S of which at least one atom is selected from N atom; R = CHO, OCH2F, OCH2F2, OCF3, etc.; R3, R4 = halo, NO2, CHO, etc.; n, m = 0-4], useful in the prevention and/or treatment of conditions associated with glycogen synthase kinase-3, were prepared and formulated. Thus, coupling 3-amino-6-bromo-N-(pyridin-3-yl)pyrazine-2-carboxamide with 4-(pyrrolidin-1-yl)sulfonylphenylboronic acid (prepn. given) in the presence of Pd(dppf)Cl2 and Na2CO3 in dimethoxyethane afforded 93% the carboxamide II. Typical Ki values for the compds. I are in the range of about 0.001 to about 10,000 nM.  
IT 486423-10-3P, 3-Amino-N-(pyridin-3-yl)-6-[4-((pyrrolidin-1-yl)sulfonyl)phenyl]pyrazine-2-carboxamide 486423-11-4P, 3-Amino-6-[4-((piperidin-1-yl)sulfonyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-12-5P, 3-Amino-6-[3-ethyl-4-((4-methylpiperazin-1-yl)sulfonyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-13-6P, 3-Amino-6-[4-((4-methylpiperazin-1-

yl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-15-8P, 3-Amino-N-[5-[3-(dimethylamino)propyl]pyridin-3-yl]-6-[4-(piperidin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide 486424-07-1P 486424-20-8P  
RL: CPS (Chemical process); PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)


RN 486423-10-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-((1-pyrrolidinyl)sulfonyl)phenyl]- (9CI) (CA INDEX NAME)




RN 486423-11-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperidinylsulfonyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-12-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-ethyl-4-((4-methyl-1-piperazinyl)sulfonyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-13-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[4-methyl-1-piperazinyl]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 486423-15-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[[5-[[3-(dimethylamino)propyl]-3-pyridinyl]-6-[[4-[[1-piperidinylsulfonyl]phenyl]-N-3-pyridinyl]-N-3-pyridinyl]-N-3-pyridinyl]-N-3-pyridinyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486424-07-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[2-aminoethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 486424-20-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




IT 486423-14-7P, tert-Butyl 4-[[4-[[5-amino-6-[[pyridin-3-yl]amino]carbonyl]pyrazin-2-yl]phenyl]sulfonyl]piperazine-1-carboxylate  
486423-76-3P 486423-80-7P 486424-13-9P  
RL: PAC (Pharmacological activity); RCT (Reactant); SPW (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USSS (Uses)  
(preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)

RN 486423-14-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[4-[[5-amino-6-[[3-pyridinylamino]carbonyl]pyrazinyl]phenyl]sulfonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 486423-76-3 CAPLUS


CN 1-Piperazinecarboxylic acid, 4-[[2-[[4-[[5-amino-6-[[3-pyridinylamino]carbonyl]pyrazinyl]phenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486423-80-7 CAPLUS  
CN 1-Piperazinecarboxylic acid, 4-[[2-[[4-[[5-amino-6-[[3-pyridinylamino]carbonyl]pyrazinyl]-2,5-difluorophenoxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 486424-13-9 CAPLUS  
CN Benzoic acid, 4-[[5-amino-6-[[3-pyridinylamino]carbonyl]pyrazinyl]- (9CI) (CA INDEX NAME)




IT 486423-16-9P, 3-Amino-N-[[5-[[3-(dimethylamino)propyl]pyridin-3-yl]-6-[[4-(pyrrolidin-1-yl)sulfonyl]phenyl]pyrazine-2-carboxamide  
486423-17-0P, 3-Amino-N-[[4-[[3-(dimethylamino)propyl]pyridin-3-yl]-6-[[4-[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]pyrazine-2-carboxamide  
486423-18-1P, 3-Amino-N-[[4-[[3-(dimethylamino)propyl]pyridin-3-yl]-


6-[[4-[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]pyrazine-2-carboxamide  
486423-19-2P, 3-Amino-6-[[4-[[N-methyl-N-(1-methylpyrrolidin-3-yl)amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-20-5P, 3-Amino-6-[[4-[[N-methyl-N-(1-methylpiperidin-4-yl)amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-21-0P, 3-Amino-6-[[4-[[N-[[3-(dimethylamino)propyl]-N-methylamino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
hydrochloride 486423-22-7P, 3-Amino-6-[[4-[[3-(dimethylamino)pyrrolidin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-23-8P, 3-Amino-6-[[4-[[morpholin-4-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-24-9P, 486423-25-0P, 3-Amino-6-[[4-[[4-ethylpiperazine-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-26-1P 486423-27-2P  
486423-28-3P 486423-29-4P, 3-Amino-6-[[4-[[N-isopropyl-N-(2-methoxyethyl)amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 486423-30-7P 486423-31-8P  
486423-32-9P, 3-Amino-N-(pyridin-3-yl)-6-[[4-[[3-(pyridin-2-yl)ethyl]amino]sulfonyl]phenyl]pyrazine-2-carboxamide 486423-33-0P  
3-Amino-6-[[4-[[2-methoxy-1-methylethyl]amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide hydrochloride 486423-34-1P  
3-Amino-6-[[4-[[2-(dimethylamino)-1-methylethyl]amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-35-2P  
3-Amino-N-(pyridin-3-yl)-6-[[4-[[3-(pyrrolidin-1-yl)propyl]amino]sulfonyl]phenyl]pyrazine-2-carboxamide  
486423-36-3P, 6-[[4-[[Acetyl]piperazin-1-yl]sulfonyl]phenyl]-3-amino-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-37-4P  
486423-38-5P 486423-40-9P, 3-Amino-6-[[4-[[N-[[2-(dimethylamino)ethyl]-N-ethylamino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-41-0P, 3-Amino-6-[[4-[[N-[[3-(dimethylamino)propyl]-N-methylamino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-42-1P, 3-Amino-6-[[4-[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-43-2P, 3-Amino-N-(pyridin-3-yl)-6-[[4-[[2-(pyrrolidin-1-yl)ethyl]amino]carbonyl]phenyl]pyrazine-2-carboxamide  
486423-44-3P, 3-Amino-N-(pyridin-3-yl)-6-[[4-[[3-(pyrrolidin-1-yl)propyl]amino]carbonyl]phenyl]pyrazine-2-carboxamide  
486423-45-4P, 3-Amino-6-[[4-[[4-methyl-1,4-diazepan-1-yl]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-46-5P, 3-Amino-6-[[4-[[N-methyl-N-(1-methylpyrrolidin-3-yl)amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-47-6P, 3-Amino-6-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-48-7P, 3-Amino-6-[[4-[[2-(dimethylamino)-1-methylethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-49-8P  
3-Amino-6-[[4-[[3-(dimethylamino)pyrrolidin-1-yl]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-50-1P  
3-Amino-6-[[4-[[1-ethylpyrrolidin-2-yl]methyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-51-2P  
3-Amino-6-[[4-[[3-(4-methylpiperazin-1-yl)propyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-52-3P  
3-Amino-6-[[4-[[N-methyl-N-(1-methylpiperidin-4-yl)amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-53-4P  
3-Amino-6-[[4-[[3-(piperidin-1-yl)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-54-5P, 3-Amino-6-[[4-[[1-ethylpiperidin-3-yl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-55-6P, 3-Amino-6-[[4-[[2-(1-methylpyrrolidin-2-yl)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
486423-56-7P, 3-Amino-N-(pyridin-3-yl)-6-[[4-[[4-(pyrrolidin-1-yl)piperidin-1-yl]carbonyl]phenyl]pyrazine-2-carboxamide  
486423-58-9P 486423-59-0P 486423-60-3P  
486423-61-4P 486423-62-5P 486423-63-6P  
486423-64-7P 486423-65-8P 486423-66-9P  
486423-67-0P 486423-68-1P 486423-69-2P  
486423-70-5P, 3-Amino-6-[[4-[[2-(4-methyl-1-

piperazinyl)ethoxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
 486423-71-6P, 3-Amino-6-[4-[[[2-(4-morpholinyl)ethyl]amino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-72-7P, 3-Amino-6-[4-[[[1-methylpyrrolidin-3-yl]oxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486423-73-0P 486423-74-9P  
 486423-75-0P 486423-76-1P 486423-77-2P 486423-78-3P  
 486423-79-4P 486423-81-8P 486423-82-9P  
 486423-83-0P 486423-84-1P 486423-86-5P  
 486423-89-6P 486423-90-9P 486423-91-0P  
 486423-92-1P 486423-93-2P 486423-94-3P  
 486423-95-4P 486423-96-5P 486423-97-6P  
 486423-98-7P 486423-99-8P 486424-00-4P  
 486424-01-5P 486424-04-8P 486424-05-9P  
 486424-06-0P 486424-08-2P 486424-09-3P  
 486424-12-8P 486424-14-0P, 3-Amino-6-[4-[[[dimethylamino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-15-1P, 3-Amino-6-[3-[[[dimethylamino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-16-2P, 3-Amino-6-[2-[[[dimethylamino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-17-3P, 3-Amino-6-[4-[[[aminosulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-19-5P, 3-Amino-6-[4-[[[3-(morpholin-4-yl)propyl]amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-21-9P 486424-22-0P, 3-Amino-6-[2,5-difluoro-4-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-23-1P, 3-Amino-6-[3-fluoro-4-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-24-2P, 3-Amino-6-[3-methyl-4-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-25-3P, 3-Amino-6-[2-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-26-4P, 3-Amino-6-[3-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-27-5P, 3-Amino-6-[2-methyl-4-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-28-6P, 3-Amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-29-7P, 3-Amino-6-[4-[[[N-[2-(dimethylamino)ethyl]-N-ethylamino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-30-0P, 3-Amino-6-[4-[[[4-methylpiperazin-1-yl]sulfonyl]-2-(trifluoromethyl)phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-31-1P, 3-Amino-6-[4-[[[2-(dimethylamino)ethoxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-32-2P, 3-Amino-6-[4-[[[2-(4-morpholinyl)ethoxy]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-33-3P, 3-Amino-6-[4-[[[N-[2-(dimethylamino)ethyl]-N-methylamino]carbonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide 486424-34-4P, 3-Amino-6-[2,5-difluoro-4-[[[pyrrolidin-1-yl]sulfonyl]phenyl]-N-[5-(3-pyrrolidin-1-yl)propyl]pyridin-3-yl]pyrazine-2-carboxamide 486424-40-2P, tert-Butyl [2-[[[4-[[[5-amino-6-[[[pyridin-3-yl]amino]carbonyl]pyrazin-2-yl]phenyl]sulfonyl]-N-(tert-butoxycarbonyl)amino]ethyl]carbamate 486424-41-3P 486424-42-4P 486424-43-5P, 3-Amino-6-[2-fluoro-4-[[[4-methylpiperazin-1-yl]sulfonyl]phenyl]-N-(pyridin-3-yl)pyrazine-2-carboxamide  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRSP (Preparation); USES (Uses)  
 (Preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)


RN 486423-16-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[4-(1-pyrrolidinyl)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-17-0 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[4-[[[dimethylamino]methyl]-3-pyridinyl]-6-[4-[[[dimethylamino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-18-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[4-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[4-[[[dimethylamino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-19-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[methyl(1-methyl-3-pyrrolidinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 486423-20-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[methyl(1-methyl-3-pyridinyl)amino]sulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 486423-21-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]methylamino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




• HCl


RN 486423-22-7 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)-1-pyrrolidinyl]sulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)



RN 486423-23-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-morpholinylsulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)




RN 486423-24-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-methyl-1-piperazinyl)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




• x HCl

RN 486423-25-0 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-ethyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl]- (9CI) (CA INDEX NAME)






RN 486423-26-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]sulfonyl]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-27-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-28-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-29-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(methoxyethyl)(1-methylethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 486423-30-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(1-ethyl-2-pyrrolidinyl)methyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-31-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(diethylamino)ethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-32-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(2-pyridinyl)ethyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-33-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(methoxy-1-methylethyl)amino]sulfonyl]phenyl]-N-3-pyridinyl-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl


RN 486423-34-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)-1-methylethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-35-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[3-(1-pyrrolidinyl)propyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-36-3 CAPLUS  
CN Pyrazinecarboxamide, 6-[4-[(4-acetyl-1-piperazinyl)sulfonyl]phenyl]-3-amino-N-3-pyridinyl- (9CI) (CA INDEX NAME)




●x HCl


RN 486423-40-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-41-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]methylamino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-42-1 CAPLUS




RN 486423-37-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-38-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)


CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(dimethylamino)propyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-43-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-44-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[[[3-(1-pyrrolidinyl)propyl]amino]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-45-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-46-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[methyl(1-methyl-3-pyrrolidinyl)amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-47-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-48-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[2-(dimethylamino)-1-methylethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-49-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[3-(dimethylamino)-1-pyrrolidinyl]methyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-50-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[1-ethyl-2-pyrrolidinyl]methyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-51-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[3-(4-methyl-1-piperazinyl)propyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-52-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[methyl(1-methyl-4-piperidinyl)amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-53-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[2-(1-piperidinyl)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-54-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[1-ethyl-3-piperidinyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486423-55-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[4-[[2-(1-methyl-2-pyrrolidinyl)ethyl]amino]carbonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486423-56-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[[4-[[1-pyrrolidinyl]-1-piperidinyl]carbonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 486423-58-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[[2,5-difluoro-4-[[4-methyl-1-

piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-59-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-60-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-61-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-62-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-63-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-64-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-65-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-66-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-2-(trifluoromethyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-67-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(dimethylamino)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-68-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-69-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(dimethylamino)ethyl]methylamino]carbonylphenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl


RN 486423-70-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486423-71-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(4-morpholinyl)ethyl]amino]carbonylphenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 486423-72-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[1-methyl-3-pyrrolidinyl]oxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486423-73-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-fluoro-4-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-74-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[5-fluoro-2-methyl-4-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-75-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-dimethyl-4-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




●x HCl

RN 486423-76-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(1-piperidinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-77-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-79-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-81-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-82-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[2-(1-pyrrolidinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-83-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,6-dimethyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-84-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486423-88-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-[4-(1-pyrrolidinylmethyl)-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)






● x HCl

RN 486423-89-6 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-pyrrolidinylsulfonyl)phenyl]-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-90-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-pyrrolidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-91-0 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(1-piperidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-92-1 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-93-2 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-94-3 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[4-[2-(1-pyrrolidinyl)ethyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-95-4 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-[4-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-6-[4-(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-96-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[4-[(1-pyrrolidinylmethyl)-3-pyridinyl]-6-[(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-97-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[4-[(dimethylamino)methyl]-3-pyridinyl]-6-[(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-98-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[4-[(dimethylamino)methyl]-3-pyridinyl]-6-[(1-piperidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486423-99-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[3-ethyl-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-00-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(4-methyl-1-piperazinyl)sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-01-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-aminoethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486424-04-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-3-pyridinyl-6-[4-[(1-pyrrolidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl


RN 486424-05-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(1-piperidinylsulfonyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)






● x HCl

RN 486424-06-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(1-piperazinylsulfonyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-08-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(2-(1-piperazinyl)ethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-09-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-(2-(1-piperazinyl)ethoxy)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-12-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-[5-[3-(dimethylamino)propyl]-3-pyridinyl]-6-[4-(1-piperidinylsulfonyl)phenyl]-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl


RN 486424-14-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[dimethylamino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486424-15-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[dimethylamino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486424-16-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-[[dimethylamino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486424-17-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-(aminosulfonyl)phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



RN 486424-19-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[3-(4-morpholinyl)propyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




RN 486424-21-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[4-methyl-1-piperazinyl]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




• x HCl


RN 486424-22-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-23-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-fluoro-4-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-24-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-methyl-4-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486424-25-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-26-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[3-[[4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-27-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-methyl-4-[[4-methyl-1-


piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-28-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]amino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-29-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]ethylamino]sulfonyl]-3-(trifluoromethoxy)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-30-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[4-methyl-1-piperazinyl)sulfonyl]-2-(trifluoromethyl)phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-31-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(dimethylamino)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-32-2 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-morpholinyl)ethoxy]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)




RN 486424-33-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[[2-(dimethylamino)ethyl]methylamino]carbamoyl]phenyl]-N-3-pyridinyl- (9CI) (CA INDEX NAME)



RN 486424-34-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2,5-difluoro-4-[(1-pyrrolidinylsulfonyl)phenyl]-N-[5-[3-(1-pyrrolidinyl)propyl]-3-pyridinyl]-9CI] (CA INDEX NAME)




RN 486424-40-2 CAPLUS  
CN Carbanic acid, [[4-[5-amino-6-[(3-pyridinylamino)carbonyl]pyrazinyl]phenyl]sulfonyl][2-[1,1-dimethylethoxy]carbonyl]amino]ethyl]-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 486424-41-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[2-(4-methyl-1-piperazinyl)ethoxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)

(NAME)




● x HCl

RN 486424-42-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[(1-methyl-3-pyrrolidinyl)oxy]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)




● x HCl

RN 486424-43-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[2-fluoro-4-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



IT 486422-09-7P, 3-Amino-6-[4-[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-N-pyridin-3-ylpyrazine-2-carboxamide  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of pyrazine-2-carboxamides as glycogen synthase kinase-3 (GSK3) inhibitors)

RN 486422-09-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-[4-[[2-(dimethylamino)ethyl]amino]sulfonyl]phenyl]-N-3-pyridinyl-, hydrochloride (9CI) (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 2002:466012 CAPLUS  
DOCUMENT NUMBER: 137:47228


TITLE: Preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiro[isobenzofuran-1,4'-piperidines] as NPVS receptor activity modulators  
INVENTOR(S): Bakthavatchalam, Rajagopal; Blum, Charles A.; Briemann, Harry L.; Darrow, James William; De Lombaert, Stephane; Hutchison, Alan; Tran, Jennifer; Zheng, Xiaozhang; Elliott, Richard Louis; Hammond, Marlye

PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer Inc.  
SOURCE: PCT Int. Appl., 134 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048152	A2	20020620	WO 2001-US47863	20011211
WO 2002048152	A3	20030508		
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002020276	A5	20020624	AU 2002-20276	20011211
US 2003036652	A1	20030220	US 2001-13846	20011211
US 6566367	B2	20030520		
EP 1347982	A2	20031001	EP 2001-270536	20011211
SP 1347982	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004520299	T2	20040708	JP 2002-549683	20011211
BR 2001016133	A	20040803	BR 2001-16113	20011211
US 2004072847	A1	20040415	US 2003-410648	20030409
US 6943199	B2	20050913		
US 2005033048	A1	20050210	US 2003-415457	20030815
US 2006040964	A1	20060223	US 2005-183615	20050718
PRIORITY APPLN. INFO.:			US 2000-154990P	P 20001212
			US 2001-13846	A3 20011211
			WO 2001-US47863	W 20011211
			US 2003-410648	A3 20030409

OTHER SOURCE(S): MARPAT 137:47228  
OI




AB Title compds. [I: X = O, H2; A, D, V, W, Y, Z independently = N, CR1; R1 = H, halo, OH, NH2, NO2, CN, CONH2, COOH; B = N, CR2; E = CR3; R2, R3 independently = H, halo, OH, NH2, NO2, CN, CONH2, COOH; G = N, NH; J = NH, N; L = bond, CO; dotted bond = single, double] capable of modulating NPVS receptor activity are prepared. Such compds. may be used to modulate ligand binding to NPVS receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of disorders (e.g., eating disorders such as obesity or bulimia, psychiatric disorders, diabetes and cardiovascular disorders such as hypertension) in humans, domesticated companion animals and livestock animals. Pharmaceutical compds. and method for treating such disorders are provided, as are methods for using such compds. for detecting NPVS receptors.

IT 486422-09-7P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3H-spiro[isobenzofuran-1,4'-piperidines] as NPVS receptor activity modulators)

✓ 162(a), (e)

RN 438190-84-2 CAPLUS  
CN Pyrazinecarboxylic acid, 3-amino-6-phenyl-, hydrazide (9CI) (CA INDEX NAME)



KR2 = "AMINO"

L9 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1997:590066 CAPLUS

DOCUMENT NUMBER: 127:257127

TITLE: Structural requirements for potent Na/H exchange inhibitors obtained from quantitative structure-activity relationships monocyclic and bicyclic aroylguanidines

AUTHOR(S): Yamamoto, Takeshi; Hori, Manabu; Watanabe, Ikuro; Tautsui, Hisayoshi; Harada, Kengo; Ikeda, Shoji; Ohtaka, Hiroshi

CORPORATE SOURCE: Product R and D Laboratory, Kanebo Ltd., Osaka, 534, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1997), 45(8), 1282-1286

CODEN: CPBTAL; ISSN: 0009-2363

PUBLISHER: Pharmaceutical Society of Japan

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The quant. structure-activity relationship (QSAR) of N-(3-amino-6-chloro-5-ethylisopropylaminopyrazine-4-carbonyl)guanidine (EIPA) 1ac and its derivs. as Na/H exchange inhibitors was analyzed using the steric parameters and an indicator variable. The results indicated that bicyclic aroylguanidines might have Na/H exchange inhibitory activity. Therefore, various bicyclic aroylguanidines were synthesized and tested for Na/H exchange inhibitory activity. The QSAR study of the bicyclic aroylguanidines showed that hydrophobic bicyclic rings seemed to be preferable for potent activity. The hydrophobicity of the aroyl ring moiety was thought to be particularly important. Thus, the QSAR of EIPA and its derivs. was re-analyzed using hydrophobicity and steric parameters. The results indicated that high hydrophobicity of the pseudo-ring moiety and a substituent of appropriate length at the position corresponding to the 5-position of the naphthalene ring enhance the activity. As expected from the results, 5-bromo-2-naphthoyleguanidine 3b and 5-methoxy-2-naphthoyleguanidine 3c exhibited strong activity. These findings will be helpful to design new, potent Na/H exchange inhibitors.

IT 1634-17-9

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationships monocyclic and bicyclic aroylguanidines as Na/H exchange inhibitors)

RN 1634-17-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(aminomethyl)-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1989:131753 CAPLUS

DOCUMENT NUMBER: 108:131753

TITLE: Synthesis of 3-alkyl-6-phenyl-4(3H)-pteridinones and their 8-oxides. Potential substrates of xanthine oxidase

AUTHOR(S): De Meester, J. W. G.; Kraus, W.; Van der Plas, H. C.; Brons, H. J.; Middelhoven, W. J.

CORPORATE SOURCE: Dep. Org. Chem., Wageningen Agric. Univ., Wageningen, 6703 BC, Neth.

SOURCE: Journal of Heterocyclic Chemistry (1987), 24(4), 1109-16



CODEN: JHTCAD; ISSN: 0022-152X

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 108:131753

GI



AB Synthetic routes for the preparation of 3-alkyl-6-phenyl-4(3H)-pteridinones I (R = Me, Et, Pr, Bu, CHMe2, CHMeEt, CMe3, CH2CH2OH, CMe2CH2OH, CH2CH2OH) and their corresponding 8-oxides II are described and their reactivities towards xanthine oxidase from *Arthrobacter* M-4 are determined. Only I and II (R = Me) are found to be substrates although their reactivities are still very low. Oxidation takes place at C-2 of the pteridinone nucleus. All the 3-alkyl derivs. are less tightly bound to the enzyme than 6-phenyl-4(3H)-pteridinone (I; R = H). Introduction of the N-oxide at N-8 considerably lowers the binding of the substrates. Inhibition studies have revealed that 3-methyl-6-phenyl-4(3H)-pteridinone (I; R = Me) is a noncompetitive inhibitor with a  $K_i$ -value of 47  $\mu$ M and the 3-Et derivative (I; R = Et) an uncompetitive one with a  $K_i$ -value of 19.6  $\mu$ M.

IT 113424-65-0P 113424-66-1P 113424-67-2P

113424-68-3P 113424-69-4P 113424-70-7P

113424-74-1P 113424-75-2P 113424-76-3P


113424-77-4P 113424-78-5P 113424-79-6P

113424-80-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and cyclocondensation reaction of, with tri-Et orthoformate)


RN 113424-65-0 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-methyl-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-66-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-67-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-propyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-68-3 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-butyl-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-69-4 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(1-methylethyl)-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-70-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(1-methylpropyl)-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-74-1 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-[1-(hydroxymethyl)propyl]-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-75-2 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-methyl-6-phenyl-, (9CI) (CA INDEX NAME)




RN 113424-76-3 CAPLUS


CN Pyrazinecarboxamide, 3-amino-N-ethyl-6-phenyl-, (9CI) (CA INDEX NAME)




RN 113424-77-4 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-N-propyl- (9CI) (CA INDEX NAME)




RN 113424-78-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-butyl-6-phenyl- (9CI) (CA INDEX NAME)



RN 113424-79-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(1-methylethyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 113424-80-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(1-methylpropyl)-6-phenyl- (9CI) (CA INDEX NAME)




IT 113424-71-8P 113424-72-9P 113424-73-0P

113424-81-0P 113424-82-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 113424-71-8 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(1,1-dimethylethyl)-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-72-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-hydroxyethyl)-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-73-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-hydroxy-1,1-dimethylethyl)-6-phenyl-, 4-oxide (9CI) (CA INDEX NAME)




RN 113424-81-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(1,1-dimethylethyl)-6-phenyl- (9CI) (CA INDEX NAME)



RN 113424-82-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(2-hydroxyethyl)-6-phenyl- (9CI) (CA INDEX NAME)




L9 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1988:112044 CAPLUS  
DOCUMENT NUMBER: 108:112044  
TITLE: The use of immobilized enzymes and bacterial cells in organic synthesis. Part 16. The oxidation of 6- and 7-aryl-4(3H)-pteridinones by immobilized Arthrobacter M-4 cells containing xanthine oxidase  
AUTHOR(S): De Weester, Johan W. G.; Van der Plea, Henk C.; Middelhoven, Wouter J.  
CORPORATE SOURCE: Dep. Org. Chem., Wageningen, 6703 BC, Neth.  
SOURCE: Journal of Heterocyclic Chemistry (1987), 24(2), 441-51  
CODEN: JHTCAD; ISSN: 0022-152X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 108:112044  
GI




AB 6- and 7-(p-substituted phenyl)-4(3H)-pteridinones I and II (R = H, Me, MeO) were prepared. The oxidation of these compds. by immobilized Arthrobacter M-4 cells containing xanthine oxidase has been studied. The oxidation usually goes fast, except for II (R = Me, MeO) which are oxidized slowly. Small laboratory-scale oxidns. were carried out with bacterial cells immobilized in gelatine crosslinked with glutaraldehyde. Based on spectral data the products of the oxidation reactions are 6- and 7-aryllumazines, e.g. III.  
IT 113120-69-7P 113120-70-0P 113120-71-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and cyclization with tri-Et orthoformate)


RN 113120-69-7 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl- (9CI) (CA INDEX NAME)



RN 113120-70-0 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 113120-71-1 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




IT 113120-67-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 113120-67-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-methylphenyl)-, 4-oxide (9CI) (CA INDEX NAME)




IT 19994-59-3P 113120-68-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


RN 19994-59-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-, 4-oxide (8CI, 9CI) (CA INDEX NAME)



RN 113120-68-6 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-methoxyphenyl)-, 4-oxide (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 1973:537091 CAPLUS  
DOCUMENT NUMBER: 79:137091  
TITLE: Pteridines. XXVIII. New, general, and unequivocal pterin synthesis  
AUTHOR(S): Taylor, Edward C.; Perlman, Katherine L.; Sword, Ian P.; Sequin-Frey, Margareta; Jacobi, Peter A.  
CORPORATE SOURCE: Dep. Chem., Princeton Univ., Princeton, NJ, USA  
SOURCE: Journal of the American Chemical Society (1973), 95(19), 6407-12  
CODEN: JACSAT; ISSN: 0002-7863  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB Pterins are prepared Reaction of an  $\alpha$ -oxoaldehyde or a  $\alpha$ -oxoketoxime with esters of  $\alpha$ -aminooxyacetic acid gives 2-amino-3-alkoxycarbonylpyrazine 1-oxides (I) which cyclized with guanidine to pterin 8-oxides (II). Deoxygenation of the I and II, and the conversion of II to 7,8-dihydropterins, are described.  
IT 19994-59-3  
RL: RCT (Reactant); RACT (Reactant or reagent) (cyclization of)  
RN 19994-59-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-, 4-oxide (8CI, 9CI) (CA INDEX NAME)




L9 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 1971:88051 CAPLUS  
DOCUMENT NUMBER: 74:88051  
TITLE: Antiinflammatory arylhydroxypyrazine- and pyrimidinecarboxylic acids  
INVENTOR(S): Shen, Taung-Ying; Welford, Gordon L.; Witzel, Bruce E.  
PATENT ASSIGNEE(S): Merck and Co., Inc.  
SOURCE: Ger. Offen., 64 pp.  
CODEN: GWKXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2031228	A	19710128	DE 1970-2031228	19700624
US 3660403	A	19720502	US 1969-836647	19690625
US 3745161	A	19730710	US 1970-30294	19700420
NL 7008625	A	19701229	NL 1970-8625	19700612
IL 34719	A1	19730629	IL 1970-34719	19700615
GB 1269484	A	19720406	GB 1970-1269484	19700618
ES 380932	A1	19730401	ES 1970-380932	19700619
BE 752456	A	19701224	BE 1970-752456	19700624
FR 2053012	A5	19710416	FR 1970-23325	19700624
FR 2053012	B1	19740524		
ZA 7004319	A	19700223	ZA 1970-4319	19700624
CH 537390	A	19730713	CH 1970-9556	19700625
			US 1969-836647	A 19690625
			US 1970-30294	A 19700420

PRIORITY APPLN. INFO.:  
GI For diagram(s), see printed CA Issue.  
AB The antiinflammatory title compds. (I and II) were prepared Thus, reaction of H<sub>2</sub>NCOCH(NH<sub>2</sub>)CH<sub>2</sub>SHCl with p-FC6H<sub>4</sub>COCHO gave I (R = R<sub>1</sub> = NH<sub>2</sub>, p-FC6H<sub>4</sub> in the 5-position), which was refluxed 8 hr in N NaOH to give the free acid (III). Reaction of III with H<sub>2</sub>SO<sub>4</sub> (method A) gave the 2-hydroxy derivative, which was also prepared by heating 2-amino-6-(p-fluorophenyl)-4-hydroxypyridine 24 hr with 4N NaOH at 170°. Similarly prepared by method A were I (R = R<sub>1</sub> = OH and p-FC6H<sub>4</sub> in 6-position) and II (R = OH) (R<sub>1</sub> and position of COR and p-FC6H<sub>4</sub> given); 5-OH, 4, 2 (IV); 4-OH, 5, 2. Refluxing IV 8 hr with MeOH and H<sub>2</sub>SO<sub>4</sub> gave II (R = MeO, R<sub>1</sub> = 5-OH, COR in 4-position, p-FC6H<sub>4</sub> in 2-position), which on refluxing with MeI in MeOH and hydrolysis gave the 5-methoxy derivative Reaction of II (R = OEt, R<sub>1</sub> = 4-OH, COR in 5-position, p-FC6H<sub>4</sub> in 3-position) with POCl<sub>3</sub>-PCl<sub>5</sub> gave the 4-chloro derivative, which on reaction with EtONa gave the 4-ethoxy derivative, which was hydrolyzed to give the free acid. Also prepared were 3 addnl. II, 2 addnl. I as well as Me 5-[p-aminophenyl]-2-hydroxy-3-pyrazinecarboxylate, Me 2-[p-(methylthio)phenyl]-4-hydroxy-5-pyrimidinecarboxylate, and 2-[p-(methylsulfinyl)phenyl]-5-acetoxypyrimidinecarboxylic acid.  
IT 30838-86-9P, Pyrazinecarboxamide, 3-amino-6-(p-fluorophenyl)-  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)

RN 30838-86-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-(4-fluorophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 1968:467334 CAPLUS  
DOCUMENT NUMBER: 69:67334  
TITLE: An unequivocal synthesis of 6-substituted-pteridine 8-oxides, pteridines, and 7,8-dihydropteridines  
AUTHOR(S): Taylor, Edward C.; Lenard, Katherine  
CORPORATE SOURCE: Princeton Univ., Princeton, NJ, USA  
SOURCE: Journal of the American Chemical Society (1968), 90(9), 2424-5  
CODEN: JACSAT; ISSN: 0002-7863  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB 6-Substituted pteridine 8-oxides, which are easily reduced to 7,8-dihydropteridines and subsequently oxidized to 6-substituted pteridines, are prepared by condensation of an RCH(CN)NH<sub>2</sub> with an R1C(O)CH<sub>2</sub>NH<sub>2</sub>, followed by cyclization with guanidine.  
IT 19994-59-3P  
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
RN 19994-59-3 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-6-phenyl-, 4-oxide (8CI, 9CI) (CA INDEX NAME)



L9 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 1968:436173 CAPLUS  
DOCUMENT NUMBER: 69:436173  
TITLE: (3-Amino-2-pyrazinecarboxyl)guanidines  
INVENTOR(S): Cragoe, Edward J., Jr.  
PATENT ASSIGNEE(S): Merck and Co., Inc.  
SOURCE: U.S., 26 pp.  
CODEN: USKXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 3313813 19670411 US 1963-313315 19621030  
DE 1795438 DE


GI For diagram(s), see printed CA Issue.  
AB Title compds. I are prepared from II, III, and IV. Thus, 3318 g. SO<sub>2</sub>Cl<sub>2</sub> is added in 30 min. to 765 g. Me 3-amino-2-pyrazinecarboxylate in 5.1 C6H6; the mixture is agitated 3 hr, refluxed 5 hrs., and agitated overnight to give 724 g. Me 3-amino-5,6-dichloropyrazinecarboxylate (V), m. 233-4° (MeCN). A mixture of 100 g. V and 1.1 Me<sub>2</sub>SO is heated to 65° and NH<sub>3</sub> gas is introduced into the mixture in 45 min. at 65-70°; the mixture is cooled to 10° and NH<sub>3</sub> is introduced in 1.25 hrs. to give 91.5% Me 3,5-diamino-6-chloropyrazinecarboxylate, m. 212-13° (MeCN). Also prepared, by known methods are the following II (X, Y, Z, and m.p. given): MeO, NH<sub>2</sub>, H, 252-4° (decomposition); MeO, NH<sub>2</sub>, Br, 217-19°; MeO, NH<sub>2</sub>, iodine, 200-2°; MeO, PhNH, Cl, 171.5-73°; MeO, p-ClC<sub>6</sub>H<sub>4</sub>NH, Cl, 207-8°; MeO, Me<sub>2</sub>N, Cl, 145.5-6.5°; MeO, MeS, Cl, 214-16°; MeO, MeSO, Cl, 217.5-40.5° (decomposition); MeO, OH, Cl, .apprx.245° (decomposition); MeO, OH, H, 220-60° (decomposition); MeO, NH<sub>2</sub>, H, 252-4° (decomposition); MeO, Me<sub>2</sub>N, H, 242.5-3.5°; MeO, MeO, H, 205.5-7.5°; MeO, PhCH<sub>2</sub>NH, H, 157-8°; MeO, MeO, MeO, Cl, 255-7°; MeO, MeS, Cl, 212-14°; MeO, SH, Cl, 207-8° (decomposition); MeO, EtO, Cl, 123-5°; MeO, H, Me, 138.5-40.5°; MeO, Cl, Me, 176.5-9.5°; MeO, Me<sub>2</sub>N, Me, 108.5-10.5°; MeO, Me, H, 165-7°; MeO, Me, Br, 179-81°; NH<sub>2</sub>, H, Et, 165.5-8.5°; OH, H, Et, 149-52°; MeO, H, Et, 85-7.5°; OH, cyclohexyl, H, 182.5-3.5°; MeO, cyclohexyl, H, 173-4.5°; NH<sub>2</sub>, H, cyclohexyl, .; OH, H, cyclohexyl, .; MeO, H, cyclohexyl, 126.5-8.0°; NH<sub>2</sub>, H, cyclopropyl, 185.5-7.5°; OH, H, cyclopropyl, 169-72°; MeO, H, cyclohexyl, 112.5-14.5°; MeO, Ph, H, 221-2°; MeO, H, Ph, 140-1°; MeO, Cl, Ph, 187.5-91.5°; MeO, Ph, Br, 217-21°; OH, H, p-ClC<sub>6</sub>H<sub>4</sub>, 213-15°; MeO, H, p-ClC<sub>6</sub>H<sub>4</sub>, 181.5-3.5°; MeO, Cl, Ph, 187.5-90.5°; MeO, Me<sub>2</sub>N, Ph, 167-9.5°; MeO, H, Cl, 142° (decomposition); MeO, MeNH, Cl, 221-2°; MeO, EtNH, Cl, 149-50°; MeO, PhNH, Cl, 118-40°; MeO, iso-PrNH, Cl, 125.5-6.5°; MeO, CH<sub>2</sub>-CH<sub>2</sub>CH<sub>2</sub>NH, Cl, 105.6-5°; MeO, BuNH, Cl, 140-2°; MeO, sec-BuNH, Cl, 106-8°; MeO, iso-BuNH, Cl, 113.5-15.5°; MeO, tert-BuNH, Cl, 98-108°; MeO, Me(CH<sub>2</sub>)<sub>4</sub>NH, Cl, 100.5-2.5°; MeO, BuCHMeNH, Cl, .; MeO, Et<sub>2</sub>CHNH, Cl, .; MeO, Me(CH<sub>2</sub>)<sub>5</sub>NH, Cl, 72.5-5.5°; MeO, cyclopropylmethylamino, Cl, 132-3°; MeO, cyclopropylamino, Cl, 167-9°; MeO, cyclopentylamino, Cl, 119.5-21.5°; MeO, PhCH<sub>2</sub>NH, Cl, 187-8°; MeO, p-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>NH, Cl, 112.5-14.5°; MeO, o-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>NH, Cl, 171-4°; MeO, p-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>NH, Cl, 136-7°; MeO, PhCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 115-19°; MeO, PhCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 153-4°; MeO, PhCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 124.5-5.5°; MeO, HOCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 155-7°; MeO, HOCH<sub>2</sub>(CH<sub>2</sub>)<sub>4</sub>CH<sub>2</sub>NH, Cl, 172-5°; MeO, H<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 265°; MeO, Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>NH, Cl, 257°; MeO, 4-pyridylmethylamino, Cl, 95-7°; Me, 2-furylmethylamino, Cl, 148-9°; MeO, MeCN, Cl, 102-4°; MeO, MePN, Cl, 83.5-5.5°; MeO, iso-PrMeN, Cl, 75.5-7.5°; MeO, Me(CH<sub>2</sub>-CH<sub>2</sub>)<sub>2</sub>N, Cl, 90.5-2°; MeO, MeBun, Cl, 59.5-61.5°; MeO, Et<sub>2</sub>N, Cl, 99-101°; MeO, EtPrN, Cl, .; MeO, iso-PrEtN, Cl, .; MeO, Et(CH<sub>2</sub>-CH<sub>2</sub>)<sub>2</sub>N, Cl, .; MeO, EtBun, Cl, 77.5-9.5°; Me, Pr<sub>2</sub>N, Cl, 68.5-71.5°; MeO, PrBun, Cl, .; MeO, 1-pyrrolidinyl, Cl, 168-71°; MeO, hexamethylenimino, Cl, 109-11°; MeO, 4-methylpiperazino, Cl, 186-8°; MeO, MeNHNH, Cl, 136.5-8°; MeO, Me<sub>2</sub>NCH<sub>2</sub>CH<sub>2</sub>O, Cl, 134.5-6.5°; NH<sub>2</sub>, H, Cl, 227-30°; OH, H, MeSO<sub>2</sub>, 219-42° (decomposition).  
p-Methylbenzylamine is treated with H<sub>2</sub>NC(CH<sub>3</sub>)<sub>2</sub>MeO. 0.5H<sub>2</sub>SO<sub>4</sub> to give 281 Me-(PhCH<sub>2</sub>)NC(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>HCl, m. 153-5°. Similarly prepared are Me-(PhCH<sub>2</sub>)NC(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>HCl, m. 122.5-5.5°, and the following R<sup>1</sup>NC(CH<sub>3</sub>)<sub>2</sub>NH<sub>2</sub>HCl (R and m.p. given): o-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 131-6°; p-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 162.5-4.5°; p-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 132-7°; 2,4-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, 105-15°; 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, 145-8°; 3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, 153-7°; PhCH<sub>2</sub>CH<sub>2</sub>, 135-8°; PhCH<sub>2</sub>,

221-2\*: PrBuN, 215-7\* (1-pyrroldinyl), 244.5-5.5\*;  
hexamethylenamino, 224-5\* (4-methylpiperazin-), - (2HCl salt m;  
229-300\*)<sup>1</sup>; MeNH<sub>2</sub>, 234\*<sup>1</sup>; Cl<sub>2</sub>N, - (HCl salt m;  
259-61\*)<sup>1</sup>; MeNH, 218-19\* (decomposition); Me<sub>2</sub>NH<sub>2</sub>, - (2HCl salt m;  
265\* (decomposition)); Me<sub>2</sub>N, 210\* (decomposition) [sic]; Me<sub>2</sub>N,  
245\* (decomposition); Me<sub>2</sub>N, - (HCl salt m, 288\* (decomposition));  
EtNH, 218-9\* (decomposition); cyclohexylamino, 221-30\* (decomposition);  
(decomposition); cyclohexylamino, 221-30\* (decomposition); cyclopropylamino,  
196.5-9\* (decomposition); PhNH, 224-6\* (decomposition); PhNH,  
194.5-5.5\* (decomposition) [sic]; Ph<sub>2</sub>N, 234.5-5.5\*<sup>1</sup>; Ph<sub>2</sub>CH,  
214-16\* (decomposition); PhBuN, 214-6\* (decomposition); p-ClC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>,  
282-5\* (decomposition); MePhN, 212-13\* (decomposition); MePhN,  
218-19\* (decomposition) [sic]; Me<sub>2</sub>NHPh, 204-6\* (decomposition);  
1-pyrroldinyl, 220-5\*<sup>1</sup>; 3-pyrrolyl, 211-13\*<sup>1</sup>;  
4-chloro-1-pyrrolyl, 214-7\* (decomposition); (3-isopropylideneamino-6-  
anilino-2-pyrazinecarbonyl)guanidine, 214-16\* (decomposition);  
(3-acetoamido-6-methylthio-2-pyrazinecarbonyl)guanidine, 220-2\*;  
the following I (R = NH<sub>2</sub>, Y = Cl) (R, R<sub>1</sub>, m.p., and m.p. HCl salt given):  
H, HOCH<sub>2</sub>CH<sub>2</sub>, -, 228.5-9.5\* (decomposition); H, Ph, -, -, [MeSO<sub>3</sub>H salt m;  
272\* (decomposition)]; H, PhCH<sub>2</sub>, 215-16\* (decomposition); H, R,  
p-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 216-19\* (decomposition); -, H, PhCH<sub>2</sub>Me, 153-60\*  
(decomposition); -, H, 2-ClCH<sub>2</sub>CH<sub>2</sub>, 216-19\* (decomposition); -, H,  
3-pyridinylthyl, 280.5-3.5\* (decomposition); -, H, p-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>,  
210-12\* (decomposition); -, Me, PhCH<sub>2</sub>, 274.5\* (decomposition); -, H,  
o-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 220-3\* (decomposition); -, H, p-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 204-6\*  
(decomposition); -, H, p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, 175.5-9.5\* (decomposition); -, H,  
2,4-Me<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, 220-2\* (decomposition); -, H, 2,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, -,  
267.5-70.5\* (decomposition); -, H, 3,4-Cl<sub>2</sub>C<sub>6</sub>H<sub>3</sub>CH<sub>2</sub>, 216-19\*  
(decomposition); -, H, PhCH<sub>2</sub>CH<sub>2</sub>, 216-19\* (decomposition); -, Me, Me,  
218-19\* (decomposition) [HCl·H<sub>2</sub>O salt m, 275\* (decomposition)]; H,  
octahydro-azacyclopent-, -, Et, Et, 265\* (decomposition); -, Bu, Bu,  
148-9\*<sup>1</sup>; -, (RR<sub>1</sub> = ) (CH<sub>2</sub>)<sub>4</sub>, -, (RR<sub>1</sub> = ) 3-oxapentamethylene, -,  
-; the following I (R = R<sub>1</sub> = Me, Y = Cl) (K and n.p. given): iso-PrNH,  
238-40.5\*<sup>1</sup>; CH<sub>2</sub>:CHCH<sub>2</sub>NH<sub>2</sub>, 213-15\*<sup>1</sup>; BuNH<sub>2</sub>, 187.5\*<sup>1</sup>;  
cyclopropylmethylenamino, 196-7\*<sup>1</sup>; Me<sub>2</sub>N, 219\*<sup>1</sup>; Me<sub>2</sub>NH,  
217-18\*<sup>1</sup>; iso-PrMeN, 209-11\*<sup>1</sup>; Et<sub>2</sub>N, 212-14\*<sup>1</sup>; (R = H,  
R<sub>1</sub> = HOCH<sub>2</sub>CH<sub>2</sub>, Y iso-PrNH<sub>2</sub>, 181-2\*<sup>1</sup>; HCl·H<sub>2</sub>O salt m, 185-6\*  
(decomposition)); and 1-(3,5-diamino-6-chloro-2-pyrazinecarbonyl)2,3-  
dimethylguanidine.

IT 1634-17-9P 1634-21-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 1634-17-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-(4-chlorophenyl)-  
(9CI) (CA INDEX NAME)



RN 1634-21-5 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-phenyl- (9CI) (CA  
INDEX NAME)



L9 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN  
ACCESSION NUMBER: 1968:427459 CAPLUS  
DOCUMENT NUMBER: 69:27459  
TITLE: 3-amino-6-substituted-pyrazinoyl guanidines  
INVENTOR(S): Cragoe, Edward J., Jr.  
PATENT ASSIGNER(S): Merck and Co., Inc.  
SOURCE: U.S. 9 pp. Continuation-in-part of U.S. 3313813  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3360517		19671226	US 1966-534638	19640311

AB For diagram(a), see printed CA 313, 613. The title compds. (I) which  
Continuation-in-part of U.S. 3,313,613. The title compds. (I) which  
possess diuretic and natriuretic properties, were prepared by treating II (R  
= alkoxy) with a guanidine or by treating II (R = OH) with a lower  
alkaric acid to give III. The title compds. were prepared by treating a guanidine  
and the product hydrolyzed. Thus, 52.5 g. ammoniumnonanediimidate-di-HCl  
was added to an ice cold solution of 28.8 g. ethylglycol in 450 ml. H<sub>2</sub>O,  
.apprx.65 ml. concentrated NH<sub>4</sub>OH solution and the basic solution kept 20  
hrs. at  
room temperature to give 17.5 g. II (R<sub>1</sub> = Et, X = H, R<sub>2</sub> = NH<sub>2</sub>), m. 160-7°  
(iso-OPH). A mixture of 24.6 g. of this and 200 ml. 10% NaOH was stirred  
on a steam bath and worked up to give 22.8 g. II (R<sub>1</sub> = Et, R<sub>2</sub> =  
OH, X = H) m. 149-52°. A solution of 14 g. of this in 160 ml. 33% HCl  
in MeOH was stirred 24 hrs. at room temperature and worked up to give 4.3 g. II  
(R<sub>1</sub> = Et, R<sub>2</sub> = OMe, X = H) m. 85-75° (iso-PROH). A mixture of 5.8  
g. guanidine-HCl and a solution of 1.1 g. Na in 30 ml. MeOH was concentrated in  
vacuo to a sirup, 0.012 mole of the sirup ester added and the mixture  
heated 20 min. on ice-water bath and worked up to give 5.1 g. II (R<sub>1</sub> = Et, R<sub>2</sub> =  
R<sub>3</sub> = R<sub>4</sub> = X = H) m. 207-9° (decomposition). A mixture of 31 g. II (R<sub>1</sub> =  
Me, R<sub>2</sub> = NH<sub>2</sub>, X = H) and 320 ml. 10% NaOH was heated 30 min. on a steam  
bath to give 25 g. of the acid Na salt. A mixture of 97 g. of the Na salt,  
77 g. Me<sub>2</sub>SO, and 700 ml. MeOH was stirred 19 hrs. at room temperature to give  
16 g. II (R<sub>1</sub> = Me, R<sub>2</sub> = OMe, X = H) m. 138-40°. Treatment of the  
salt with gaseous CO<sub>2</sub> at 40° for 6 hrs. gave 87% II (R<sub>1</sub> = Me, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X =  
H), m. 218-19° (decomposition). The following were similarly prepared: II  
(R<sub>1</sub> = cyclohexyl, R<sub>2</sub> = NH<sub>2</sub>, X = H); II (R<sub>1</sub> = cyclohexyl, R<sub>2</sub> = OH, X = H);  
II (R<sub>1</sub> = cyclohexyl, R<sub>2</sub> = OMe, X = H), m. 126.5-8.0°; 61% II (R<sub>1</sub> =  
cyclohexyl, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m. 228-30°; II (R<sub>1</sub> =  
cyclopropyl, R<sub>2</sub> = NH<sub>2</sub>, X = H), m. 185.5-7.5°; II (R<sub>1</sub> = cyclopropyl,  
R<sub>2</sub> = OH, X = H), m. 112-5.4°; II (R<sub>1</sub> = cyclopropyl, R<sub>2</sub> = OMe, X = H),  
m. 112.5-4.5°; 61% II (R<sub>1</sub> = cyclopropyl, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m.  
196.5-9.0° (decomposition); II (R<sub>1</sub> = Ph, R<sub>2</sub> = OMe, X = H), m.  
140-1°; 34% II (R<sub>1</sub> = Ph, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m.  
194.5-5.5°; II (R<sub>1</sub> = PhCH<sub>2</sub>CH<sub>2</sub>, R<sub>2</sub> = OH, X = H); II (R<sub>1</sub> = PhCH<sub>2</sub>CH<sub>2</sub>,  
R<sub>2</sub> = OMe, X = H); II (R<sub>1</sub> = p-ClC<sub>6</sub>H<sub>4</sub>, R<sub>2</sub> = NH<sub>2</sub>, X = H); II (R<sub>1</sub> = p-ClC<sub>6</sub>H<sub>4</sub>,  
R<sub>2</sub> = OH, X = H), m. 112-5.4°; II (R<sub>1</sub> = p-ClC<sub>6</sub>H<sub>4</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H),  
m. 181-5.3°; and 70% II (R<sub>1</sub> = p-ClC<sub>6</sub>H<sub>4</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H),  
282.5° (decomposition). With vigorous stirring, .apprx.140 g. Cl was


passed through a solution just <40° of 3180 ml. H<sub>2</sub>O, 750 ml. HOAc, and 90. g. II (R<sub>1</sub> = X = H, R<sub>2</sub> OMe) 25 min. to give II (R<sub>1</sub> = Cl, R<sub>2</sub> = OMe, X = Cl), m. 142° (decomposition), which on stirring at 25° with 150 g. NaHSO<sub>3</sub> in 900 ml. H<sub>2</sub>O gave 55% II (R<sub>1</sub> = Cl, R<sub>2</sub> = OMe, X = H), m. 159-61°. A solution of 18.8 g. of this, 15 g. PhNH<sub>2</sub>, 2.5 ml. concentrated HCl, and 150 ml. MeOAc was refluxed 16 hrs. to give 7.4 g. II (R<sub>1</sub> = anilino, R<sub>2</sub> = isopropylamino, R<sub>3</sub> = R<sub>4</sub> = H, X = H) (m. 160-61°). Treatment of the ester with guanidine hydrochloride gave 35% I (R<sub>1</sub> = anilino, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, NHR<sub>5</sub> = isopropylaminamino) m. 214-16° (decomposition). A mixture of 300 g. II (R<sub>1</sub> = Cl, R<sub>2</sub> = OMe, X = H) and 2.1. concentrated NH<sub>4</sub>OH was stirred 16 hrs. at room temperature to give 260 g. I (R<sub>1</sub> = Cl, R<sub>2</sub> = OMe, X = H), m. 227-30°. A mixture of 3.3 g. of this amide, 200 ml. Ac<sub>2</sub>O, and 200 ml. [EtO]3CN was refluxed 1.5 hrs. to give 20 g. IV (R<sub>1</sub> = Cl, R<sub>2</sub> = H) m. 268-70° (decomposition). A solution of 5.5 g. IV (R<sub>1</sub> = Cl, R<sub>2</sub> = H) and 4.4 g. benzyl mercaptan in 4% NaOH was heated 30 min. on a steam bath to give 5.5 g. IV (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = H), m. 233-5° (iso-PrOH). A solution of 42 g. IV (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = H) in 600 ml. 5% NaOH was heated 8 hrs. on a steam bath to give 10 g. II (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = OH, X = H), m. 127-39°. A solution of 8.5 g. of this acid in 50 ml. Ac<sub>2</sub>O was heated 5 hrs. on a steam bath to give 6.6 g. III (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = Me), m. 116.5-18.5° (C<sub>6</sub>H<sub>6</sub>). To a solution of 1.0 g. Na in 30 ml. iso-PrOH was added 5 g. guanidine-HCl and 3.4 g. III (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = Me), and the mixture kept 1 hr. at room temperature to give 1.1 g. I (R<sub>1</sub> = PhCH<sub>2</sub>S, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m. 171-37° (aqueous iso-PrOH). Similarly prepared were: IV (R<sub>1</sub> = MeS, R<sub>2</sub> = H), m. 289.5-91.5°; II (R<sub>1</sub> = MeS, R<sub>2</sub> = OH, X = OH, m. 182-4° (decomposition); III (R<sub>1</sub> = MeS, R<sub>2</sub> = Me), m. 193-91°; 68% I (R<sub>1</sub> = MeS, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac), m. 120-2°, and 20% I (R<sub>1</sub> = MeS, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = H), m. 203-5°. A solution of 1.05 g. KMnO<sub>4</sub> in 35 ml. H<sub>2</sub>O was added to a solution of 0.92 g. II (R<sub>1</sub> = MeS, R<sub>2</sub> = OH, X = H) and 15 ml. of a 2.5% NaOH solution to give 0.5 g. II (R<sub>1</sub> = MeSO<sub>2</sub>, R<sub>2</sub> = OH, X = H), m. 239-42° (decomposition). Also prepared were: III (R<sub>1</sub> = MeSO<sub>2</sub>, R<sub>2</sub> = Me), m. 214-16°; 27% I (R<sub>1</sub> = MeSO<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = H), m. 224-4° (decomposition); 20% I (R<sub>1</sub> = PhCH<sub>2</sub>SO<sub>2</sub>, R<sub>2</sub> = OH, X = H), m. 160-61°; 20% I (R<sub>1</sub> = PhCH<sub>2</sub>SO<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m. 142-4°; IV (R<sub>1</sub> = MeO, R<sub>2</sub> = Me), m. 232-4°; III (R<sub>1</sub> = MeO, R<sub>2</sub> = Me), m. 190-2°; 92% I (R<sub>1</sub> = MeO, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac) [as nitrate, m. 225-9°]; I (R<sub>1</sub> = MeO, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); II (R<sub>1</sub> = Cl, R<sub>2</sub> = NH<sub>2</sub>, X = Me), m. 152.5-4.5°; I (R<sub>1</sub> = Cl, R<sub>2</sub> = OH, X = H), m. 217.5-19.5°; I (R<sub>1</sub> = Me, R<sub>2</sub> = Me), m. 256-8°; II (R<sub>1</sub> = MeO, R<sub>2</sub> = OH, X = H), m. 164.5-5.5°; III (R<sub>1</sub> = NMe<sub>2</sub>, R<sub>2</sub> = Me), m. 212° (decomposition); I (R<sub>1</sub> = NMe<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac) [as nitrate, m. 236.5° (decomposition)]; I (R<sub>1</sub> = NMe<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H), m. 196.5° (decomposition); IV (R<sub>1</sub> = isopropylamino, R<sub>2</sub> = Me); II (R<sub>1</sub> = isopropylamino, R<sub>2</sub> = OH, X = H) Na salt; I (R<sub>1</sub> = PhCH<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = H) [as nitrate, m. 203-5° (decomposition)]; I (R<sub>1</sub> = isopropylamino, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); IV (R<sub>1</sub> = PhCH<sub>2</sub>NH, R<sub>2</sub> = Me), m. 212-14°; I (R<sub>1</sub> = PhCH<sub>2</sub>NH, R<sub>2</sub> = OH, X = H), m. 130-2° (decomposition); III (R<sub>1</sub> = PhCH<sub>2</sub>NH, R<sub>2</sub> = Me), m. 168-70°; I (R<sub>1</sub> = PhCH<sub>2</sub>NH, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac) [as nitrate, m. 225-8°]; I (R<sub>1</sub> = PhCH<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); I (R<sub>1</sub> = piperidino, R<sub>2</sub> = Me), m. 107-8°; I (R<sub>1</sub> = piperidino, R<sub>2</sub> = OH, X = H); II (R<sub>1</sub> = piperidino, R<sub>2</sub> = Me), m. 172-4°; I (R<sub>1</sub> = piperidino, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac) [as nitrate, m. 228°]; I (R<sub>1</sub> = piperidino, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); IV (R<sub>1</sub> = MeONH, R<sub>2</sub> = Me), m. 232-4°; II (R<sub>1</sub> = MeONH, R<sub>2</sub> = ONa, X = H); III (R<sub>1</sub> = MeONH, R<sub>2</sub> = Me), m. 190-2°; I (R<sub>1</sub> = MeONH, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H, X = Ac), m. 258-8°; I (R<sub>1</sub> = MeONH, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); I (R<sub>1</sub> = NH<sub>2</sub>, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); I (R<sub>1</sub> = MeNH, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H); I (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = Me, R<sub>5</sub> = X = H) I [R<sub>1</sub> = Me, R<sub>2</sub> = X = H, (R<sub>3</sub>R<sub>4</sub> = ) tetramethylene]; I (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = Me, R<sub>4</sub> = X = H); 2-hydroxyguanidine sulfate, m. 127.5-35.5° (hygroscopic); I.HCl (R<sub>1</sub> = Me, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = X = H, R<sub>5</sub> = CH<sub>2</sub>CH<sub>2</sub>CONH<sub>2</sub>); I (R<sub>1</sub> = Me, R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = Ph); benzylguanidine sulfate, and I (R<sub>1</sub> = R<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = Me, R<sub>5</sub> = H).

EXAMPLE 3. A formulation for a dry filled capsule containing 50 mg. PhCH<sub>2</sub>S.


mg. of I.HCl (R1 = Me2N, R2 = R3 = R4 = X = H) as the active ingredient and a combination dosage form in a dry filled capsule containing 50 mg. I.HCl (R1 = Me, R2 = R3 = R4 = X = H) and 50 mg. hydrochlorothiazide are given.

IT 1634-17-99 1634-21-5P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 1634-17-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 1634-21-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-phenyl- (9CI) (CA INDEX NAME)




L9 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1967:500105 CAPLUS  
 DOCUMENT NUMBER: 67:100105  
 TITLE: Pyrazine diuretics. III. 5- and 6-alkyl-, -cycloalkyl-, and -aryl derivatives of N-amidino-3-aminopyrazinecarboxamides  
 AUTHOR(S): Bickling, John B.; Robb, Charles M.; Kwong, Sara F.; Cragoe, Edward J., Jr.  
 CORPORATE SOURCE: Merck and Co. Inc., West Point, PA, USA  
 SOURCE: Journal of Medicinal Chemistry (1967), 10(4), 598-602  
 CODEN: JMCMAH; ISSN: 0022-2623  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI For diagram(s), see printed CA Issue.  
 AB cf. CA 63: 11561e; 66: 37887h. In evaluations of N-amidino-3-aminopyrazinecarboxamides as diuretics, a series of 5- and 6-alkyl-, -cycloalkyl-, and -aryl deriva. was synthesized and studied for effects on renal electrolyte excretion. Several comds. reverse the electrolyte excretion effects of deoxycorticosterone acetate in the adrenalectomized rat, the most highly active being N-amidino-3-amino-6-methylpyrazinecarboxamide (I). 16 references.  
 IT 1634-21-5P 16014-43-0P 16014-59-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)

RN 1634-21-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-phenyl- (9CI) (CA INDEX NAME)




RN 16014-43-0 CAPLUS  
 CN Pyrazinecarboxamide, N-amidino-3-amino-6-(p-chlorophenyl)-, monohydrochloride (8CI) (CA INDEX NAME)



• HCl

RN 16014-59-8 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



L9 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1966:67873 CAPLUS  
 DOCUMENT NUMBER: 64:67873  
 ORIGINAL REFERENCE NO.: 64:12698g-h, 12699a-h, 12700a-b  
 TITLE: Pyrazine diuretics  
 PATENT ASSIGNER(S): Merck & Co., Inc.  
 SOURCE: 30 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 6409714		19651001	NL	19640331

PRIORITY APPL. INFO.:  
 GI For diagram(s), see printed CA Issue.  
 AB Diuretics with structure I were prepared in 4 steps: (1) preparation of the 2-pyrazinecarboxamide, (2) hydrolysis of the amide to the acid, (3) esterification, and (4) treatment with guanidine. An alternative method makes use of the corresponding pteridines. Step 1: to an ice-cold solution of 28.8 g. ethylglyoxal in 450 ml. H2O 52.5 g. aminomelonsamide amine was added followed by the addition of approx. 65 ml. concentrated aqueous NH4OH before


allowing the mixture to stand 20 hrs. at room temperature to give 17.5 g. II (A = NH2, R1 = Et), m. 160-7° (iso-PROH). Step 2: a mixture of 24.4 g. II (A = NH2, R1 = Et) and 200 ml. 10% aqueous NaOH was heated 30 min. on a steam bath with stirring and then worked up to obtain 22.8 g. III (A = NH2, R1 = Et), m. 149-52°. Step 3: a solution of 14 g. III (A = NH2, R1 = Et) in 160 ml. 31% methanolic HCl was stirred 24 hrs. at room temperature, then the solvent evaporated in vacuo, and the residue triturated with NaHCO3 solution to obtain 4.3 g. IV (A = NH2, R1 = Et), m. 85-7.5° (iso-PROH). Step 4: to a solution of 1.1 g. Na in 30 ml. MeOH 5.8 g. guanidine-HCl was added, the solution then concentrated in vacuo to a sirup to which 0.012 mole IV (A = NH2, R1 = Et) was then added and warmed 20 min. on a steam bath, the mixture diluted with ice water followed by 15 ml. 5N HCl, then filtered, and treated with 2 ml. concentrated HCl to obtain the HCl salt as a precipitate, which was then dissolved in H2O and treated with aqueous NaOH to give the free base V (A = NH2, R1 = Et), m. 207-9°. Similarly the following comds. (A = NH2) were prepared (comps., R1, and m.p. given): IV, Me, 138.5-40.5°; V, Me, 218-19° (decomposition); IV, cyclohexyl, 126.5-8.0°; II, cyclohexyl, --; III, cyclohexyl, --; V, cyclohexyl, 228-30° (decomposition); II, cyclopropyl, 185.5-7.5°; III, cyclopropyl, 169-72°; IV, cyclopropyl, 112-14.5°; V, cyclopropyl, 196.5-9.0°; IV, Ph, 140-3°, V, Ph, 194.5-5.8°; II, 4-ClC6H4, --; III, 4-ClC6H4, 211-15°; IV, 4-ClC6H4, 181.5-3.5°; V, 4-ClC6H4, 282-5° (decomposition). In a 5-l. flask 90 g. IV (A = NH2, R1 = H) was added to a warm (approx. 38°) solution of 750 ml. HOAc in 3.18 l. H2O, which was then warmed to 41° with stirring until the mixture was a solution, then cooled to just below 40° with vigorous agitation, and 140 g. Cl introduced over 25 min. to give a white precipitate IV (A = NHCl, R1 = Cl), decomposed 142° (HOAc), which was then added to a solution of 150 g. NaHCO3 in 900 ml. H2O in a 4-l. beaker and stirred 0.5 hr. with occasional addition of ice to keep the temperature at 25°, filtered off, washed with ice water several times and once with 50 ml. cold iso-PROH, and air-dried to give 55 IV (A = NH2, R1 = Cl), m. 159-6°. A solution of 18.8 g. IV (A = NH2, R1 = Cl), 15 g. PhNH2, and 2.5 ml. concentrated HCl in 150 ml. Me2CO was refluxed 16 hrs., cooled, and filtered to remove 7.4 g. IV (A = NMe2, R1 = PhNH), m. 195.5-7.5° (iso-PROH). V (A = NMe2, R1 = PhNH), decomposed 214-16° (H2O), was obtained in 35% yield with Step 4. II (A = NH2, R1 = Cl), m. 227-30°, was obtained by stirring 16 hrs. a mixture of 300 g. IV (A = NH2, R1 = Cl) and 2 l. concentrated NH4OH at room temperature

A mixture of 33 g. II (A = NH2, R1 = Cl), 200 ml. Ac2O, and 200 ml. HCl(OEt)3 was refluxed 1.5 hrs. and filtered to give 20 g. VI (R1 = Cl), decomposed 268-70° (aqueous iso-PROH). A solution of 5.5 g. VI (R1 = Cl) and 4.4 g. PhCH2SH in 100 ml. 4N NaOH was warmed 30 min. on a steam bath, cooled, treated with 20 ml. 40% NaOH, filtered, and the residue then dissolved in 250 ml. hot H2O and acidified to give 5.5 g. VI (R1 = PhCH2S), m. 233-5° (aqueous iso-PROH). III (A = NH2, R1 = PhCH2S), m. 138-8° (EtOAc), was obtained in 23 g. yield by heating gently 42.2 g. VI (R1 = PhCH2S) 8 hrs. in 600 ml. 5N NaOH, filtering, and acidifying the residue in aqueous solution. Treatment of 8.5 g. III (A = NH2, R1 = PhCH2S) with 50 ml. Ac2O while heating 5 hrs. on a steam bath followed by drying in vacuo gave 6.6 g. VII (R1 = PhCH2S), m. 116.5-18.5° (PhH). To a solution of 5 g. guanidine-HCl and 1 g. Na in 30 ml. iso-PROH 3.4 g. VII (R1 = PhCH2S) was added, and the mixture allowed to stand 1 hr. at room temperature and then worked up to obtain 1.1 g. V (A = NH2, R1 = PhCH2S), decompose 171-3° (aqueous iso-PROH). Analogously the following comds. were prepared (R1 = MeS; compound, A, and m.p. given): VI, --, 289.5-91.5°; III, NH2, 182-4° (decomposition); VII, --, 189-91°; V, NHAc, 220-2°; V, NH2, 203-5°. V (A = NHAc, R1 = MeS) was readily hydrolyzed in aqueous HCl to give V (A = NH2, R1 = MeS). Treatment of 0.92 g. III (A = NH2, R1 = MeS) in 15 ml. 2.5N NaOH with a solution of 1.05 g. KOH in 35 ml. H2O gave III (A = NH2, R1 = MeSO2), decomposed 239-42°


(iso-PROH), which was then treated with Ac2O to obtain VII (R1 = MeSO2), m. 214-16°, and then with guanidine to obtain V (A = NH2, R1 = MeSO2), decomposed 224-6° (aqueous iso-PROH). A suspension of 20 g. IV (A = NH2, R1 = Cl) in 200 ml. 40% MeNH2 was stirred 20 hrs. at room temperature to give 85% IIA (A = NH2, R1 = Cl), m. 152.5-4.5° (EtOH). VIII (R1 = Cl), m. 217.5-19.5° (MeOH), was obtained in 82% yield by refluxing 2 hrs. 20 ml. HCl(OEt)3 and 20 ml. Ac2O to which 3 g. IIA (A = NH2, R1 = Cl) had been added. Warming 5 ml. 25% aqueous Me2NH in 40 ml. MeOCH2CH2OH after addition of 4 g. VIII (R1 = Cl) 2.5 hrs. on a steam bath produced 72% VIII (R1 = Me2N), m. 256-8° (MeOH), which was converted into III (A = NH2, R1 = Me2N), decomposed 164.5-5.5° (MeOH), by warming 2.5 hrs. in 15 ml. 10N NaOH. By means of these methods the comds. in the table were prepared. Benzylguanidine sulfate (IX), m. 203-7°, was obtained in 78 g. yield by combining 80.3 g. PhCH2NH2 and 69.5 g. MeSC(=NH)NH2.H2SO4 in 200 ml. H2O at room temperature 18 hrs. IX was

treated with 48.8 g. BaCl2.2H2O to obtain benzylguanidine-HCl, m. 175-8° (aqueous alc.), in 55% yield. Similarly 2-hydroxyethylguanidine, m. 127.5-35.5°, was prepared

IT 1634-17-9 Pyrazinecarboxamide, N-amidino-3-amino-6-(p-chlorophenyl)- 1634-21-5 Pyrazinecarboxamide, N-amidino-3-amino-6-phenyl- (preparation of)  
 RN 1634-17-9 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 1634-21-5 CAPLUS  
 CN Pyrazinecarboxamide, 3-amino-N-(aminoiminomethyl)-6-phenyl- (9CI) (CA INDEX NAME)




L9 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 1965:440720 CAPLUS  
 DOCUMENT NUMBER: 63:80720  
 ORIGINAL REFERENCE NO.: 63:14885c-f  
 TITLE: β-Hydroxyalkylidimethylxanthines  
 INVENTOR(S): Sommer, Armin; Kern, Rudi; Doff-Sotta, Manfred  
 SOURCE: 3 pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Unavailable  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------



DD 31894 19650426 DD 19620528  
AB Theobromine (I) and theophylline (II) were converted into their N-β-hydroxyalkyl derivs. by heating with a 1,2-epoxide and an amine in H<sub>2</sub>O, also, or their salts. Primary, secondary, or tertiary amines containing similar or different alkyl or hydroxyalkyl groups of up to 3 C atoms were suitable catalysts. Pure colorless products were obtained without recrystn. Mother liquors could be used repeatedly without adding more catalyst. Thus, 100 g. I, 50 g. propylene oxide (III), and 40 ml. MeN(CH<sub>2</sub>CH<sub>2</sub>OH)<sub>2</sub> (IV) in 600 ml. BuOH were refluxed 1.5 hrs. with stirring. Charcoal was added, the solution filtered hot, and cooled to give 91% 1-(β-hydroxypropyl)theobromine (V), m. 141-2°. When 10 ml. Et<sub>2</sub>NH was used instead of IV and the mixture refluxed 3 hrs., a 89.5% yield of V resulted. The use of the Et<sub>2</sub>NH-containing mother liquor as a solvent produced V in 97% yield. Ethylene oxide (45 g.) was added slowly into a boiling mixture of 100 g. I, 10 ml. Et<sub>2</sub>NH, 450 ml. MeOH, and 50 ml. H<sub>2</sub>O, and the mixture boiled 5 hrs., treated with charcoal, filtered, and cooled to give 99 g. 7-(β-hydroxyethyl)theophylline (VI, R = H), m. 159-60°; another 17 g. was obtained on concentration of the mother liquor. A mixture of 20 g. II, 20 g. III, 100 ml. MeOH, and 2 ml. Et<sub>2</sub>NH was refluxed 6 hrs. and most MeOH distilled to leave VI (R = Me), m. 133°. II (20 g.), 15 g. epichlorohydrin, 120 ml. iso-PrOH, and 2 ml. Et<sub>2</sub>NH, refluxed 2.5 hrs. and a part of iso-PrOH distilled, gave VI (R = CH<sub>2</sub>Cl), m. 146-7° (aqueous MeOH). Cf. CA 58, 1473e.  
IT 3584-28-9. Pyrazinecarboxamide, 3-amino-N-benzimidoyl-6-phenyl- (preparation of)  
RN 3584-28-9 CAPLUS  
CN Pyrazinecarboxamide, 3-amino-N-benzimidoyl-6-phenyl- (7CI, 8CI) (CA INDEX NAME)



L9 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1965:82636 CAPLUS  
DOCUMENT NUMBER: 62:82636  
ORIGINAL REFERENCE NO.: 62:14698t-h, 14699a-h, 14700a-h, 14701a-h, 14702a-b  
TITLE: Substituted guanidines  
INVENTOR(S): Crapoe, Edward J., Jr.  
PATENT ASSIGNOR(S): Merck & Co., Inc.  
SOURCE: 99 pp.  
DOCUMENT TYPE: Patent  
LANGUAGE: Unavailable  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
BE 639386	BE	19640430	US	19621030

PRIORITY APPL. INFO.:  
GI For diagram(s), see printed CA Issue.  
AB A suspension of 765 g. Me 3-aminopyrazinecarboxylate in 5 l. C<sub>6</sub>H<sub>6</sub> was treated with 1.99 l. SO<sub>2</sub>Cl<sub>2</sub>, refluxed for 5 hrs., and left overnight at room temperature to give 888 g. crude Me 3-amino-5,6-dichloropyrazinecarboxylate (I), m. 233-4°. Into a solution of 100 g. I in 1 l. dry Me<sub>2</sub>SO dry NH<sub>3</sub> was passed under stirring at 65-70° for 45 min., then at 10°

for 1.25 hrs. to give 82.5 g. Me 3,5-diamino-6-chloropyrazinecarboxylate (II), m. 212-13°. A mixture of 14.2 g. II, 9 g. Pd-C, 4 g. MgO, and 250 ml. MeOH was shaken under H for 18 hrs. at room temperature to give Me 3,5-diaminopyrazinecarboxylate (III), m. 253-4° (decomposition) (iso-PrOH). Bromination of a suspension of 2 g. III in 25 ml. AcOH at 50° with 2.1 g. Br in 10 ml. AcOH gave 1.2 g. Me 3,5-diamino-6-bromopyrazinecarboxylate (IV), m. 217-19°. Hg(OAc)<sub>2</sub> (3.2 g.) and a solution of 2.5 g. iodine in 20 ml. warm dioxane was added rapidly to a suspension of 1.7 g. III in 30 ml. H<sub>2</sub>O at 70°, the mixture heated for 5 min., cooled to room temperature, and treated with 50 ml.

158 KI solution precipitated 1.2 g. Me 3,5-di-amino-6-iodopyrazinecarboxylate, m. 200-2°. I (11.1 g.), 500 ml. iso-PrOH, 14.4 g. PhNH<sub>2</sub>, and 12.8 g. PhNH<sub>2</sub>.HCl was refluxed 24 hrs. under stirring to give 10 g. Me 3-amino-5-anilino-6-chloropyrazinecarboxylate, m. 171.5-73° (iso-PrOH). Similarly were prepared Me 3-amino-5-(p-chloroanilino)-6-chloropyrazinecarboxylate, m. 207-8° (MeOH), and Me 3-amino-5-dimethylamino-6-chloropyrazinecarboxylate (V), m. 145.5-6.5° (MeOH). A solution of 10 g. MeSH in 17 ml. 20% NaOH and 100 ml. MeOH was added to a boiling mixture of 17.7 g. I and 1 l. MeOH and refluxed 15 min. to precipitate 12 g. Me 3-amino-5-methylthio-6-chloropyrazinecarboxylate (VI), m. 212-16° (MeOH). VI (23.4 g.), 35 ml. 30% H<sub>2</sub>O<sub>2</sub>, and 300 ml. AcOH was stirred 18 hrs. at room temperature to give 18.5 g. the 5-methylsulfinyl analog (VII), m. 237.5-40.5° (decomposition) (MeOH-AcOEt-HCONH<sub>2</sub>). Hydrolysis of 7.5 g. VII in 75 ml. AcOH and 12 ml. H<sub>2</sub>O on a steam bath for 3 hrs. produced 3.7 g. Me 3-amino-5-hydroxy-6-chloropyrazinecarboxylate (VIII), m. approx. 245° (decomposition) (HCONH<sub>2</sub>-H<sub>2</sub>O). Hydrogenation of VIII with Pd-C and MgO at room temperature resulted in Me 3-amino-5-hydroxypyrazinecarboxylate, decomposes 220-60°. Also were prepared Me 3-amino-5-dimethyl-aminopyrazinecarboxylate, m. 242.5-3.5°, Me 3,5-diaminopyrazinecarboxylate, m. 252-4° (decomposition), and Me 3-amino-5-methoxypyrazinecarboxylate, m. 205.5-7.5°. A mixture of 8.9 g. I and 20 ml. PhCH<sub>2</sub>NH<sub>2</sub> was heated on a steam bath for 30 sec. to give 7.5 g. Me 3-amino-5-benzylamino-6-chloropyrazinecarboxylate (IX), m. 157-8° (MeOH). Hydrogenation of IX yielded Me 3-amino-5-benzylaminopyrazinecarboxylate, m. 189.5-91.5°. Treatment of 1.1 g. I with MeONa in 200 ml. boiling absolute MeOH produced 1 g. Me 3-amino-5-methoxy-6-chloropyrazinecarboxylate, m. 255-7° (MeCN). Na<sub>2</sub>S (9.6 g.) and 10 g. S was refluxed in 80 ml. absolute EtOH. Addition of

8.9 g. I at 25° and stirring for 1 hr. gave 7.8 g. Me 3-amino-5-mercaptop-6-chloropyrazinecarboxylate, m. 207-8° (decomposition). To a refluxing solution of 4.44 g. I in 300 ml. EtOH was added guanidine (from 1.98 g. guanidine-HCl) in 50 ml. absolute EtOH in 15 min. and the mixture refluxed 0.5 hr. to give 3.1 g. Me 3-amino-5-ethoxy-6-chloropyrazinecarboxylate, m. 123-5° (iso-PrOH). 3-Amino-6-methylpyrazinoylamide (31 g.) was heated 10 min. with 320 ml. 10% NaOH. The resulting Na salt of the acid (97 g.) was methylated with 77 g. Me<sub>2</sub>SO<sub>4</sub> in 700 ml. MeOH 19 hrs. at room temperature to give 18 g. Me 3-amino-6-methylpyrazinecarboxylate (X), m. 138.5-40.5° (C<sub>6</sub>H<sub>6</sub>). Chlorination of 9.2 g. X with 45 ml. SO<sub>2</sub>Cl<sub>2</sub> under cooling produced 4.4 g. Me 3-amino-5-chloro-6-methylpyrazinecarboxylate, m. 108.5-10.5° (C<sub>6</sub>H<sub>6</sub>-cyclohexane). A mixture of 30 g. 3-amino-5-methylpyrazinecarboxylic acid and a solution of 30% HCl in 650 ml. MeOH was stirred 42 hrs. at room temperature to give 15.4 g. Me 3-amino-5-methylpyrazinecarboxylate (XI), m. 165-7° (H<sub>2</sub>O). A solution of 4.18 g. Br in 3 ml. AcOH was added to a solution of 4.2 g. XI in 15 ml. AcOH in 20 min. to produce 3.6 g. Me 3-amino-5-methyl-6-bromopyrazinecarboxylate, m. 179-81°. Aminomalonamidamide-2HCl (52.5 g.) was added to an ice-cooled solution of 28.8 g. ethylglyoxal in 450 ml. H<sub>2</sub>O. The mixture was made alkaline with approx. 65 ml. concentrated NH<sub>4</sub>OH and left 20 hrs. at room temperature to precipitate 17.5 g. 3-amino-6-ethylpyrazinecarboxamide, m. 165.5-8.5° (iso-PrOH), which

was saponified 30 min. on a steam bath with 10% NaOH to give 3-amino-6-ethylpyrazine-carboxylic acid (XII), m. 149-52°. Stirring 1 g. XII in a solution of 33% HCl in 160 ml. MeOH 24 hrs. at room temperature gave 4.3 g. XII Me ester, m. 85-7° (iso-PrOH). Also prepared were 3-amino-6-p-chlorophenylpyrazinecarboxylic acid, m. 207-13°, and 3-amino-6-methylpyrazinecarboxylic acid, m. 181.5-3.5°. To a suspension of 17.9 g. 5,6-diaminouracil in 250 ml. H<sub>2</sub>O at 60° 14.9 g. 2-cyclohexylglyoxal-0.5 H<sub>2</sub>O was added and the mixture heated 1 hr. on a steam bath to give 7.5 g. 7-cyclohexyllumazine (XIII), m. 229-31° (aqueous AcOH). A solution of 18.5 g. XIII and 9 g. NaOH in 90 ml. H<sub>2</sub>O was heated in an autoclave 17 hrs. at 105° to give 8 g. 3-amino-5-cyclohexylpyrazinecarboxyl. acid, m. 182.5-3.5° (aqueous iso-PrOH); Me ester m. 173-4.5°. Similarly were prepared Me 3-amino-6-cyclohexylpyrazinecarboxylate, m. 126.5-28°. Me 3-amino-6-cyclopropylpyrazinecarboxylate, m. 112.5-14.5° (amide m. 185.5-7.5°, free acid m. 169-72°). Me 3-amino-5-phenylpyrazinecarboxylate (XIV), m. 231-2°, and Me 3-amino-6-phenylpyrazinecarboxylate (XV), m. 140-1°. Chlorination of 25.6 g. XV with 90 ml. SO<sub>2</sub>Cl<sub>2</sub> 1.5 hrs. at room temperature gave Me 3-amino-5-chloro-6-phenylpyrazinecarboxylate, m. 187.5-91.5° (AcOH). Bromination of 10.5 g. XIV in 700 ml. AcOH with 11.2 g. Br 21 hrs. at 85° gave 10.5 g. Me 3-amino-5-phenyl-6-bromopyrazinecarboxylate, m. 171-21° (AcOH). To a suspension of 103.59 g. 4,5-diamino-2,6-dihydroxypyrimidine in 1500 ml. H<sub>2</sub>O and 500 ml. concentrated NH<sub>4</sub>OH at 60° 103.71 g. 1-phenyl-1,2-propanedione was added and the mixture heated at 90° under vigorous stirring to give 82.4 g. 6-(or 7)-methyl-7(or 6)-phenyllumazine, m. 281.5-2.5° (AcOH), and 32 g. 6(or 7)-phenyl-7(or 6)-methylumazine (XVI), m. 254.5-5.5°. Saponification of XVI with 8% NaOH in an autoclave 3.5 hrs. at 170° gave 3-amino-5(or 6)-phenyl-6(or 5)-methylpyrazinecarboxylic acid, m. 193.5-4.5°; Me ester m. 163-4° (MeOH). Similarly were prepared 3-amino-5(or 6)-methyl-6(or 5)-phenylpyrazine carboxylic acid, m. 155-6°; Me ester m. 162.5-3.5° (MeOH). Me 3-amino-6-phenylpyrazinecarboxylate was chlorinated with SO<sub>2</sub>Cl<sub>2</sub> to give Me 3-amino-5-chloro-6-phenylpyrazinecarboxylate, m. 187.5-90.5° (AcOH), and subsequently treated with Et<sub>2</sub>NH in MeOH to give Me 3-amino-5-dimethylamino-6-phenylpyrazinecarboxylate, m. 167.5-9.5° (MeOH). To 750 ml. AcOH and 3180 ml. H<sub>2</sub>O at 38°, 90 g. Me 3-aminopyrazinecarboxylate was added and Cl passed through in 25 min. to give Me 3-amino-6-chloropyrazinecarboxylate (XVII), m. 142° (decomposition) (H<sub>2</sub>O). A solution of 18.6 g. XVII, 15 g. PhNH<sub>2</sub>, and 2.5 ml. concentrated HCl in 150 ml. Me<sub>2</sub>CO was refluxed 16 hrs. to give 7.4 g. Me 3-isopropylideneamino-6-anilino-pyrazinecarboxylate, m. 195.5-7.5° (iso-PrOH). A mixture of 9.3 g. 3-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acid and 230 ml. absolute MeOH of 10° was treated with 30 ml. concentrated H<sub>2</sub>SO<sub>4</sub> in 1 hr. and left 24 hrs. at room temperature to give 1.6 g. the Me ester, m. 154-5° (15% MeOH-H<sub>2</sub>O). A solution of 60 g. 4-chloro-6-phenylatediamine in 60 ml. H<sub>2</sub>O and 50 ml. HCl was treated with a solution of 61.44 g. alloxan-H<sub>2</sub>O in 100 ml. H<sub>2</sub>O and stirred 1 hr. at 90° to give a precipitate of 78.4 g. 8-chloroalloxazine, m. 365-6° and 40.36 g. 7-chloro-alloxazine, (XVIII) m. 380° (Me<sub>2</sub>SO). A mixture of 44.2 g. XVIII and 190 ml. concentrated NH<sub>4</sub>OH was heated in an autoclave 10 hrs. at 165° to give 27.3% 3-amino-7-chloroquinazolin-2-carboxylic acid, m. 191-2° (decomposition); Me ester m. 224.5-5.5° (MeCN). Also prepared are the following XIX (R, R<sub>1</sub>, & yield, and m.p. given): Me, H, 88, 221-2°; Et, H, 89, 149-50°; Pr, H, 75, 138-40°; iso-Pr, H, 70, 125.5-6.5°; CH<sub>2</sub>:CHCH<sub>2</sub>, H, 69, 105-6.5°; Bu, H, 91, 140-2°; sec-Bu, H, 75, 106-8°; iso-Bu, H, 51, 113.5-15.5°; MeEt, H, 38, 98-108°; Am, H, 72, 100.5-2.5°; MePrCH, H, ---; EtCH<sub>2</sub>, H, ---; C<sub>6</sub>H<sub>13</sub>, H, 70, 72.5-5.5°; cyclopropylmethyl, H, 78, 132-3° cyclopropyl, H, 98, 167-9°; cyclopentyl, H, 93, 119.5-21.5°; PhCH<sub>2</sub>, H, 64, 157-8°; p-MeC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, 66, 112.5-14.5°; o-FC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, 84, 171-4°; p-ClC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>, H, 93, 136-7°; PhCH<sub>2</sub>CH<sub>2</sub>, H, 59, 115-19°; CPCH<sub>2</sub>, H, 97, 153-4° CP<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, H, 76,

124.5-5.5°; HOCH<sub>2</sub>CH<sub>2</sub>, H, 100, 155-7°; HOCH<sub>2</sub>(CHOH)CH<sub>2</sub>, H, 60, 172-5°; NH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, H, 96, 265°; MeNH<sub>2</sub>CH<sub>2</sub>, H, 40, 257°; 4-pyridylmethyl, H, 69, 95-7°; 2-furylmethyl, H, 81, 148-9°; Me, Et, 73, 102-4°; Me, Pr, 58, 83.5-5.5°; Me, iso-Pr, 78, 75.5-7.5°; Me, CH<sub>2</sub>:CHCH<sub>2</sub>, 70, 90-5-92°; Me, Bu, 74, 59.5-61.5°; Et, Et, 54, 99-101°; Et, Pr, ---; Et, iso-Pr, ---; Et, CH<sub>2</sub>:CHCH<sub>2</sub>, ---; Et, Bu, 91, 77.5-9.5°; Pr, Bu, ---; Pr, Pr, 66, 68.5-71.5°; (NRR<sub>1</sub> = ) pyrrolidino, 95, 168-71°; (NRR<sub>1</sub> = ) 1 (hexahydroazepinyl), 75, 109-11°; (NRR<sub>1</sub> = ) N-Methylpiperazino, 88, 186-8°; Me, NH<sub>2</sub>, 67, 136-38° Guanidine-HCl (XX) (26.3 g.) was added to a solution of MeONa (5.75 g. Na in 150 ml. absolute MeOH), the precipitated NaCl filtered off, and the filtrate concentrated to 30 ml. After addition of 11.5 g. V the mixture was boiled 1 min., then maintained 1 hr. at room temperature to give 93% (3-amino-5-dimethylamino-6-chloropyrazinecarbonyl) guanidine (XXa), m. 216-17° HCl salt m. 298° (decomposition). Similarly were prepared (3,5-diamino-6-bromopyrazinecarbonyl)guanidine, m. 232.5-5.5° (decomposition), (3,5-diamino-6-iodopyrazinecarbonyl)guanidine-HCl, m. 273-4° (decomposition) and (3-isopropylideneamino-6-anilino-pyrazinecarbonyl)guanidine, m. 214-16° (decomposition). To a solution of 920 mg. Na in 50 ml. absolute iso-PrOH 3.85 g. XX was added and the NaCl filtered off. Adding 4.4 g. I and refluxing the mixture 15 min. gave (3-amino-5,6-dichloropyrazinecarbonyl)guanidine HCl salt (XXb), m. 259-61°. The solution of XXb in 5 ml. HCONH<sub>2</sub> was treated with 1 ml. 25% aqueous Me<sub>2</sub>NH 1 hr. on a steam bath to give XXa. Reaction of 11.1 g. I with 55 ml. Me<sub>2</sub>NHCH<sub>2</sub>CH<sub>2</sub>OH 20 min. on a steam bath gave 9.5 g. Me 3-amino-5-(2-dimethylamino-ethoxy)-6-chloropyrazinecarboxylate (XXII), m. 134.5-6.5° (C<sub>6</sub>H<sub>6</sub>-cyclohexane). To 10 g. XX in iso-PrOH (4 g. Na in 100 ml. iso-PrOH) 9.4 g. XXI was added and the mixture heated 30 min. on a steam bath to give 2.5 g. (3-amino-5-guanidino-6-chloropyrazinecarbonyl)guanidine-2HCl, m. 340°. A mixture of 2 l. concentrated NH<sub>4</sub>OH and 300 g. XVIII was stirred 16 hrs. at room temperature to

give 260 g. 3-amino-6-chloropyrazinecarboxamide (XXIII), m. 227-30°. 100 g. XXIII in H<sub>2</sub>O gave 84% (3-amino-6-methyl-6-chloropyrazinecarboxylate) (XXIII), m. 268-70° (decomposition) (iso-PrOH). A solution of 5.5 g. XXIII and 4.4 g. PhCH<sub>2</sub>SH in 100 ml. 4% NaOH was heated 30 min. on a steam bath to give 5.5 g. 4-hydroxy-6-benzylthiopteridine, m. 233-5° (aqueous iso-PrOH), which was converted into 3-amino-6-benzylthiopyrazinecarboxylic acid (XXIV), m. 138-9°, by 8 hrs. hydrolysis with 5% MeOH. XXIV (4.5 g.) in 50 ml. Ac<sub>2</sub>O was heated 5 hrs. on a steam bath to give 6.6 g. 2-methyl-6-benzylthio-4H-pyrazino[2,3-d][1,3]oxazin-4-one (XXV), m. 116.5-18.5° (C<sub>6</sub>H<sub>6</sub>). To 1 g. Na in 30 ml. iso-PrOH 5 g. XX and 3.4 g. XXV were added to give, after 1 hr. at room temperature, 1.1 g. (3-amino-6-benzylthiopyrazinecarbonyl)guanidine, m. 171° (decomposition). Similarly were prepared 4-hydroxy-6-methylthiopteridine, m. 289.5-91.5° (aqueous iso-PrOH), 3-amino-6-methylthiopyrazinecarboxylic acid (XXVI), m. 182-4° (decomposition) (AcOEt), 2-methyl-6-methylthio-4H-pyrazino[2,3-d][1,3]oxazin-4-one, m. 189-91° (C<sub>6</sub>H<sub>6</sub>), and 3-acetamido-6-methylthiopyrazinecarbonylguanidine (XXVII), m. 220-2°. Addition of HCl to XXVII in H<sub>2</sub>O gave 84% (3-amino-6-methylthiopyrazinecarbonyl)guanidine, m. 203-5°. A solution of 0.92 g. XXVI in 15 ml. 2.5% NaOH was treated with 1.05 g. MeONa in 35 ml. H<sub>2</sub>O to give 0.5 g. 3-amino-6-methylsulfonylpyrazine-carboxylic acid, m. 239-42° (decomposition) (iso-PrOH), which gave, after 5 hrs. heating in Ac<sub>2</sub>O, 2-methyl-6-methylsulfonyl-4H-pyrazino[2,3-d][1,3]oxazin-4-one, m. 214-16° (Me<sub>2</sub>CO). XXVIII was heated into 27% 3-amino-6-methylsulfonylpyrazinecarbonylguanidine, m. 224-6° (decomposition) (iso-PrOH). Similarly are prepared the following XXVIA (R, R<sub>1</sub>, & yield, and m.p. given): H, H, 93, 240.5-1.5°; 293-5° (HCl salt); Me, H, 89, 238-9°; Et, H, 63, 217-18°; Pr, H, 93, 221-2°; iso-Pr, H, 75, 215°; CH<sub>2</sub>:CHCH<sub>2</sub>, H, 84, 213-14°; Bu, H, 65, 219-5°; Me-ETCH, H, 74, 208-9°;

iso-Bu, H, 76, 221\*; tert-Bu, H, 84, 222-23\*; Am, H, 70, 215-16\*; MePrCH, H, 89, 186.5-8.5\*; Et2CH, H, 82, 209-11\*; C6H13, H, 100, 194.5-6.5\*; cyclopropylmethyl, H, 95, 220-1\*; cyclopropyl, H, 85, 213-15\*; cyclopentyl, H, 65, 219-20\*; PhCH2, H, 44, 206-9\*; p-MeC6H4CH2, H, 57, 216-17\*; o-FC6H4CH2, H, 100, 206-8\*; p-ClC6H4CH2, H, 96, 225-6\*; PhCH2CH2, H, 57, 199-202\*; CF3CH2, H, 77, 232-3\*; CF3CH2CH2, H, 65, 221-2.5\*; HO-CH2CH2, H, 63, 273-3\*; HOCH2 (CHOH)4CH2, H, 68, 223-4\*; NH2CH2CH2, H, 68, 311\*; MeNHCH2CH2, H, 58, 192.4-4.5\*; 4-pyridylmethyl, H, 64, 219-40\*; o-furylmethyl, H, 92, 217-18\*; Ph, H, 92, 246.5-8.5\*; p-ClC6H4, H, 95, 276-8\*; Me, Et, 95, 229-30\*; Me, Pr, 97, 214-15\*; Me, iso-Pr, 70, 207-8\*; Me, CH2CHCH2, 95, 207-8\*; Me, Bu, 95, 208-9\*; Et, Et, 75, 215\*; Et, Pr, 92, 224-5\*; Et, iso-Pr, 75, 207-8\*; Et, CH2CHCH2, 92, 208-9\*; Et, Bu, 98, 200.5-1.5\*; Pr, Pr, 100, 221-22\*; Pr, Bu, 84, 215-17\*; (NRR1) a) pyrrolidino, 90, 244.5-5.5\*; (NRR1) a) 1-hexahydroazepinyl, 49, 224-5\*; (NRR1 a) N-methylpiperasino, 74, 299-300\*; Me, NH2, 92, 234\*.

Also prepared are the following XXVIIb (X, Y, & yield, and m.p. base and m.p. HCl salt given): H, HO, 10, >310\* (decomposition); H, NH2, 8, 286-8\* (decomposition); --; H, NMe2, 45, 224-5\* (decomposition); --; H, MeO, 62, --, 229-30\* (decomposition); H, PhCH2NH, 56, --, 231-7\* (decomposition); Cl, MeO, 90, --, 257\*; Cl, MeS, 100, 234.5-6.5\*; --; Cl, HO, 24, --, >300\* (decomposition); Cl, SH, 100, 236.5\*; --; Cl, HO, 81, 215-16\*; --; Cl, Cl, 72, --, 259-61\*; Me, H, 87, 218-19 (decomposition); --; Me, Me2N, 42, --, 245\* (decomposition); HCl; H, Me, 13, 210\* (decomposition); --; Me, Me, 38, 245\* (decomposition); --; Br, Me, 35, 288\* (decomposition); --; Et, H, 53, 207.5-9.5\* (decomposition); --; H, cyclohexyl, 71, 221-2\* (decomposition); --; cycloheptyl, H, 61, 228-30\* (decomposition); --; cyclopropyl, H, 61, 196.5-99\* (decomposition); --; H, Ph, 51, 224-6\* (decomposition); Ph, H, 34, 194.5-5.5\* (decomposition); --; Ph, Ph, 87, 234.5-5.5\*; Ph, Cl, 69, 214-15\* (decomposition); --; Br, Ph, 68, 234-6\* (decomposition); --; p-ClC6H4, H, 70, 282-5\* (decomposition); --; Me (or Ph), Ph (or Me), 77, 212-13\* (decomposition); --; Ph (or Me), Me (or Ph) 90, 218-19\* (decomposition); --; Ph, Me2N, 40, 205-6\* (decomposition); --; (XY) = (CH2)4, 29, 220-1\*; --; (XY) = CH2CHCH2, 56, 211-13\*; --; (XY) = HC.CClCH2CH, 70, 246-7\* (decomposition); --. A solution of 13.9 g. 2-methyl-2-pseudothiuronium sulfate (XXVIII) and 9.2 g. H2NCH2CH2OH in 40 ml. H2O was heated 20 min. to give 12.5 g. (2-hydroxyethyl)guanidine sulfate, m. 127.5-35.5\*, which was added to a solution of 2g. Na in 25 ml. MeOH, MeOH distilled, and the residue treated with 4.1 g. II 5 min. on steam bath to give 1.2 g. 1-(3,5-diamino-6-chloropyrazinoyl)-3-(2-hydroxyethyl)guanidine-HCl, m. 228.5-9.5\* (aqueous iso-PrOH).

1-(3-Amino-5-isopropylamino-6-chloropyrazinoyl)-3-(2-hydroxyethyl)guanidine-HCl. 0.5H2O, m. 185-6\* (decomposition), was prepared from Me 3-amino-5-isopropylamino-6-chloropyrazinecarboxylate. A mixture of 6.1 g. II, 6.8 g. phenylguanidine, and 3 ml. iso-PrOH was heated 6 hrs. to give 1-(3,5-diamino-6-chloropyrazinoyl)-3-phenylguanidine, isolated as the MeSOH salt, m. 272\* (decomposition) (H2O). Ph-CH2NH2 (60.3 g.) and 69.5 g. XXVIII in 200 ml. H2O kept 18 hrs. at room temperature gave benzylguanidine sulfate, which was converted into the HCl salt (XXIX) (51.5 g.), m. 175-8\* (aqueous EtOH), by treating its aqueous solution with aqueous

BaCl2. To a solution of 1 g. Na in 30 ml. iso-PrOH 9.3 g. XXIX was added and half the volume distilled. Addition of 2 g. II and heating the mixture 15 min. yielded 1 g. 1-(3,5-diamino-6-chloropyrazinoyl)-3-benzylguanidine, m. 215-16\* (decomposition) (aqueous iso-PrOH). With the appropriate starting materials the following 3-substituted 1-(3,5-diamino-6-chloropyrazinoyl)guanidines were prepared (3-substituent and m.p. (decomposition) given): p-fluorobenzyl 216-19.5\*; α-methylbenzyl 153-60\*; 3-pyridylmethyl, 280.5-3.5\*; 2-naphthylmethyl

243.5-5.5\*. Also prepared were the following RRI-NC(=NH)NH2.HCl (R, R1, & yield, and m.p. given): p-Me-C6H4CH2 H, 28, 153-5\*; o-ClC6H4CH2, Me, 32, 122.5-5.5\*; PhCH2, H, 71, 131-6\*; p-ClC6H4CH2, H, 55, 152.5-4.5\*; p-MeOC6H4CH2, H, 69, 132-7\*; 2,4-Me2C6H3CH2, H, 52, 105-15\*; 2,4-Cl2C6H3CH2, H, 67, 145-8\*; 3,4-Cl2C6H3CH2, H, 77, 155-7\*; PhCH2CH2, H, 71, 135-8\*.

Also prepared were the following XXIXa [R, R1, & yield, and m.p. (decomposition) given]: p-MeC6H4CH2, H, 27, 210-12\*; PhCH2, Me, 35, 274.5\* (HCl salt); o-ClC6H4CH2, H, 39, 220-3\*; p-ClC6H4CH2, H, 46, 204-6\* p-MeOC6H4CH2, H, 27, 175.5-9.5\*; 2,4-Me2C6H3CH2 H, 59, 220-2\*; 2,4-Cl2C6H3CH2, H, 30, 267.5-70.5\* (HCl salt); 3,4-Cl2C6H3CH2, H, 47, 216-19\*; PhCH2CH2, H, 46, 219-21.5\*. To a solution of 2.3 g. Na in 200 ml. absolute MeOH 15 g. dimethyl-guanidine sulfate was added, the mixture refluxed

1 hr. and cooled, Na2SO4 filtered off, the solution concd, to 30 ml., 10.15 g. II added, and the mixture heated 30 min. and kept 1 hr. at room temperature to give 3.6 g. 1-(3,5-diamino-6-chloropyrazinoyl)-3,3-dimethyl-guanidine (XXXI), decomposing at 240° HCl salt m. 275\* (decomposition). To a solution of 36.57 g. Et2NH in 100 ml. H2O and 41 ml. concentrated HCl adjusted, with 3.66 g. Et2NH to pH 9.2 a solution of 50% aqueous cyanamide (65.16 g.) was added dropwise at 100° in 4 hrs. After refluxing 1 hr. and standing over night at room temperature the mixture was treated with 50 ml. of


40% NaOH and CO2 passed through under cooling to give 1,1-diethylguanidine, isolated as the HCl salt (XXXI) (35 g.), m. 147-9\*. Similarly, 1,1-dibutylguanidine-HCl (XXXII), m. 104.5-106\* (H2O), was obtained in 84% yield. The following comds. were also prepared: 88.6% 1-(3,5-diamino-6-chloropyrazinoyl)-3,3-diethylguanidine, m. 265\* (decomposition), from II and XXXI and 72% 1-(3,5-diamino-6-chloropyrazinoyl)-3,3-dibutylguanidine, m. 148-9\* (iso-PrOH), from II and XXXII.

Also prepared were the following XXXIII (R, R1, & yield, and m.p. given): iso-Pr, H, 35, 238.5-40\*; CH2CHCH2, H, 39, 215\*; Bu, H, 17, 187.5\*; cyclopropylmethyl, H, 3, 196-7\*; Me, Me, 69, 219\*; Me, Et, 49, 218\*; Me, iso-Pr, 61, 209-11\*; Et, Et, 40, 214\*. The comds. are effective in the treatment of abnormal electrolyte excretion.

IT 1634-17-9. Pyrazinecarboxamide, N-amidino-3-amino-6-(p-chlorophenyl)- 1634-21-5. Pyrazinecarboxamide, N-amidino-3-amino-6-phenyl- (preparation of)


RN 1634-17-9 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(aminoinimomethyl)-6-(4-chlorophenyl)- (9CI) (CA INDEX NAME)



RN 1634-21-5 CAPLUS

CN Pyrazinecarboxamide, 3-amino-N-(aminoinimomethyl)-6-phenyl- (9CI) (CA INDEX NAME)



L9 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 1960:23156 CAPLUS

DOCUMENT NUMBER: 54:23156

ORIGINAL REFERENCE NO.: 54:4601a-f

TITLE: Pteridines. XVIII. A direct synthesis of 2-aminopyrazine-3-carboxamides

AUTHOR(S): Vogl, O.; Taylor, Edward C.

CORPORATE SOURCE: Princeton Univ., Princeton, NJ

SOURCE: Journal of the American Chemical Society (1959), 81, 2472-4

DOCUMENT TYPE: JOURNAL

CODEN: JACSAT; ISSN: 0002-7863

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 54:23156

AB Dry glyoxal bisulfite (45 g.) and 40 ml. concentrated NH4OH added dropwise to 30

g. aminomelonomidamide-2HCl (I) in 300 ml. H2O at 0°, the mixture stirred overnight at room temperature, and filtered gave 76% crude 2-aminopyrazine-3-carboxamide (II), m. 241-2\* (H2O or vacuum sublimation at 180°/0.01 mm.). When com. glyoxal was used, the yield was 32%. II (3.1 g.) in 20 ml. 3N NaOH refluxed 1.5 hrs., acidified with concentrated HCl (pH 3), and chilled gave 78% 2-aminopyrazine-3-carboxylic acid, m. 196\* (decomposition). Pyruvaldehyde (7.2 g.) in 60 ml. H2O added to 19 g. I in 200 ml. H2O at 10°, the mixture adjusted to pH 8-9 with 10 ml. concentrated NH4OH, stirred overnight, and cooled to 0° gave 54% 2-amino-5-methylpyrazine-3-carboxamide (III), m. 203-4\* after sublimation (180°/0.01 mm.) and recrystn. from MeOH. III (1.52 g.) in 10 ml. 3N NaOH refluxed, acidified (pH 3) with concentrated HCl, and cooled gave 60% 2-amino-5-methylpyrazine-3-carboxylic acid, m. 171-3\* (H2O). 2-Amino-6-methylpyrazine-3-carboxylic acid was reported, m. 210\* and 211-12\* (decomposition). Phenylglyoxal-H2O (7 g.) in 150 ml. ice-cold H2O added to 7.5 g. I in 250 ml. ice-cold H2O, the solution held at 0-5° while concentrated NH4OH was added while stirring to keep the pH at 8-9 30 min., stirred at room temperature overnight, and filtered gave 36.6% 3-amino-5-phenylpyrazine-3-carboxamide (IV), m. 239-40\* (absolute EtOH). Hydrolysis of IV as described above gave 70% 2-amino-5-phenylpyrazine-3-carboxylic acid (V), m. 196\* (decomposition). V (0.511 g.) in 15 ml. cold concentrated H2SO4 treated with 0.25 g. NaNO2 in 5 ml. cold concentrated H2SO4, the red solution held at 0° 4 hrs. and at room temperature 4 hrs., and stirred at room temperature overnight gave 58.5% 2-hydroxy-5-phenylpyrazine-3-carboxylic acid, m. 210\* (decomposition) (H2O and EtOH). I (28.5 g.) in 300 ml. H2O at 10° added slowly with stirring to 13 g. biacetyl in 60 ml. EtOH, the mixture then treated with concentrated NH4OH, stirred several hrs., cooled to 0°, and filtered gave 92% isomers (VIIa) and (VIIb) of 2-amino-5,6-dimethylpyrazine-3-carboxamide m. 285-60\* (decomposition). Extraction of 10 g. of the mixture in a Soxhlet apparatus 5 days with EtOH and evaporation of the extract gave mostly VIIa (7.47 g.), purified by vacuum distillation, m. 255\* (decomposition). Extraction of the Soxhlet residue 10 min. with boiling 50% aqueous HCONMe2 and recrystn. of the residue from the extraction with boiling 50% aqueous HCONMe2 gave 1.19 g. VIIb, decompose slowly above 280°, complete decomposition between


320-30°. λ 244, 377 mμ, log ε 4.01, 4.06.

Caustic hydrolysis of VIIa as described above yielded 81% 2-amino-5,6-dimethylpyrazine-3-carboxylic acid, m. 208\* (decomposition).

IT 133120-69-7, Pyrazinamide, 3-amino-6-phenyl- (preparation of)

RN 133120-69-7 CAPLUS

CN Pyrazinecarboxamide, 3-amino-6-phenyl- (9CI) (CA INDEX NAME)



=> LOG HOLD

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	132.00	346.49

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-18.75	-24.00

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:24:03 ON 06 APR 2006